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ABSTRACT
Dendritic cells (DCs) are the most potent professional antigen presenting cells
(pAPCs) of the immune system and play a fundamental role in coordinating innate and
adaptive immune responses. Through the expression of a wide array of pattern recognition
receptors (PRRs), such as toll-like receptors (TLRs), DCs recognize a variety of microbial
pathogens and infectious stimuli. Stimulation of DCs through TLR ligation results in a
rapid series of activation-associated events, termed “maturation,” which include the
upregulation of surface co-stimulatory molecule expression, inflammatory cytokine
secretion, and stimulation of naïve T cells via antigen presentation by MHC molecules.
Activation of DCs through TLRs is coupled with an increased metabolic demand
fulfilled by a rapid change in DC glucose metabolism and characterized by increased
aerobic glycolysis rates. TLR-driven glycolytic reprogramming plays an essential role in
generating building blocks required for high level protein synthesis associated with
maturation. Although glucose imported from extracellular environments has been broadly
considered as the major driver of glycolytic metabolism in immune cells, the contributions
of intracellular glucose stores to these processes are not well-defined. The role of
intracellular stores of glucose, in the form of glycogen, is widely appreciated in nonimmune systems. However, very little is known about the implication of glycogen
metabolism in DC immune responses. This work unveils the role and potential regulatory
mechanisms of glycogen metabolism in support of DC effector function.
The first part of this work primarily focuses on our characterization of the role of
glycogen metabolism in early DC activation responses; while in the last chapter, we
describe a potential regulatory mechanism of DC glycogen metabolism by activationassociated nitric oxide (NO) production. In this work, we tested the overarching hypothesis
that DC-intrinsic glycogen metabolism supports the early glycolytic reprogramming
required for effector responses and that nitric oxide can regulate this metabolism. We
demonstrate that DCs possess the enzymes required for glycogen metabolic machinery and
that glycogen metabolism supports DC immune effector response, particularly during early
activation and in nutrient-limited environments. More importantly, we uncover a very
intriguing metabolic phenomenon, in which DCs engage in the differential metabolic
pathways driven by carbons derived distinctively from glycogen and free glucose. Our
studies present the fundamental role and regulatory mechanisms of DC-intrinsic glycogen
metabolism and underline the differential utilization of glycogen and glucose metabolism
to support their effector responses. Overall, this work adds to a growing field of immunometabolism an improved understanding of an intricate layer of metabolic mechanisms that
immune cells undertake in response to immune stimuli.
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CHAPTER 1
Comprehensive Literature Review

1

1.1: Brief overview of the innate immune system
The innate immune system, recognized as the very initial phase of immune
response, is the first line of defense against infection and elicits non-specific immunity
against invading pathogens (Janeway, 2005). Early recognition of inflammatory stimuli
and inflammation responses of the innate immune system is orchestrated by both cellular
and non-cellular factors. First, epithelial cell surfaces provide a protective layer and the
first line of defense against pathogen invasion. The cellular part of the innate immune
system includes innate immune cells, such as neutrophils, macrophages, dendritic cells,
eosinophils, and basophils (Abbas and Janeway, 2000; Nathan, 2002), and these cells are
readily stationed at points of entry in mammalian organisms and work in a coordinated
fashion to protect against infections. Once the epithelial barrier is breached and a focus of
infection is established, innate immune cells act as first responders in initial recognition
and capture of invading pathogens, secretion of anti-microbial and chemoattractant
proteins, and elimination of microbial and cellular debris (Nowarski et al., 2013). Soluble
components of the innate immune system include a cascade of opsonin proteins, which
make up the “complement system,” and proteolytic enzymes and antimicrobial proteins
secreted by epithelial cells and leukocytes (Janeway, 2005).

1.1.1: Cells of the innate immune system
Leukocytes of the immune system are systematically derived from hematopoietic
precursors originated from bone marrow, which then develop into two major progenitors,
namely common myeloid progenitors (CMP) and common lymphoid progenitors (CLP).
Committing to one or the other of the lineage progenitors results in the loss of developing
2

into alternative cell lineages in response to the initial differentiation signals. In general,
cells of myeloid origin mainly constitute innate immunity and are canonically described
as the first responders to infectious stimuli, whereas CLPs generally give rise to B and T
lymphocytes, major players of the adaptive immunity (Kondo, 2010). There is also a
well-appreciated role for some classes of non-myeloid innate immune cells of lymphoid
origin, such as innate lymphoid cells (ILCs) (Kumar, 2014) and natural killer cells
(Abbas and Janeway, 2000; Janeway and Medzhitov, 2002) in early inflammatory
responses. Accumulation of phagocytes at the site of infection is one of the first and early
characteristics of innate defense mechanisms against invading pathogens (Abbas and
Janeway, 2000; Janeway, 2005; Janeway and Medzhitov, 2002). Phagocytes are largely
classified into granulocytic and mononuclear phagocytes.
Granulocytic phagocytes are comprised of neutrophils, eosinophils, basophils, and
mast cells. Neutrophils are the most efficient phagocytes among these granulocytes and
represent the most abundant population in the circulation, constituting about 50-70% of
total peripheral white blood cells (Mayadas et al., 2014). Also known as
polymorphonuclear leukocytes (PMNs) due to their characteristic multi-lobed nuclei,
these short-lived, highly motile cells are recruited to the sites of infection by chemoattractants released from activated endothelial layers and tissue-resident innate immune
cells. After phagocytosis, they destroy invading pathogens by several mechanisms, such
as lysosomal acidification, respiratory burst, and a release of neutrophil extracellular
traps (NETs), a meshwork of intracellular contents containing chromatin and DNA
(Mayadas et al., 2014; Nowarski et al., 2013; Segal, 2005). Eosinophils, as motile as
neutrophils, can migrate from the circulation to tissues. Their specialized role is defense
3

against multicellular parasites, such as worms, by releasing intracellular toxic granules
that contain cytolytic enzymes, proteases, and cytokines, resulting in membrane damage
and death of invading parasites (Weller and Spencer, 2017). Unlike neutrophils and
eosinophils, basophils are rather immobile. Basophils contain intracellular granules
potent against eradicating helminth and parasitic infections. Histamine is one of the most
well-recognized of the basophilic granular contents, responsible for triggering allergy
symptoms (Voehringer, 2013). Another type of granulocytes functionally similar to
basophils and believed to share the ontogeny with basophils are called mast cells.
Although the developmental process between mast cells and basophils are not fully
understood, both cell types are known to cause IgE mediated allergic responses and
potently induce TH2 mediated adaptive immunity (Siracusa et al., 2013; Voehringer,
2013).
The mononuclear phagocytic system consists of monocytes, macrophages, and
dendritic cells, and originates from hematopoietic cells of bone marrow. One of the wellappreciated functional aspects of these cells is their specialized ability in antigen
processing and presentation (Haniffa et al., 2015; Hume, 2006, 2008). Monocytes are the
most abundant mononuclear phagocytes (5-10%) in the circulation whereas macrophages
and DCs primarily reside in tissue niches. In most cases, monocytes serve as immediate
precursors for both macrophages and DCs, which then migrate into tissue environments.
Macrophages, a major phagocyte population in many tissues, are appreciated as the most
efficient phagocytes in eliminating cellular debris as well as pathogenic particles.
Although the phagocytic ability of DCs is not as potent as macrophages, their specialized
ability to traffic to secondary lymphoid organs and their role as key antigen presenting
4

cells is fundamental in coordinating both innate and adaptive immune responses (Haniffa
et al., 2015; Janeway, 2005; Janeway and Medzhitov, 2002). The antigen processing and
presenting function of macrophages and DCs is discussed at length in the following
subsections.

1.1.2: MHC molecules and Antigen Presenting Cells (APCs)
Major histocompatibility complex (MHC) molecules, encoded by a cluster of
genes called the MHC, also known as human leukocyte antigens (HLA) and located on
chromosome 6 short arm, are critically involved in presenting antigenic peptides on the
surface of antigen presenting cells to T cells, which will screen presented peptides for
self- versus non-self-antigenic signatures (Cunliffe and Trowsdale, 1987; Matzaraki et
al., 2017). Subsequent to T cell receptor engagement with cognate peptide/MHC
complexes, DCs assist in the induction of T cell-mediated adaptive immune responses
(Abbas and Janeway, 2000; Janeway, 2005; Matzaraki et al., 2017; Roche and Furuta,
2015; Rock et al., 2016). The mechanisms of antigen processing and presentation via
MHC differ greatly between the two major classes of MHC molecules, classified as MHC
class I and II. For MHC class I presentation, intracellular proteins of endogenous origins
or derived from intracellular pathogens are degraded in the cytosol or nucleus and
threaded into the endoplasmic reticulum (ER) lumen via a transporter associated with
antigen presentation (TAP). Class I molecules are also assembled in the ER lumen by
partial folding with the aid of TAP, which helps bind MHC with the two chaperone
proteins, calreticulin and ERp57. Calreticulin, ERp57, and an additional chaperone called
PDI help stabilize MHC I. Peptides translocated via TAP are sometimes trimmed by ER
5

aminopeptidase associated with antigen processing (ERAAP). The modified peptides
then bind to MHC-I peptide binding region, forming a peptide-MHC complex ready to be
exported out of the ER and expressed on the cell surface for antigen presentation to
CD8+ T cells (Neefjes et al., 2011; Porgador et al., 1997; Rock et al., 2016).
Similar to the MHC-I assembly, MHC-II molecules are also assembled in the ER,
however, in a different fashion than the former. Exogenous proteins such as extracellular
microbial pathogens are processed and presented by the MHC class II pathway.
Extracellular microbes endocytosed by immune cells are degraded into peptides in
phago-lysosomes and late endosomes. In the ER lumen, MHC-II molecules are
assembled in alpha and beta chains, in association with the invariant chain (Ii), which is
then cleaved into a Class II associated Ii peptide, called CLIP. CLIP is bound in the
peptide-binding region of MHC molecules and keeps the MHC from pre-mature binding
to the antigenic peptides originated in the ER. The MHC molecules are then transported
into endosomes where the processed peptides are located. With the help of HLA-DM,
which facilitates the exchange of CLIP, the exogenous peptide is degraded in the phagoendosomal pathway. The fully assembled MHC-peptide complex is then transported onto
the cell surface to present the peptide to CD4+ T cells (Neefjes et al., 2011; Roche and
Furuta, 2015).
Any nucleated cells in our body express MHC class I on their surfaces. However,
a class of cells that possess an ability to present antigenic peptides to CD8+ T cells and
initiate adaptive immune responses by stimulating T cells are termed antigen presenting
cells (APCs). APCs include fibroblasts, epithelial cells, endothelial cells, mesenchymal
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cells, and immune cells such as dendritic cells, macrophages, and B cells (Rock et al.,
2016; Steinman, 2001).
While all nucleated cells express MHC-I, those expressing high levels of MHC-II are
further classified as “professional” antigen presenting cells (pAPC) due to their
specialized ability to present antigens from both endogenous and exogenous sources
(Sprent). Efficient stimulation of T cells is proposed to require two major signals, both of
which are provided by pAPCs. The first signal is presentation of antigenic peptides to T
cells via MHC molecules. APCs with an ability to provide co-stimulatory signals, also
known as second signals, are considered to initiate a much stronger T cell response, and
for this process, pAPCs are well-equipped to express co-stimulatory ligands, such as
CD40, CD80, and CD86 (Lipscomb and Masten, 2002). It has also been proposed that a
third signal, cytokines released from both APCs and T cells, enhance the process,
although certain schools of thought refute this idea (Abbas and Janeway, 2000). In
general, the major elements of pAPCs are characterized by the ability to uptake invading
pathogens; process pathogen-associated proteins into peptides ready to be presented via
MHC-I/ II; the surface expression of co-stimulatory molecules; and the ability to migrate
to the T cell-rich lymphoid areas and present processed peptides to T cells; thereby
initiating adaptive immune responses.
Although recent studies showed that other hematopoietic innate immune cells
such as basophils, mast cells, and eosinophils express MHC II molecules and are
proposed to be categorized as APCs, it is still unclear whether these cells could be
defined as pAPCs (Abbas and Janeway, 2000; Kambayashi and Laufer, 2014).
Nevertheless, dendritic cells (DCs), macrophages, and B cells are long-considered as the
7

major canonical pAPCs. The degree of antigen presentation capacity vastly differs among
the three types of pAPCs, which is likely due to the inherent functional differences and
their distinct cellular shapes and structures.

1.1.2.1: B cells
B cells primarily function as antibody producing cells of the immune system. In
contrast to macrophages and DCs, B cells have a relatively limited capacity to
phagocytose/engulf large particulate antigens, which is considered one of the important
attributes of an APC. B cell interaction with antigen is manifested by the binding of
surface immunoglobulins to the antigenic particles released from macrophages, which
release antigenic protein molecules during phagocytic/macropinocytic processes
(Ronchese and Hausmann, 1993; Unanue, 1984). Therefore, the antigen presenting ability
of B cells is reported to be facilitated by external help from macrophages or DCs. Despite
this, the potency of B cells to effectively stimulate naïve T cells is still very poor (Lassila
et al., 1988; Ronchese and Hausmann, 1993). Several studies have later supported the
idea that antigen specific B cells, not naïve B cells, can activate T cells that have been
stimulated by the same antigen (Lassila et al., 1988; Ronchese and Hausmann, 1993).
B lymphocytes are primarily known as antibody-producing cells. During
development, B cells undergo VDJ recombination, a process that involves
rearrangements of Variable (V), Diversity (D), and Joining (J) gene segments to generate
diverse B cell receptors (BCR). Upon successful VDJ recombination, matured B cells
express immunoglobulin D and M (IgD and IgM) (LeBien and Tedder, 2008). Unlike the
term “maturation” in DCs, B cell maturation refers to a developmental process, in which
8

developing B cells undergo VDJ rearrangements of immunoglobulin (Ig) chains of a
BCR. B cells have several different functions including, but not limited to, antibodysecretion, cytokine production, and antigen presentation (Hoffman et al., 2016). In regard
to antigen presentation functionality, BCRs capture antigens and become clustered on the
B cell surface at which stage, B cells become activated (Hoffman et al., 2016; LeBien and
Tedder, 2008). Clustered BCRs are internalized, and activated B cells bearing antigencontaining BCRs in the intracellular compartments then travel to T- and B-cell borders of
lymph nodes. Because B cells also express co-stimulatory molecules required for antigen
presentation, they can stimulate antigen-specific T cells, not naïve T cells (Hoffman et
al., 2016). Some of the activated B cells are then transformed into plasma cells, forming
primary foci in the lymph node, whereas other B cells form germinal centers in primary
follicles, where somatic hypermutation and the generation of high-affinity antibody
production occurs (Abbas and Janeway, 2000; Janeway, 2005; LeBien and Tedder,
2008).

1.1.2.2: Macrophages
Macrophages are of myeloid origin and perform a diverse array of functions in the
immune system. Like DCs, macrophages are also tissue resident innate immune cells
highly specialized in phagocytosis and clearance of microbial organisms (Condeelis and
Pollard, 2006; Hashimoto et al.; Janeway, 2005). Due to their best ability to clear
engulfed particles and antigens, macrophages are implicated in tissue homeostatic
functions, such as tissue remodeling and resolution of inflammation after infection or
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tissue injury. Activated macrophages are rich in lysosomes that contain hydrolytic
enzymes to break down engulfed materials.
Lysosomal digestion is a major pathway for processing antigens in macrophages
(Banchereau and Steinman, 1998a). Although macrophages are unquestionably better
pAPCs than B cells, there are still ongoing debates about whether or not macrophages are
less efficient in antigen presenting capacity than DCs. Since the functional roles of
macrophages in the innate immune system are diverse, they possess the flexibility to
respond to a broad range of stimuli. The exposure to particular types of stimuli is thought
to initiate the generation of two primary macrophage populations (Pearce and Pearce,
2013). Such a phenomenon is called macrophage polarization, in which the exposure to
IFN and TLR-agonists can produce “M1” or classically activated macrophages, whereas
“M2” or alternatively activated macrophages are induced by stimulation with canonical
Th-2 cytokines IL-4 and IL-13 (Elhelu, 1983; Galván-Peña and O’Neill, 2014;
Hashimoto et al., 2011). A more detailed description of M1 and M2 macrophages in
regard to their metabolic and functional differences will be later discussed in the
comprehensive metabolism review of this chapter –Section 1.3.1.1 Metabolic
reprogramming in macrophages.

1.1.2.3: Dendritic cells (DCs)
DCs, first characterized by Paul Langerhans in the 1800’s as Langerhans cells
(LCs) in the tissue epidermal layer (Silvano, 2014), were later illustrated in the 1970’s by
Ralph Steinman as cells possessing a strange dendritic branch-like membrane protrusion
with the ability to present exogenous antigens to T cells in an MHC-dependent manner
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(Silvano, 2014). DCs are primarily considered as tissue resident cells and largely exist in
various lymphoid organs, epithelial layers, and connective tissues, whilst a small
percentage is found in peripheral blood (Banchereau and Steinman, 1998a; Steinman,
2001, 2012; Steinman and Hemmi, 2006). Because of the heterogeneous nature of their
localization in tissues/organs and a diverse expression of surface markers, DCs have been
categorized into a number of different subsets (Lipscomb and Masten, 2002), which are
discussed in the following section.
As sentinels of the innate defense line, DCs constantly sample particulates in
tissue micro-environments and possess a high capacity for phagocytosis of both
exogenous and endogenous sources of antigens (Banchereau and Steinman, 1998a;
Steinman, 2001). They can also capture antigens via receptor-mediated mechanisms due
to a high expression of a variety of pattern recognition receptors, expressed both
intracellularly and on the surface, such as toll-like receptors (TLRs), C-type lectin
receptors (CLR), and NOD-like receptors (NLRs) (Hammer and Ma, 2013). When
resting DCs encounter pathogens, they become activated and subsequently downregulate
the expression of PRRs. Capture of a pathogen prompts DCs to engage in a process called
maturation, characterized by upregulation of surface MHC-I and –II molecules, costimulatory molecules (CD40, CD80, and CD86), and the secretion of chemokines and
pro-inflammatory cytokines. DCs at this stage are termed “mature” DCs and are capable
of delivering Signal 1 and Signal 2 for naïve T lymphocyte activation. One of the critical
functions of mature DCs is the migration to draining lymphoid tissues where they present
antigenic peptides to naïve T cells. DC migration to secondary lymphoid organs is driven
by upregulation of chemokine receptor CCR7 upon PRR signaling and maturation
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(Banchereau and Steinman, 1998b; Steinman, 2001). Two striking qualities of mature
DCs is that a single DC can interact with multiple T cells at the same time and that DCs
innately possess copious amount of MHC-class II containing lysosomal compartments
(MIIC) (Nijman et al., 1995; Pierre et al., 1997), which are considered “specialized”
components for antigen presentation, compared to other pAPCs. On these accounts, DCs
are considered the most efficient pAPCs in the immune system (Banchereau and
Steinman, 1998a; Nijman et al., 1995). This dissertation will thoroughly explore the
metabolic regulations of TLR- and fungal-ligand-activated DCs in their effector
responses.

1.1.3: DC subsets and heterogeneity
DCs exist as a heterogeneous population of cells originating from the
hematopoietic lineage (Hashimoto et al., 2011). Regardless of the shared characteristics
in processing and presenting antigens and the ability to travel to secondary lymphoid
organs to activate T cells, the class of DCs still represent functionally and phenotypically
diverse subsets in different tissues sources (Steinman, 2012). After developing from
macrophage-dendritic cell precursors (MDP), developing DCs lose granulocyte
components and become committed to the DC lineage. Cells at this stage are termed as
common DC precursors (CDP), which then give rise to fully developed DCs of different
subsets under the influence of distinct growth factors (Hashimoto et al.). Under certain
conditions, DCs can also develop directly from monocyte precursors and are termed as
monocyte-derived DCs (mDCs). A similar phenomenon is also seen in a subset of
macrophages that are originated from monocytes (monocyte-derived macrophages). An
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illustration of DC development and a general characterization of DC subsets are depicted
in
Figure 1 -1. Major subsets of DCs and developmental pathways

Figure 1 -1. Major subsets of DCs and developmental pathways
(illustration adapted from Hashimoto et al. (Hashimoto et al., 2011))
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To date, DCs are broadly categorized into conventional or classical DC (cDCs)
and plasmacytoid DC (pDCs) subsets (Steinman, 2012). cDCs can be of lymphoid or
non-lymphoid origins (Sichien et al., 2017; Silvano, 2014). Two major subsets of cDCs
are: CD11b+ cells that induce CD4+ T cell activation and differentiation, and CD11b+
CD8+ DCs that are specialized in cross-presentation of antigens and activation of CD8+
T cells (Crowley et al., 1989; den Haan et al., 2000; Hashimoto et al.; Silvano, 2014;
Vremec et al., 1992). Initially thought to arise from lymphoid tissues, pDCs, one of the
non-classical DC types, were later discovered to be originated from bone marrow
precursors as well. These pDCs then circulate in peripheral blood and migrate to
lymphoid tissues upon encountering antigens (Banchereau and Steinman, 1998a). pDCs
are a primary source of type-1 IFN upon viral infections (Chistiakov et al., 2015; Diebold
et al., 2004; Nakano et al., 2001; Saas et al., 2017; Siegal et al., 1999) and highly express
TLR7 and TLR9 (Steinman, 2012). A common trait of both cDCs and pDCs is that both
cell types are dependent on growth factor fms-like tyrosine-3 ligand (Flt3L) for their
development (Guo et al., 2016; Kingston et al., 2009), a model used for both in vitro and
in vivo generation of cDCs and pDCs from mouse. Another major type of non-classical
DCs is monocyte-derived DCs (mDCs). mDCs are also known as inflammatory DCs
(iDCs) and found in the peripheral blood. As the name implies, mDCs are transformed
from circulating CD14+ monocytes in the event of infection and represent prototypical
inflammatory DCs, that are believed to migrate to peripheral tissues upon activation
(Chow et al., 2017; Collin et al., 2013; Hashimoto et al.; Lee and Iwasaki, 2007; Mildner
and Jung, 2014). In addition to these major subtypes, there are still several subsets of
tissue DCs throughout our body localizing in skin (Langerhans cells), intestine
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(CD103+DCs), and lungs (Hashimoto et al.) by bearing different markers on their surface.
The lack of specific lineage markers on DCs has posed a difficult problem in
characterizing the underlying molecular mechanisms for differentiating specific DC
subsets.
Two primary models used in the field of mouse DCs are in vitro generation of
DCs from bone marrow hematopoietic stem cells by using the cytokines granulocytemacrophage-colony-stimulating-factor (GM-CSF) and Flt3 Ligand. The former is
generally termed bone-marrow derived DCs (BMDCs) and the latter produces Flt3L DCs
(Merad et al., 2013; Mildner and Jung, 2014). Regardless of diversity, a number of DC
subsets share common immune characteristics with BMDCs; thus, the use of BMDCs as
an experimental model provides us with insightful information about DC biology and
functionality. Tissue resident DCs such as splenic or lymphoid DCs can also be isolated
directly from organs and tissues by isolation of CD-marker specific DCs. For instance,
CD11c+ splenic DCs and CD11b+ CD8+/CD8- DCs are isolated from spleen
connective tissues and lymph nodes, respectively. On the other hand, in vitro generation
of human DCs greatly differ from murine DC isolation. A commonly-used method for
isolating human DCs is in vitro culture differentiation of CD14+ circulating monocytes
with cytokines GM-CSF and IL-4 (Collin et al., 2013; Sallusto and Lanzavecchia, 1994,
2018). The immunophenotypic outcome of the two widely-accepted models of mouse and
human DCs, BMDCs and GM-CSF/IL-4 derived DCs respectively, is thought to closely
reflect that of mDCs (or iDCs) in vivo (Mildner and Jung, 2014; Thwe and Amiel, 2018).
More recent discoveries of DC subsets localized in different tissue niches, with distinct
cell surface markers and ontogeny, have been made with the aid of technological
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advances (Chow et al., 2017; See et al., 2017; Silvano, 2014; Steinman, 2012; Villani et
al., 2017; Young, 2012). Along with these discoveries comes the necessity to explore the
functional details of these subsets and compare them with previously defined DC models.

1.2: Pattern recognition receptors (PRRs)
Pattern recognition receptors (PRR), originally proposed by Janeway to possess
the ability to distinguish self from non-self-molecules, are well-appreciated as major
drivers in recognizing evolutionarily conserved microbial pathogens and triggering
effector responses of innate immunity (Takeuchi and Akira). PRRs are a family of germline encoded receptors located both intracellularly and extracellularly in or on innate
immune cells. While PRRs were initially thought to be expressed on macrophages and
DCs only, PRRs such as TLRs have been found on other cell types such as epithelial cells
and fibroblasts, which also play an important role in barrier defense (Mogensen, 2009).
PRRs serve as initial sensors of microbial organisms by recognizing conserved molecular
structural components called pathogen associated molecular patterns (PAMPs). They can
also recognize host cell-derived damage associated molecular patterns (DAMPs)
resulting from host cellular and tissue damage regardless of the presence or absence of
infection (Takeuchi and Akira). The initial recognition of microbial stimuli by PRRs is
important in controlling infections (Mogensen, 2009) and maintaining cellular
homeostasis to prevent catastrophic outcomes in the host. Strategic localizations of PRRs
both inside and outside of a cell provide the host an advantage to clear any invading
inflammatory stimuli in a timely manner. PRRs are generally classified into five major
family members, which include toll-like receptors (TLR), C-type lectin receptors (CLRs),
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retinoic acid inducible gene (RIG)-1 like receptor (RLRs), NOD-like receptors (NLRs),
and the AIM-2 receptors (ALRs) (Brubaker et al., 2015; Takeuchi and Akira). A detailed
outline of PRR families, with their cellular localization and ligand recognition is
mentioned in Table 1.
Activation of PRRs via binding of a cognate ligand leads to a dynamic array of
transcriptional and translational changes resulting in innate inflammatory responses, such
as a release of pro-inflammatory cytokines, chemoattractants, (Brubaker et al., 2015) and
cell adhesion molecules accompanied by increased expression of immunoreceptors
(Mogensen, 2009). Downstream effects of PRR activation are orchestrated by a number
of intracellular signaling pathways, which, in fact, are primarily initiated by the
association of receptors with intracellular adaptor(s), that relay signals from the receptors
to downstream effector proteins/enzymes. Some adaptors share a common domain with
more than one receptor, thus the signals between different categories of receptors are
more efficiently relayed to downstream targets via conserved and convergent signaling
processes. Innate immune responses cannot be achieved by receptors alone but rather
through the protein-protein interactions between receptors and adaptor molecules. Albeit
not all receptors require adaptor molecules, they play a crucial role in ligand recognition
(Brubaker et al., 2015); detailed functions of some major adaptor molecules will be
discussed later in this chapter. Among the above-mentioned PRR family members, our
studies primarily investigate the metabolic regulation of DCs activated via toll-like
receptor 4 (TLR4) and a C-type lectin receptor family member, Dectin-1.
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Table 1: Summary of major PRRs, cognate ligands, and cellular localizations
Type of

Localization

Ligand

Origin of ligand

Plasma membrane

Triacyl Lipoprotein

Bacteria

Plasma membrane

Lipoprotein

Bacteria, Virus,

PRRs
TLRs
TLR1 (works
in concert
with TLR2)
TLR2

parasite, self-antigen
TLR3

Endolysosome

dsRNA

Virus

TLR4

Plasma membrane

LPS

Bacteria, virus, selfantigen

TLR5

Plasma membrane

Flagellin

Bacteria

TLR6 (works

Plasma membrane

Diacyl lipoprotein

Bacteria, virus

Endolysosome

ssRNA

Virus, Bacteria, self-

in concert
with TLR2)
TLR7

antigen
TLR8

Endolysosome

ssRNA

(human)
TLR9

Virus, Bacteria, selfantigen

Endolysosome

CpG-DNA

Bacteria, virus,
protozoa, self
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TLR10

Endolysosome

Unknown

Unknown

TLR11

Plasma membrane

Profilin-like

Protozoa

molecule
TLR12

Unknown

Unknown

Protozoa

TLR13

Unknown

Unknown

Unknown

RIG-I

Cytoplasm

Short dsRNA

RNA and DNA viruses

MDA-5

Cytoplasm

Long dsRNA

RNA viruses

AIM2

Cytoplasm

dsDNA

Bacteria, viruses

NOD1

Cytoplasm

LPS

Bacteria, self

NOD2

Cytoplasm

LPS

Bacteria, self

Plasma membrane

-glucan

Yeast and hyphae of

RLR

NLR

CLR
Dectin-1

fungi
Dectin-2

DC-SIGN

Plasma membrane

Plasma membrane

Mannose, -linked

Fungal yeasts and

mannans

Hyphae

Glycan

Self, Viruses, Fungi
(Garcia-Vallejo and
van Kooyk, 2013)

MINNCLE

Plasma membrane

SAP130
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Fungi, Self-antigen

1.2.1: Toll-like receptors (TLRs)
TLRs are the most studied PRRs in the field of innate immunity. The discovery of
mammalian’s toll protein is linked to the finding of Drosophila Protein Toll, which was
originally observed to play a role only in fruit fly development. Right before the
discovery of the function of Toll, IL-1R type 1 was identified to be implicated in T cell
activation as well as in acute phase inflammatory reactions. IL-1R was soon revealed to
be homologous to the Toll of Drosophila, which was then reassessed and shown to be
also involved in fruit fly immunity against fungal pathogens. The cytoplasmic tails of
TLRs and IL-1R have been shown to possess a conserved homology domain, known as
the TIR domain, which is responsible for initiation of signaling cascades (Akira, 2003;
Akira and Takeda, 2004; O'Neill et al., 2013). At the extracellular region, leucine rich
repeats are conserved across all TLRs (O'Neill et al., 2013). While more than 20 TLRs
were identified in invertebrate species, such as channel catfish (Quiniou et al., 2013), 11
TLRs have been discovered to date in humans and mice, with some controversial reports
on the expression of TLR11, TLR12, and TLR13 in humans.
Regardless of their structural similarities in leucine rich repeat motifs in the
extracellular domain, TLRs can recognize diverse arrays of ligands, which are
differentially localized across the cell. TLR1, TLR2, TLR4, TLR5, TLR6 are located in
the plasma membrane and generally recognize extracellular pathogens (Brown et al.,
2011; Brubaker et al., 2015; Medzhitov, 2007; Takeda and Akira, 2005). TLR3, TLR7,
TLR8, and TLR9 are found in the cytoplasm, localized across endosomal or lysosomal
membranes, and recognize intracellular PAMPs, such as nucleic acid motifs expressed in
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viral and bacterial genomes (Akira, 2003; Akira and Takeda, 2004; Janeway and
Medzhitov, 2002; Takeda and Akira, 2004, 2005; Uematsu and Akira, 2007).
TLR2 recognizes a broad range of ligands originated from Gram positive bacteria,
mycobacteria, fungi, and viruses. It heterodimerizes with TLR1 for recognition of
triacylated lipopeptides or with TLR6 for recognition of diacylated lipopeptides (Lee and
Iwasaki, 2007; Santos-Sierra et al., 2009; Shen et al., 2010; Takeda and Akira, 2005;
Takeuchi and Akira, 2004). Among the TLRs, TLR2 recognizes the widest variety of
ligands, even including glycosylphosphatidylinositol lipid from the parasite Trypanosoma
cruzi. Of note, TLR1 and TLR6 are thought to be constitutively expressed on the surface
of any cell types, whereas TLR2 is identified mostly on macrophages, dendritic cells, and
endothelial cell, and TLR2 expression on these cells is highly regulated (Beutler, 2004;
Brubaker et al., 2015; O'Neill et al., 2013; Takeda and Akira, 2005).
TLR3 is predominantly expressed in DCs (Muzio et al., 2000) and recognizes
double-stranded RNA, a major component of many viruses and a molecular signature of
an active viral replication cycle (Alexopoulou et al., 2001; O'Neill et al., 2013). Ligation
of TLR3 receptor results in NF-B activation and Type I IFN signaling, and abolishing
the expression of TLR3 causes a defective defense against dsRNA viral infections and
impaired immune responses to Poly IC, a synthetic ligand for TLR3 (Alexopoulou et al.,
2001).
The first characterized TLR in mammals was TLR4. The importance of TLR4
was discovered in C3H/HeJ mice, harboring a mutation in a region of the TLR4 gene that
was later identified to contain a LPS responsive area, and this mutation was manifested
by LPS-hyporesponsiveness and increased susceptibility of these animals to endotoxic
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shock elicited by infection with Gram-negative bacteria (Hoshino et al., 2016; Poltorak et
al., 1998). This finding was also confirmed in TLR4 deficient mice (Hoshino et al., 2016;
Poltorak et al., 1998; Rosenstreich et al., 1977). The structure and assembly of TLR4 is
distinct from other TLR members because TLR4 itself does not directly bind to the LPS
ligand. The binding of LPS to TLR4, however, is facilitated by two other accessory
proteins, CD14, which is an essential receptor for LPS, and MD-2, complexed to TLR4
(da Silva Correia et al., 2001). This dissertation work uses TLR4 ligand stimulation as a
model to investigate the influence of metabolic pathways in the regulation of DC immune
responses during inflammatory conditions.
TLR5 recognizes the conserved flagellin protein that makes up flagella (Hayashi
et al., 2001; Medzhitov, 2007; O'Neill et al., 2013; Uematsu et al., 2006; Yoon et al.,
2012) in both Gram positive and negative bacteria (Hayashi et al., 2001). TLR5 is highly
expressed in lamina propria cells in the intestine; however, intestinal epithelial cells,
originally thought to have higher expression of TLR5, have been later shown to express
low levels of TLR5 (Uematsu et al., 2006). TLR5 plays a crucial role in mucosal areas by
not only initiating the innate immune responses against bacterial infection but also
inducing adaptive T helper cell responses, particularly in TH-17 differentiation (Hawn et
al., 2003; Uematsu et al., 2008; Uematsu et al., 2006), suggesting the important roles of
TLRs beyond innate immunity.
Single stranded nucleic acids (ssRNAs), particularly guanosine and uracil rich
nucleotides derived from viruses and bacteria are recognized by TLR7 and TLR8
(Diebold et al., 2004; Gorden et al., 2006; Heil et al., 2004; Jurk et al., 2002; O'Neill et
al., 2013). The recognition of ssRNAs via TLR7 and/or TLR8 was originally thought to
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be species specific, in which murine TLR8 was believed to be nonfunctional while, in
human, both TLR7 and TLR8 can recognize single stranded viral RNA ligands (Heil et
al., 2004; Jurk et al., 2002). However, Gorden et al demonstrated in a later study that
murine TLR8 can be successfully activated by a synergistic action of a synthetic immune
response modifier (IRM) and polyT oligodeoxynucleotides, TLR7/8 agonist (Gorden et
al., 2006), suggesting the structural differences between TLR7 and TLR8 may be a
culprit in the adjuvant requirement for TLR8 in recognizing its cognate ligands. ssRNAs
exist in large quantities in human cells; however, TLR7 and/or TLR8 hardly detect hostderived ssRNAs most likely due to the localization of these receptors in endosomes
(Takeda and Akira, 2005).
TLR9 recognizes unmethylated CpG nucleotide motifs derived not only from
bacterial DNAs but also from viruses, such as Herpes simplex virus-1 and -2 and MCMV
(Medzhitov, 2007; O'Neill et al., 2013). TLR9 distinguishes mammalian CpG due to the
low frequency methylation of nucleotides (Hemmi et al., 2000). The discovery of TLR9
recognition of viral DNAs was elegantly demonstrated by a collaborative effort of Akira,
Medzhitov, Takeda, and Colonna. Proper antiviral responses such as secretions of IFN-,
IFN-, and other inflammatory cytokines involved in functional activation of NK cells
require the ability of TLR9 to recognize viral DNAs (Krug et al., 2004a; Krug et al.,
2004b; Lund et al., 2003). TLR9 is recruited to endosomal compartments, where it is
complexed with DNA ligands with the aid of endosomal acidification during the process
of endocytosis (Hemmi et al., 2000).
The role of TLR10 has not been extensively studied. TLR10 is detected in human
macrophages, neutrophils, activated B cells, and plasmacytoid dendritic cells (Bourke et
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al., 2003; Hasan et al., 2005; Lee et al., 2014). It shares the same locus with TLR1 and
TLR6; therefore, it is postulated to heterodimerize with TLR1 (Akira and Takeda, 2004;
Hasan et al., 2005; O'Neill et al., 2013). While the ligand for TLR10 is not well-defined,
influenza viral infection in macrophages and B cells mediated via TLR10 is reported to
induce potent innate immune responses (Fernandes et al., 2014). On the other hand, other
studies have indicated the anti-inflammatory roles mediated by TLR10 (Oosting et al.,
2014). These findings altogether suggest that TLR10 possesses both pro- and antiinflammatory responses in modulating immune responses.
TLR11 and TLR12 have recently been shown to dimerize upon Toxoplasma
gondii infection in mice (Andrade et al.). TLR11, however, exists in human as a
pseudogene, and TLR12 is not entirely expressed in human (Andrade et al.; Quiniou et
al., 2013). Although the expression of these two TLRs seem unimportant in humans, the
fact that they play a critical role in rodent toxoplasma susceptibility suggest potential
relevance to human immunology (Andrade et al.).

1.2.1.1: TLR signaling pathways
The cytoplasmic tail of TLRs is made up of a highly conserved Toll/IL1-R (TIR)
domain, which forms a TIR-TIR structure upon dimerization of TLRs in encountering a
cognate ligand. Such dimerization, such as homo-dimerization in TLR3 or heterodimerization in TLR2 with TLR1 or TLR6 (Ozinsky et al., 2000), initiates signal
transduction in order to produce specific immune responses elicited by TLR-ligand
interactions (Weber et al., 2005). Binding of adaptors at the TIR domains triggers a TLR
signaling cascade. Five adaptor molecules involved in TLR signaling have been
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discovered to date: myeloid derived differentiation factor 88 (MyD88); TIR-domain
containing adaptor inducing IFN- (TRIF); TIRAP/MyD88-adaptor like (Mal); TRIFrelated adaptor molecule (TRAM); and Sterile-alpha and Armadillo motif-containing
protein (SARM). Out of these five, MyD88 is recognized as a major signaling adaptor
implicated in almost all TLRs, with the exception of TLR3. In general, two major
signaling pathways are engaged upon TLR-ligand interactions: MyD88-dependent and
MyD88-independent pathways.
MyD88 was the first TIR adaptor to have been discovered (Lord et al., 1990) and
later recognized to play an essential role in TLR and IL-1 signaling (Bernard and O'Neill,
2013; Bonnert et al., 1997; Deguine and Barton, 2014; Medzhitov et al., 1998; Muzio et
al., 1998; Muzio et al., 1997). MyD88 is comprised of two domains: a death domain
(DD) in the N-terminal and a TIR domain in the C-terminal. TIR-TIR association
between MyD88 and TLR domains phosphorylates IRAK, IL-1 receptor associated
kinase-4, which then associates with TRAF6 and IRAK-1, subsequently diverging into
two distinct pathways – activation of NF-B and AP-1 (Medzhitov et al., 1998; Wang et
al., 2001). Activation of NF-B is achieved by a series of phosphorylation of molecules,
such as a complex of TGF- activated kinase (TAK) proteins and inhibitors of NF
(IKK) (Wang et al., 2001; Zandi et al., 1997). Activated NF-κB is then translocated to
nucleus, where it induces the transcription of a number of genes for pro-inflammatory
cytokines (Ghosh et al., 1998; Zandi et al., 1997). On the other hand, TAK1 complex
activated by phosphorylated TRAF6/IRAK-1 triggers a series of phosphorylation events
in MAPK Kinases, such as MAPKK, MKK3, and MKK7, eventually leading to
activation of p38 and JNK (Wang et al., 2001), with a final outcome of the transcriptional
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factor activator protein-1 (AP-1) activation. AP-1 is accountable for induction of several
genes encoding inflammatory cytokines and acute phase reactant proteins (Lee and Kim,
2007).
In TLR7 and TLR9 activation, MyD88 signaling also induces the transcription
factor Interferon regulatory factors (IRFs) for type I interferon production in addition to
NF-κB dependent cytokines (Hacker et al., 2006; Oganesyan et al., 2006). The MyD88dependent pathway in TLR2 activation requires the Mal/TIRAP adaptor, one of the five
TLR adaptors with a TIR domain as mentioned above, for proper signal transduction
(Santos-Sierra et al., 2009). Originally discovered as a bridging adaptor in the assembly
of MyD88 complex to the TIR domain of TLRs (Gay et al., 2011), Mal has been later
identified to function independent of MyD88 in TLR2 and TLR4 (Equils et al., 2004;
Fitzgerald et al., 2001; Santos-Sierra et al., 2009).
The MyD88-independent pathway, originally discovered in MyD88 knock-out
mice that display intact NF-κB and MAPK activities in response to LPS (Kawai et al.,
1999), was later found to be facilitated by the TRIF adaptor molecule, one of the TIR
domain containing adaptors homologous to MyD88 (Hoebe et al., 2003; Oshiumi et al.,
2003; Yamamoto et al., 2003a). These findings were confirmed in TRIF3 knock-out
mice, displaying impaired IFN production upon challenges with Poly I:C, a synthetic
ligand for TLR3, indicating that TLR3 signaling is exclusively dependent on TRIF3
(Brown et al., 2011; Hoebe et al., 2003; Takeda and Akira, 2005; Yamamoto et al.,
2003a). This pathway is interchangeably referred to as TRIF-dependent or MyD88independent pathway. Both TLR3 and TLR4 engage in a MyD88-independent pathway,
although TLR4 is unique among the TLR family in that also signals through the MyD8826

dependent pathway (Takeda and Akira, 2004; Yamamoto et al., 2003a). Association of
TRIF in TIR-TIR domains initiates a series of phosphorylation cascades leading to the
activation of IRF3, which induces IFN-. IFN-, in turn, activates STAT1 for induction
of more IFN-inducible genes (Sato et al., 2003). Similar to Mal, which serves as a bridge
in MyD88-dependent pathways, a second adaptor called TRAM was later found to be
required for TRIF signaling in TLR4 activation (Yamamoto et al., 2003b).

1.2.2: C-type lectin receptors
C-type lectin transmembrane receptors (CLRs) are one of the family members of
PRRs and mainly recognize carbohydrate cell wall components of microbial origin
(Brubaker et al., 2015; Dennehy and Brown, 2007; Takeuchi and Akira). It has been
demonstrated later that CLRs can also recognize non-carbohydrate structures, such as
lipids, proteins, and nucleic acids (Brown et al., 2003b; Dambuza and Brown, 2015; Plato
et al., 2013). The CLR family is comprised of relatively large members, including
Dectin-1, Dectin-2, mannose, MCL (macrophage C-type lectin), DC-SIGN (dendritic cell
specific ICAM3-grabbing non-integrin), and CLEC9A. CLRs are widely expressed in
myeloid cells, predominantly in dendritic cells and macrophages, and to some extent in B
cells and neutrophils (Dambuza and Brown, 2015). CLR activation is achieved through
the recognition of polysaccharide antigens in C-type lectin domains of the receptors and
generally gives rise to induction of NFB or NFAT-mediated signaling pathways.
Cytoplasmic tails of CLRs are composed of intracellular signaling motifs, such as ITAMs
(immunoreceptor tyrosine-based activation motifs), ITIMs (immunoreceptor tyrosinebased inhibitory motifs), and non-immunoreceptor tyrosine-based motifs (Plato et al.,
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2013). CLR signal transduction occurs either through a direct activation of these
intracellular domains or indirectly via binding of adaptors to immuno-modulatory motifs
(Plato et al., 2013; Takeuchi and Akira). The induction of CLRs via ITAMs generally
leads to phagocytosis, cellular proliferation and differentiation, and migration (Plato et
al., 2013). For instance, in myeloid immune cells, such as DCs and macrophages, CLR
activation initiates inflammatory responses such as increased phagocytosis, respiratory
burst, and pro-inflammatory cytokine release (Brown et al., 2003b; Dambuza and Brown,
2015; Plato et al., 2013). However, the activation of inhibitory motifs usually results in
negative regulation of CLR-mediated signaling pathways (Kerrigan and Brown, 2010).

1.2.2.1: Dectin-1 receptor
Dectin-1 is the most well-characterized CLR family member. The expression of
Dectin-1 was originally believed to be restricted to dendritic cells (Ariizumi et al., 2000);
however, several studies have later indicated that it is also expressed on monocytes,
macrophages, neutrophils, and occasionally on B cells, eosinophils, and a small
population of T cells (Brown et al., 2003b; Drummond and Brown, 2011; Taylor et al.,
2002). The extracellular portion of Dectin-1 receptor consists of carbohydrate binding
domains, just like any other types of CLRs. However, the intracellular component of
Dectin-1 consists of ITAM-like motifs at its cytoplasmic tail, which is unique compared
to other CLRs operating via a true ITAM domain (Brown, 2006; Kerrigan and Brown,
2010; Underhill and Goodridge, 2007). Two major signaling pathways, known as spleen
tyrosine kinase (Syk) and CARD, downstream of ITAMs are reported to be implicated in
Dectin-1 activation, which will be explained in detail later.
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Dectin-1 recognizes both 1,3- and 1,6-  glucans, which are carbohydrate
polymers and major components of plant and fungal cell walls (Batbayar et al., 2012).
These  glucan molecules possess an immuno-modulatory capacity through the dectin-1
receptor and elicit pro-inflammatory responses, such as release of cytokines, chemokines,
and reactive oxygen species (ROS) in dendritic cells (Underhill et al., 2005).
Fungal cell walls are composed of approximately 60% of -glucans, 10-20% of
chitin, and about 40% of mannan proteins (Batbayar et al., 2012; Netea et al., 2008;
Shepherd, 1987). The exposure of -glucan on fungal cell wall surfaces allows Dectin-1
to serve as the primary receptor in recognizing yeast pathogens. Since some fungi exist
only as yeasts while others, such as Candida albicans, can switch between yeast and
hyphal forms, such morphological transformation changes the exposure of cell wall
structural components on the surface. For instance, while the yeast form of C.albicans is
primarily recognized by Dectin-1, its hyphae are recognized by Dectin-2, which
preferentially binds mannose and alpha-mannans present in fungal hypha (Alexopoulou
et al., 2001; Kapteyn et al., 2000; Shepherd, 1987). In that case, a morphologic change
from yeast to hyphae can potentially alter the ultimate immune outcomes due to
potentially different signaling mechanisms downstream of each receptor-ligand pair. In
addition, some TLRs, such as TLR2, TLR4, TLR6, and TLR9, can also recognize
phospholipo-mannan, O-linked mannans, zymosan, and fungal DNA, respectively (Netea
et al., 2008). The redundant and/or collaborative recognition of highly complex fungal
structural components by both CLRs and TLRs (Ferwerda et al., 2008; Netea et al., 2006)
pose challenges in understanding immune responses elicited by a specific ligand-receptor
pair. Of interest, although Dectin-1 is an innate immune receptor, it’s implication in
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generating trained innate immunity or innate immune memory was illustrated in human
monocytes that are initially primed with -glucan followed by subsequent re-activation
with C. albicans yeast. Trained innate immunity is the memory responses of innate
immune cells, whereby innate immune signaling can induce epigenetic changes that
cause the innate immune cells to exhibit long-term effector responses upon challenge
with microbial pathogens (Cheng et al., 2014). In this dissertation, we have undertaken
to identify the downstream metabolic and immune responses induced by Dectin-1
specific ligands and have examined the similarities and differences between metabolic
reprogramming in DCs driven by this canonical CLR as compared to TLRs.

1.2.2.5: Dectin-1 signaling pathway
Activation of CLRs is achieved through signal transduction via immuno-receptor
tyrosine-based activation motifs (ITAMs) at the cytoplasmic tail of the receptor. Unlike
signal transductions by the ITAMs of other CLRs, which is largely carried out by two
domains of tyrosine phosphorylation sites of ITAM motifs, Dectin-1 signaling is uniquely
transduced through a single tyrosine phosphorylation at its ITAM - hence namely ITAMlike motifs (Fuller et al., 2007; Rogers et al., 2005). Phosphorylation at ITAM-like motif
recruits an adaptor molecule called spleen tyrosine kinase (Syk) (Brown, 2006; Fuller et
al., 2007; Kerrigan and Brown, 2010; Plato et al., 2013; Rogers et al., 2005; Underhill et
al., 2005), originally thought to be restricted only in the lymphocyte development and
function (Mocsai et al., 2010), and later discovered to play a crucial role in signal
transduction in non-lymphoid cells. The importance of Syk in Dectin-1 activation was
elegantly demonstrated in Syk-/- mice challenged with Zymosan, a fungal cell wall
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protein-carbohydrate complex extracted from Saccharomyces or Candida albicans with
the potent immuno-stimulatory capacity, resulting in failure to produce inflammatory
cytokines (Rogers et al., 2005). Phosphorylated Syk then induces NF-B transcription via
activation of CARD9, caspase-recruitment domain 9, which then forms a complex with
Bcl-10 (B-cell lymphoma protein 10) (Gross et al., 2006; LeibundGut-Landmann et al.,
2007). Syk-CARD9-Bcl10 axis in Dectin-1 activated DCs is crucial in initiating Th1 and
Th17 differentiation in a MyD88-independent manner (Kingeter and Lin, 2012;
LeibundGut-Landmann et al., 2007). Several studies have also reported that Sykdependent Dectin-1 activation not only gives rise to inflammatory cytokine production
but also generates ROS (Underhill et al., 2005) and activates the inflammasome complex.
These findings indicate an interplay between the metabolic regulation of Syk-kinase and
inflammasome signaling pathway. Our work here will set out to identify this association
in the context of fungal infection.
A few years after the role of Syk in Dectin-1 signaling was identified, Gringhuis
et al showed that Dectin-1 is also activated by Syk-independent pathway for NK-B
induction. Activation of Syk-independent pathway is achieved through Raf1 kinase
signaling and is known as the non-canonical NF-κB activation pathway (Gringhuis et al.,
2009). Raf1 signaling in Dectin-1 activation seems to crosstalk with TLR2 and TLR4.
This is not surprising given the fact that Dectin-1 ligands are cooperatively recognized by
TLRs, such as TLR2 and TLR4, due to the complex nature of fungal cell wall
composition.

31

1.2.3: NLRP3 inflammasomes and IL-1
Nucleotide binding oligomerization domain leucine rich repeats receptors (NLRs)
are another family members of PRRs that can sense insults derived from both microbial
and non-microbial origins of PAMPs and DAMPs. NLRs then initiate immune responses
in the intracellular compartments; thus, these receptors are exclusively localized in the
cytosol (Prochnicki et al., 2016; Sutterwala et al., 2014). NLRs consist of a number of
subfamily members, categorized into four main types based on their N-terminal effector
domains (Sutterwala et al., 2014; Ting et al., 2008). These members include NLRP that
contains pyrin domain, CARD that contains caspase activation and recruitment domain,
BIRC that has Baculoviral inhibitory repeats, and the NLR containing an acidic
transactivation domain (Ting et al., 2008). Each NLR family member further consists of
sub-family members, and approximately 22 total members of NLRs have been identified
to date (Sutterwala et al., 2014). Upon receiving signals, which are either cellular stress
and damage or microbial pathogens, the NLR members associate with other
inflammatory proteins and form multiprotein complexes, known as inflammasomes. An
inflammasome is typically composed of NLR or pyrin domain containing proteins, an
adaptor protein called apoptosis associated speck-like protein containing domain (ASC),
and cysteine protease Pro-caspase-1. Inflammasome formation results in the autocatalysis
of caspase-1, which then catalyzes pro IL-1 and pro IL-18 and releases the active forms
of these pro-inflammatory cytokines. Activation of inflammasomes is crucial in
triggering acute inflammatory responses. To date, NLRP1, NLRP3, NLRC4, and AIM2
(absent-in-melanoma 2) have been characterized to form inflammasomes (He et al.;
Lamkanfi and Dixit, 2014; Próchnicki and Latz, 2017; Prochnicki et al., 2016; Sutterwala
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et al., 2014), although some studies have later reported the potential activation of
inflammasomes mediated by NLRP6, NLRP7, and NLRP12 (He et al.; Sutterwala et al.,
2014).
NLRP3 (NLR protein3) is the most studied member among the NLR family.
Activation of NLRP3 inflammasome leads to caspase-1 activation, which results in the
production of active IL-1 and IL-18. Active IL-1 is a highly potent pro-inflammatory
cytokine and serves as one of the earliest inflammatory responses initiated by innate
immune cells, thus playing a crucial role in early anti-microbial recognition and defense.
IL-1 also mediates the release of other cytokines, such as TNF- and IFN- from other
cells. Not only does it recruit innate immune cells, such as macrophages, monocytes, and
neutrophils, but also induces Th1 and Th17 responses of adaptive immunity (Lamkanfi
and Dixit, 2014). Despite the well-known association of IL-1 activation and NLRP3
inflammsomes, IL-1 activation can also be achieved by an NLRP3 inflammasomeindependent manner (Bossaller et al., 2012; Gringhuis et al., 2012).
Because of the potency and strength in amplification of inflammatory responses,
IL-1 is not constitutively expressed but is synthesized as an inactive form. The inactive
form protects this interleukin molecule from inadvertent inflammation initiation, until it
is ready to be released into the extracellular milieu. Lacking a signal sequence (Auron et
al., 1984; Lopez-Castejon and Brough, 2011), IL-1 secretion is distinct from the
canonical protein ER-Golgi secretory pathway. Several mechanisms of IL-1 secretion
have been proposed: exocytosis of secretory lysosomes, exosomes, or autophagosomes,
plasma membrane shedding, and cellular exit through a specialized transporter across the
plasma membrane (Lopez-Castejon and Brough, 2011). Although it is still not exactly
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clear why several different mechanisms exist only to secrete a single cytokine of active
IL-1, it is possible that the types and strengths of stimuli could potentially influence
specific immune mechanisms for this purpose (Lopez-Castejon and Brough, 2011;
Martinon et al., 2002; Netea et al., 2010).
Due to highly potent inflammatory effects of inflammasome components, NLRP3
formation is tightly controlled (Eder, 2009; Lamkanfi and Dixit, 2014; Prochnicki et al.,
2016; Sutterwala et al., 2014). While NLRP3 was thought to be triggered by potassium
efflux, mitochondrial DNA, or reactive oxygen species, several lines of evidence have
indicated the requirement of two signals for NLRP3 inflammasome formation (He et al.;
Lamkanfi and Dixit, 2014; Próchnicki and Latz, 2017; Prochnicki et al., 2016; Sutterwala
et al., 2014). Signal one is known as “priming,” which is essentially a transcriptional
regulatory checkpoint in generating pro IL-1 and pro-caspase-1. This step is mediated by
PAMPs that induce the NF-B dependent pathway via activation of TLRs and NLRs as
well as cytokine receptors, such as IL-1R1 and TNF-R (Lamkanfi and Dixit, 2014;
Sutterwala et al., 2014). Signal two represents “activation,” a process characterized by
the assembly of inflammasome components and caspase-1 activation, resulting in a
release of active IL-1 . Activators for signal two can be both endogenous and exogenous
molecules such as intracellular microbial infections, monosodium urate crystals and alike
(alum and asbestos), toxins such as nigericin, and potassium depleting molecules such as
adenosine triphosphate (ATP) (Sutterwala et al., 2014). Since NLRP3, in its inactive
state, is known to be highly ubiquitinated under normal basal conditions, these activators
then deubiquitinate NLRP3 and subsequently promote the full activation of NLRP3
inflammasomes (Juliana et al., 2012; Lin et al., 2014).
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While the classical outcome of NLRP3 inflammsome formation is caspase-1
activation, along with processing of IL-1 and IL-18 from their inactive forms, active
caspase-1 can also cause pyroptosis, a form of cell death depicted by membrane rupture
and cell swelling. Although caspase-1-mediated pyroptosis is an alternative outcome of a
canonical NLRP3 inflammasome pathway (Qiu et al., 2017; Sutterwala et al., 2014;
Wellington et al., 2014), a non-canonical pathway of NLRP3 inflammasome formation is
mainly carried out via caspase-11, whose activation is achieved by sensing intracellular
LPS or a LPS component (acylated lipid A) and results in pyroptosis as well (Kayagaki et
al., 2013; Yang et al., 2015).
In addition to the aforementioned two-signal tiered regulation of NLRP3
formation, metabolic regulations contributed by both the host and microbes also play a
major role in proper NLRP3 inflammasome-mediated immune responses. With an
emerging interest in cellular metabolic regulation of immune responses, NLRP3
inflammasome activation has been shown to be coupled with an increase in cellular
glycolytic flux (Moon et al., 2015). NLRP3 inflammasome formation can be triggered in
the events of perturbations in metabolic pathways and enzymatic activities. For instance,
inhibition of hexokinase (HK), a major rate-limiting enzyme of glycolysis, by the
bacterial-derived citrate metabolite (Wolf et al., 2016) or N-acetylglucosamine (NAG)containing bacterial peptidoglycan (Spiro, 1958) can induce NLRP3 inflammasome
processing. Studies have reported the induction of inflammasomes by an increased level
of mitochondrial reactive oxygen species (ROS) (Zhou et al., 2010), which has also been
demonstrated to be a product of caspase-1 activation in a NLRP3-independent fashion
(Yu et al., 2014).
35

Although TLR-mediated priming signals for NLRP3 inflammasomes were
extensively studied, only in recent years has significant attention been given to
elucidating the mechanisms of inflammsome activation via other PRRs, particularly
Dectin-1 activation (Cheng et al., 2011; Gross et al., 2009; Hise et al.; Kankkunen et al.,
2010) in response to fungal pathogens. There is also an emerging interest in how cellular
metabolism is implicated in this process. This dissertation will discuss the metabolic
regulation of NLRP3 inflamasome activation mediated by Dectin-1 recognition of fungal
ligand.

1.3. Metabolism overview
Metabolism in eukaryotic cells is categorized into catabolism and anabolism, in
which biomolecules, such as carbohydrates, fatty acids, amino acids, and nucleic acids,
are broken down and synthesized, respectively. While the catabolism-driven generation
of energy, mostly in the form of ATP, is essential, the need to generate metabolic
intermediates for molecular building blocks renders cellular metabolism a core regulator
of cellular function and homeostasis. Metabolic pathways are orchestrated by a series of
enzymatic reactions, with one or more regulatory (rate-limiting) enzymes serving as a
check-point for many of those pathways. Metabolic reactions are highly regulated at both
cellular and systemic levels, in response to the cues from cell-cell interactions and
external stimuli, thus adding complexity to various metabolic networks. Therefore, the
intricately interconnected and redundant metabolic networks allow for rapid cellular
adaptation to environmental insults, such as metabolic pathway inhibition or nutrient
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deprivation. This dissertation discusses the metabolic changes in immune cells,
particularly myeloid cells, in response to infectious stimuli.
Major metabolic pathways include, glycolysis, the citric acid (TCA) cycle and
oxidative phosphorylation, pentose phosphate pathway (PPP) or hexose monophosphate
shunt, glycogen metabolism, fatty acid synthesis and degradation, and nucleotide
synthesis. Glucose is a fundamental carbon source for rapid energy production and is
primarily broken down via glycolysis, which yields 2 net ATP molecules. The end
product of glycolysis, pyruvate, enters the TCA cycle and mitochondria for a complete
oxidation of carbons, with a higher yield of 32 net ATPs. Pyruvate enters the TCA cycle
after being converted to acetyl co-A in the cytoplasm or oxaloacetate (OAA) in
mitochondria. Under certain conditions, such as limited oxygen supply, pyruvate is
reduced to lactate, a condition well-known as anaerobic glycolysis in bacterial and yeast
carbohydrate metabolism (Voet et al., 2013). Since ATP is not the only form of cellular
energy, cells can also obtain NADPH via the PPP, an alternative pathway to glycolysis.
Glucose-6-phosphate (G6P), liberated from glucose by the rate-limiting enzyme
hexokinase, enters the PPP, one of the crucial anabolic pathways entirely responsible to
generate not only NADPH, used for a number of anabolic processes such as fatty acid
synthesis, but also ribose-5-phosphate for nucleic acid building blocks (Voet et al., 2013).
Another potential fate of glucose is glycogen metabolism, in which excess cellular
glucose is converted to glycogen for storage, which is then later utilized based on the
physiological needs of the cell (Dashty, 2013; Schwartz, 1976). Details of glycogen
metabolism will be extensively discussed later in this chapter. Additionally, G6P and
pyruvate are considered key intermediates of glucose metabolism; the metabolic flux of
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these molecules is one of the main focuses of this dissertation. While glycolysis,
glycogen metabolism, and PPP occur in the cytosol, the TCA cycle operates in
conjunction with electron transport chain/oxidative respiration in mitochondria.
From the perspective of cellular energy generation, fatty acid oxidation provides
the highest energy yield to support ATP-dependent anabolic reactions and physiological
processes. Each round of fatty acid -oxidation results in acetyl-CoA, which is further
oxidized in the TCA cycle electron transport chain, resulting in an extremely large
amount of energy output. For instance, an approximate net total of ~106 ATP is
generated from oxidation of one molecule of palmitate. Unlike -oxidation, fatty acid
synthesis occurs in the cytosol. The starting material acetyl-CoA, generated from
mitochondria, is transported across the mitochondrial membrane in the form of citrate,
which is then converted back to acetyl-CoA. While the fatty acid synthesis process is
generally considered to be energy consuming, this pathway plays a crucial role in
immune cell activation responses to infectious stimuli, which is discussed in great detail
in the following subsection.
Amino acids are building blocks of a number of compounds such as proteins,
polypeptides, and other biomolecules, such as cytokines, chemokines, and several
inflammatory mediators. Besides the essential amino acids that are obtained from the
diet, a number of glycolytic and the TCA cycle intermediates generate amino acids
required for basal cellular functions. For instance, alanine can be generated from
pyruvate, -KG (keto-glutarate) from the TCA cycle can be converted to glutamate,
which can also be converted to glutamine. It has been widely known that glutamine, in
addition to glucose, is a primary fuel source among other amino acids for rapidly
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proliferating and metabolically active cells, such as tumor cells and lymphocytes (Everts
and Pearce, 2014; Galván-Peña and O’Neill, 2014; Matarese et al., 2014; Newsholme and
Newsholme, 1989; Norata et al., 2015; Pavlova and Thompson, 2016; Pearce and Pearce,
2013; Saeed et al., 2014; Warburg et al., 1927).

1.3.1 Metabolic reprogramming in cancer and immune cells
The idea of cellular metabolic reprogramming was introduced in tumor cells by a
German physiologist Otto Warburg, who demonstrated that cancer cells “ferment”
glucose and heavily depend on glycolysis even in the presence of abundant oxygen in the
circulation. Cancer cells are rapidly proliferating cells with an increasing demand of
energy and metabolic substrates. From an energy standpoint, glycolysis is not
energetically efficient compared to mitochondrial respiration. Yet, cancer cells are more
dependent on glycolysis than non-transformed cells, which Warburg proposed was due to
the impairment of the mitochondrial respiratory chain (Warburg, 1956; Warburg et al.,
1927). However, this fact has been proven otherwise in most recent studies (PalssonMcDermott and O'Neill, 2013; Warburg, 1956). While the breakdown of glucose is
generally considered as a catabolic process, an increase rate of glycolysis in these cancer
cells serves to support anaplerosis, whereby metabolic intermediates are generated for
biosynthetic materials required during cell proliferation (Palsson-McDermott and O'Neill,
2013).
The study of metabolism in immune cells dates back to the early 1910’s, when
Meyer and Lepine demonstrated the formation of two three-carbon sugars from glucose
molecules in dog leukocytes (Levene and Meyer, 1912). It was in the 1920’s when Otto
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Warburg introduced the idea of a metabolic switch in cancer cells, that a link between
leukocyte and cancer metabolism was established by two seminal findings of the Dutch
and German scientists, who demonstrated a reduced rate of aerobic respiration and an
increase in glycolysis in white blood cells isolated from exudates (Nagy and Haschemi,
2015). Due to technical disadvantages in isolating pure leukocyte populations and
challenges in metabolism assays, metabolic studies in immune cells were not prioritized
until a recent reemergence in the past few decades.
The first study on peripheral blood monocytes and polymorphonuclear
phagocytes defined the cellular needs for active glycolysis in support of the immediate
energy demand during an initial phase of phagocytosis, followed by a later phagocytic
stage in which the cells uptake more oxygen via aerobic respiration (Sbarra and
Karnovsky, 1959). Unlike lymphocytes and other myeloid cells, neutrophils are
dependent almost exclusively on glycolysis due to a relatively small number of
mitochondria (Fossati et al., 2003; Maianski et al., 2004; Rodriguez-Espinosa et al.,
2015). Recent studies also showed that neutrophils undergo two different metabolic
phases for neutrophil extracellular trap (NET) formation, in which the early stage does
not require exogenous glucose whereas extracellular glucose serves as a major fuel
source to drive the later phase (Rodriguez-Espinosa et al., 2015).

1.3.1.1 Metabolic reprogramming in macrophages
A link between the metabolism and immune responses in macrophages was
demonstrated by the pioneering work of Hard in the late 1960’s, which showed that
activated macrophages consume low oxygen and depend on glycolysis (Hard, 1970).
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After two decades, macrophage utilization of major nutrient sources and intermediary
metabolites, such as glucose, glutamine, ketone bodies, and fatty acids, were thoroughly
investigated by Newsholme (Newsholme et al., 1986). Consistent with the earlier
findings of Hard and Cline, Newsholme’s studies showed an increased glycolytic activity
in macrophages upon activation. However, his work also showed that the Kreb’s cycle in
these macrophages is fueled mostly by glutamine, but very little by glucose, suggesting
that OXPHOS is still functional in order to generate energy. His work also showed an
increased phospholipid turnover, indicating the membrane recycling and biogenesis
occurs during the activation process (Newsholme et al., 1986; Newsholme and
Newsholme, 1989). It was not until a few years later that the differential metabolism
between two populations of macrophages, namely M1 and M2, was discovered. Although
originally recognized by their different responses to Th1 and Th2 cytokines, IFN- and
IL-4/IL-13 respectively, these two types of macrophages can be metabolically
discriminated based on their differential arginine utilization.
Classically activated (IFN- activation) or LPS-activated M1 macrophages
upregulate iNOS, which breaks down arginine to citrulline and nitric oxide (NO),
whereas alternatively activated (IL-4/IL-13 activation) M2 macrophages upregulate
arginase 1 to produce urea, polyamines, and ornithine from arginine (Corraliza et al.,
1995). Subsequent studies have reported that pro-inflammatory M1 macrophages depend
on aerobic glycolysis and produce reactive oxygen species and NO, with very little
mitochondrial activity. On the other hand, M2 macrophages, primarily considered to be
involved in the resolution stage of inflammation, possess highly active mitochondrial
OXPHOS function (Galván-Peña and O’Neill, 2014).
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Identification of these two macrophage subsets has driven the field to
meticulously analyze metabolic phenotypes between the two populations. Indeed, the
glycolytic activity of M1 macrophages activated with LPS is different than that of M1
macrophages stimulated with IFN- (Galván-Peña and O’Neill, 2014; Tavakoli et al.,
2013), due to the fact that LPS-activated macrophages have a higher expression of Glut1
and hexokinase 2 (HK2) as opposed to IFN- stimulated counterparts (Kelly and O'Neill,
2015; Rodriguez et al., 2017). These findings suggest differences in metabolic profiles in
response to distinct stimuli. Regardless of activation of LPS and/or IFN-, proinflammatory M1 macrophages actively engage in the pentose phosphate pathway (PPP),
a phenomenon not observed in M2 macrophages. This is essential for generating NADPH
for the production of ROS and NO by M1 macrophages (Nagy and Haschemi, 2015).
Instead, M2 macrophages down-regulate glycolysis and fully engage in OXPHOS. A
common characteristic of M1 and M2 macrophages is that glucose still fuels both cell
types although the Krebs cycle is disrupted in M1 macrophages, termed as TCA cycle
break (Van den Bossche et al., 2017). This break occurs after citrate and succinate
generation. The first break causes an accumulation of citrate (Jha et al., 2015), which is
funneled towards fatty acid synthesis, essential in membrane biogenesis and
prostaglandin formation. Citrate also supports the production of NO (Infantino et al.,
2011; O'Neill, 2011) and itaconic acid, a metabolite newly discovered to be generated by
immune response gene-1 (Irg-1) (Michelucci et al., 2013; Strelko et al., 2011) believed to
possess anti-microbial activities (Michelucci et al., 2013; Naujoks et al., 2016). The
second break is at succinate dehydrogenase enzyme leading to an accumulation of
succinate (Lampropoulou et al., 2016), which acts as a metabolite sensor in inducing
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hypoxia inducible factor-1 (HIF-1) and formation of IL-1 in acute inflammatory
responses to infection (Tannahill et al., 2013).
However, in M2 macrophages, the Krebs’ cycle is completely intact, most likely
due to the fact that these cells are heavily dependent on oxidative metabolism, which is
shown to be supported by a combination of glucose, fatty acid oxidation, and glutamine.
In contrast to M1 that favors fatty acid synthesis for inflammatory responses, M2
macrophages rely on fatty acid oxidation (FAO), which in turn is driven by fatty acid
synthesis (FAS), a paradoxical nature of fatty acid metabolism in M2 macrophages most
likely to support their longevity and tissue repair after the inflammatory phase (Everts et
al., 2014; Galván-Peña and O’Neill, 2014; Huang et al., 2014; Odegaard and Chawla,
2011; Vats et al., 2006). FAO, however, plays a role in driving M2 polarization via
activation of mammalian (mechanistic) target of rapamycin complex 2 (mTORC2) (Arts
et al., 2016). Additionally, the TCA cycle in M2 macrophages is indirectly fueled by
glutamine (Jha et al., 2015), a finding consistent with the pioneering study of
Newsholme, who had defined the metabolite utilization in macrophages even before the
characterization of M1 and M2 population was established (Newsholme et al., 1986;
Newsholme and Newsholme, 1989). An illustrated summary of metabolic pathway
utilization in M1 versus M2 macrophages is shown below (Figure 1 -2).
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Figure 1 -2. Metabolic pathways utilized by M1 and M2 macrophages.
(Adapted from Kelly and O’Neill, 2015 (Kelly and O'Neill, 2015))

1.3.1.2: Metabolic reprogramming in dendritic cells
Like macrophages, the metabolic status of DCs is highly regulated by immune
activation conditions. Naïve or resting DCs have relatively little metabolic demands and
generally undergo catabolic pathways, such as breaking down proteins and
triacylglycerol to generate ATP via OXPHOS from mitochondria. In naïve DCs, glucose
enters OXPHOS for complete oxidation. They also engage in FAO to support OXPHOS
(Deberardinis et al., 2006). On the other hand, citrate generated by these cells is exported
via citrate carriers across mitochondria into cytoplasm to convert to acetyl-CoA for use in
FAS, which is then rapidly utilized in FAO, a phenomenon observed in macrophages
(Everts and Pearce, 2014; Maroof et al., 2005; Pearce and Everts, 2015).
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Activation of DCs by TLR agonists induces the cells to rapidly undergo a process
called maturation characterized by upregulation of the expression of molecules essential
for maturation responses, increased secretion of cytokines and chemokines, and migration
to secondary lymphoid organs and ultimately presenting antigens to T cells (Banchereau
and Steinman, 1998b; Steinman, 2001, 2012; Steinman and Banchereau, 2007; Steinman
and Hemmi, 2006). In order to fulfill this anabolically demanding maturation process,
activated DCs experience rapid metabolic changes, known as metabolic reprogramming
(Everts et al., 2014; Krawczyk et al., 2010).
Similar to the Warburg’s effects in cancer cell metabolism, activated DCs undergo a
metabolic switch towards a rapid increase in glycolytic rate, a phenomenon termed
“glycolytic burst” (Everts et al., 2014; Krawczyk et al., 2010). Instead of pyruvate then
entering OXPHOS as is seen in resting DCs, a great portion of the pyruvate generated in
activated DCs is converted to lactate, allowing the regeneration of NAD+ from this
reaction to allow the cells to turn over NADH for ATP production via glycolytic burst.
This glycolytic reprogramming occurs in two waves (Thwe and Amiel, 2018): an
increased glycolytic flux at an early phase of activation (Everts et al., 2014) followed by
a sustained glycolysis characterized by fundamental metabolic changes in a late
activation stage (Krawczyk et al., 2010). The underlying cause of the two distinct
metabolic changes is discovered to be due to an upregulation of inducible nitric oxide
synthase (iNOS) that generates nitric oxide (NO), a cytotoxic molecule implicated in a
number of physiological functions. An extensive detail on iNOS and NO is discussed in a
later section.
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Acute glycolytic burst during early activation is coupled with a transient increase in
mitochondrial activity as evidenced by increased mitochondrial potentials and spare
respiratory capacity (Everts et al., 2014; Pearce and Everts, 2015). Despite the fact that
most pyruvate is shunted towards an increased formation of lactate, the increased
glycolytic flux at this early stage seems to fuel the TCA cycle for a purpose other than
generating ATP from that reaction, particularly to support the generation of TCA cycle
intermediates for downstream activation processes. Evert et al elegantly demonstrated
that citrate generated from the TCA cycle, driven by glycolytic flux, is transported across
mitochondrial membranes into the cytosol for de novo fatty acid synthesis. Fatty acid
generated from this step is believed to fulfill the need of biomass expansion in
endoplasmic reticulum and Golgi organelles for increased synthesis of proteins and
cytokines during the maturation process. Interrupting this process at any stage
tremendously impairs the immune effector function of activated DCs (Everts et al.,
2014). Because both the inflammatory BMDCs as well as monocyte-derived DCs share
similar phenotypes with M1 macrophages, it is plausible to consider that the abovementioned citrate production in DCs could represent a TCA cycle break seen in M1
macrophages. This remains an open question in the field of DC immuno-metabolism. Of
note, DCs shift their fatty acid metabolism from the resting condition by suppressing
FAO once the cells become activated by TLR agonists (Krawczyk et al., 2010). While a
lot of studies have been reported on carbohydrate metabolism and fatty acid utilization in
activated DCs, little is known about their amino acid metabolism. Although the role of
glutamine is well-highlighted to be essential for rapidly proliferating cancer cells and
lymphocytes as well as for supporting macrophage activation, its implication in DC
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effector function needs to be investigated. Whether or not glutamine serves as a major
amino acid source to generate NO in activated DCs is yet to be fully examined. A
complete illustration of metabolic pathway utilization in activated DCs is portrayed
below in Figure 1 -3.

Figure 1 -3. Glycolytic reprogramming in dendritic cells activated via a TLR.
(Adapted from O’Neil 2014 (O'Neill, 2014))

1.3.2: Epigenetic modification during metabolic reprogramming
Epigenetic modification is defined as changes in the gene expression and
activities, without any changes in DNA sequences. Transcriptional accessibility to the
genome by histone modification is mediated by acetylation/deacetylation, methylation,
and SUMO-ylation of histones, and all these alterations are considered post-translational
changes. In general, histone acetylation allows increased gene exposures to DNA binding
proteins and factors, leading to transcriptional upregulation and changes in downstream
cellular functions, whereas histone deacetylation leads to gene repression. On the other
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hand, histone methylation can cause activation or repression of gene expression
depending on the sites of modification and the number of methyl groups added to
histones (Alvarez-Errico et al., 2015; Kimura, 2013).
Post-translational modification of proteins and metabolic enzymes, such as
pyruvate kinase M2 (PKM2) isoform and peroxisome proliferator-activated-receptor 
(PPAR-) co-activator 1 (PGC-1), by acetylation or methylation have been reported to
alter metabolic pathways and cellular functions. For example, acetylation of PKM2
induces the accumulation of glycolytic intermediates, leading to uncontrolled tumor
growth and poor cancer prognosis (Lv et al., 2011; Palsson-McDermott and O'Neill,
2013). In immune cells, these alterations can be triggered by a number of factors,
including metabolites and metabolic changes occurring during immune reactions, which
can cause consequent impacts on immune effector functions. Citrate generated from
activated DCs and macrophages provides a great source of acetyl-CoA, which is believed
to be further implicated in direct acetylation of histone molecules or of metabolic
enzymes. A recent study on bone marrow-derived macrophages (BMDM) demonstrated a
correlation between histone acetylation and an increased IL-6 expression in BMDMs
treated with histone deacetylase (HDAC) inhibitors (Hu et al., 2016). In another example,
increased expression of interferon gamma (IFN-) upon histone acetylation in activated
CD4 T cells is driven by acetyl-coA turnover from glycolytic reprogramming in these
cells (Peng et al., 2016). Metabolites such as lactate, although generally considered as a
by-product, have also been reported to inhibit HDAC, thus promoting HDAC related
gene expression in cancer cells (Latham et al., 2012). On the other hand, a few studies
have also revealed the effect of deacetylation by a protein called Sirtuin on modulation of
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DC effector function, such as cytokine release and the regulation of TH17 differentiation
(Alvarez et al., 2012; Dominy et al., 2010; Yang et al., 2013). Besides acetylation and
deacetylation reactions, increased di-methylation of histones in DCs and macrophages
has been shown to induce the gene transcription as well as production of type I
interferons in viral infections, eventually resulting in viral resistance (Fang et al., 2012a;
Pearce and Everts, 2015; Saeed et al., 2014). These findings have highlighted that the
immuno-metabolic activities of immune cells are implicated by another complex level of
regulation by epigenetic changes.
The importance of epigenetic regulation in triggering trained innate immunity is
highlighted by the work of Neetea, who elegantly demonstrated a link between metabolic
reprogramming and epigenetic regulation to elicit “innate memory” in human monocytes
(Cheng et al., 2014). Specifically, immune effector genes downstream of a canonical
metabolic sensor, mTOR are highly methylated and acetylated in monocytes that are
“trained,” whereby these cells are initially primed with fungal pathogens, and
subsequently and repeatedly challenged with the similar pathogen, to induce innate
immune memory. These epigenetic changes are coupled with metabolic reprogramming,
characterized by a metabolic switch that supports the survival of trained monocytes and
their defense against infections (Cheng et al., 2014). Notably, recent studies have
demonstrated that the TCA cycle intermediate fumarate, which is derived from an
integrated effort of glycolysis, Kreb’s cycle, and glutaminolysis, induces tri-methylation
or di-methylation (Fang et al., 2012a) and acetylation of histones in monocytes, and that
inhibition of this process impairs the metabolic and immune phenotypes in these cells
(Arts et al., 2016; Fang et al., 2012b).
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The fact that epigenetic modifications of innate immune cells induce a powerful
impact on the immune responses along with metabolic regulation suggests a complex
interaction of immuno-metabolic changes under epigenetic controls. A great body of
work has demonstrated that post-translational modification of histones in immuneresponse related genes can regulate immune cell function. The link between metabolic
regulation and epigenetic changes in immune cells has only recently gained interest in the
field of immuno-metabolism and is a major area for future work.

1.4: Glycogen Metabolism
1.4.1: Overview of glycogen metabolism and regulation
Glycogen, a primary storage form of glucose in our body, is a highly complex
polymer of glucose formed by -1,6 glycosidic linkages at branch points and -1,4
glycosidic long chains. As glucose is a fundamental energy source of living organisms,
glycogen serves as an energy reservoir to provide a constant glucose supply (AdevaAndany et al., 2016; Dashty, 2013; Roach, 2002). Cells such as neurons, muscle, and red
blood cells are almost exclusively dependent on glucose for their primary fuel source;
hence, glycogen metabolism is very active in these tissues (Voet et al., 2013). Disorders
in glycogen metabolism were first described by McArdle as glycogen storage diseases, in
which inherited defects in glycogen metabolic enzymes result in impaired glycogen
breakdown that tremendously impact the energy metabolism and cellular functions in
metabolically active tissues (Mc, 1951).
Glycogen metabolism is comprised of glycogen synthesis and breakdown
pathways. Both pathways are synchronously orchestrated by a number of enzymes
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localized in the cytoplasm. The synthesis of glycogen is initiated by a linkage of 4 UDP(uridine 5’-diphosphate) glucose, formed by the help of phosphoglucomuase-1 from
glucose-1 phosphate (G1P), which is converted from glucose-6-phosphate (G6P) derived
from glucose that enters the cells via glucose transporters (Adeva-Andany et al., 2016).
The initial glycosidic linkages are initiated by glycogenin, followed by elongation and
branching of the polymer with the help of glycogen synthase (GYS), which is the rate
limiting enzyme of the synthesis pathway, and branching enzyme. On the other hand,
catabolism of glycogen happens in both cytoplasm and lysosomes. In the cytoplasm,
glycogen phosphorylase (PYG), the rate limiting enzyme of the degradation pathway,
releases G1P from 1,4-glycosidic linkage, and debranching enzyme catalyzes the
branch point 1,6-glycosidic chains. G1P released from the glycogen polymer is then
converted back to G6P, which in the liver is dephosphorylated in the endoplasmic
reticulum by glucose-6-phosphatase; therefore, free glucose can be exported out of the
cells by glucose transporters. Other tissues, however, do not express glucose-6phosphatase and recycle the released G6P molecules for their cell-intrinsic utilization
(Adeva-Andany et al., 2016; Roach, 2002; Roach et al., 2012). Glycogen breakdown also
occurs in lysosomes where lysosomal -glucosidase (acid maltase) catalyzes -1,4
glycosidic linkages of glycogen (Adeva-Andany et al., 2016; Roach et al., 2012;
Rosenfeld, 1975). The rate limiting enzymes of these two pathways exist in different
isoforms based on the tissue distribution. Specifically, PYG exists in 3 isoforms: liver
(PYGL), muscle (PYGM), and brain (PYGB or GPBB). Synthase, however, is expressed
as GYS1, which is expressed in muscles and all other tissues except the liver, and GYS2,
whose expression is restricted to the liver.
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As both glycogenesis and glycogenolysis are high-energy metabolic processes
and simultaneous reactions could be considered energetically wasteful based on
unnecessary hydrolysis of UTP, several mechanisms are at play to tightly regulate these
two pathways, particularly by reciprocal regulations of glycogen breakdown and
synthesis. Early studies on glycogen regulatory mechanisms showed that covalent
phosphorylation reactions of rate-limiting enzymes allowed them to be either in an active
or inactive state based on their phosphorylation status (Roach, 2002; Roach et al., 2012;
Wilson et al., 2010). Specifically, phosphorylated PYG, termed “phosphorylase a”, is an
active form of the enzyme, whereas phosphorylated glycogen synthase is an inactive
form. Activities of these two key enzymes are again modulated by a number of proteins
by which phosphorylation of one enzyme leads to a cascade of phosphorylation events.
The downstream activation/inactivation of these key enzymes via post-translational
phosphorylation is believed to be under the control of hormones such as insulin and
adrenaline (Voet et al., 2013).
The correlation established between the hormonal regulation and the structural
conformation/functional activities of the key glycogen enzymes in the early studies led to
many seminal discoveries about phosphoprotein phosphatases and kinases (Carlson et al.,
2018) that are directly implicated in the glycogen metabolic pathways via receptor- and
messenger-mediated regulatory mechanisms (Carlson et al., 2018; Dashty, 2013). PYG
activity is directly modulated by phosphorylase kinase, which in turn is activated by
protein kinase A, a master regulatory protein of many signaling pathways.
Dephosphorylation of PYG by protein phosphatase-1 (PP1) leads to inactivation of PYG,
especially due to insulin-induced inactivation of phosphorylase kinase when the
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circulating glucose levels are high. Phosphorylase activity is usually increased in
fight/flight conditions by the influence of hormones, such as glucagon and adrenaline. A
release of these hormones increases the levels of cyclic AMP, which in turn induces the
activity of PKA, ultimately leads to a cascade of phosphorylation events (Voet et al.,
2013). In contrast to the regulatory mechanisms of PYG, those of GYS are more complex
and involve more than phosphorylation-dephosphorylation of enzymes. PP1 also plays an
active role in synthesis by modulating the activity of glycogen targeting regulatory
subunit called RGL, which in turn regulates PP1 activity. Interestingly, one of the
mechanisms proposed in the field is a proportional increase in glucose transporter
(GLUT) expression with a rise in blood glucose levels, leading to intracellular glycogen
accumulation (Hansen et al., 1995; Kim et al., 2005; Ren et al., 1993; Rossetti et al.,
1997). Additionally, two major players of cellular nutrient and metabolic homeostasis,
AMPK, a key energy sensor protein kinase, and glycogen synthase kinase 3, GSK3, a
master regulator of many signaling events, are also involved in the regulation of glycogen
synthesis. Although insulin-induced inactivation of GSK3 by dephosphorylation in the
liver is proposed to modulate glycogen synthesis (Roach, 2002; Voet et al., 2013), further
elucidation is necessary to better understand GSK3 mediated mechanisms in a cellspecific manner. On the other hand, AMPK has long been demonstrated to be involved in
energy metabolism, including glycogen metabolism (Roach, 2002; Roach et al., 2012).
Another form of regulatory mechanism is allosteric control of enzymes by
metabolites, such as AMP, ATP, glucose, and G6P. Depending on the energy status of
the cells, these allosteric molecules regulate the activities of the rate limiting enzymes via
positive or negative feedback mechanisms. For instance, when there is a need for ATP
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during low energy statuses (i.e., high AMP and low ATP), glycogen synthesis is inhibited
but degradation is promoted. In this case, PYG is allosterically activated by AMP but
inhibited by ATP (Roach, 2002; Roach et al., 2012). The complex interrelation between
the allosteric modulation and protein kinase phosphorylation can be under hormonal or
non-hormonal controls that may also involve regulation at the transcriptional level.
When discovered in the early 1900’s, glycogen synthesis and degradation was
initially thought to occur only in the cytoplasm. Interestingly, an accumulating body of
work has strongly suggested a distinctive spatial occurrence of glycogen metabolism in a
sub-cellular level (Baker et al., 2005; Fernandez-Novell et al., 1994; Fernandez-Novell et
al., 1992; Fernandez-Novell et al., 1996; Garcia-Rocha et al., 2001; Wilson et al., 2010;
Wilson et al., 2002). The findings in both liver and muscular systems unanimously agree
that glycogen synthase is dispersed throughout the cells under various metabolic
conditions. For instance, in hepatocytes, the insulin-induced blood glucose rise initiates
the translocation of GYS to the cellular periphery, a location proximal to the membrane,
and this is identified by a cluster of newly synthesized glycogen pools along with
translocated GYS (Fernandez-Novell et al., 1994; Fernandez-Novell et al., 1992;
Fernandez-Novell et al., 1996; Garcia-Rocha et al., 2001). A similar phenomenon has
also been observed in muscle glycogen metabolism and has become broadly recognized
as “compartmentalization” (Prats et al., 2005; Prats et al., 2011; Prats et al., 2009). While
these studies were performed almost exclusively on GYS, the subcellular localization of
phosphorylase enzyme has so far been investigated in yeasts (Wilson et al., 2010). As the
differential localization of glycogen particles is found in a structure resembling vacuoles,
the term “glycosome” (Parsons, 2004) has been coined in parasite metabolism (Rybicka,
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1996). While the studies on Tryponosoma parasites mentioned that the composition of
these glycosomes is not restricted to glycogen enzymes (Michels et al., 2006; Parsons,
2004), other schools of thought highlighted the exclusive role of glycogen in those
specialized organelles (Rybicka, 1996). Another interesting fact is that vacuoles in yeast
cells provide a specialized environment for glycogen storage (Roach et al., 1998; Wilson
et al., 2010; Wilson et al., 2002). In animals, cellular autophagy plays a crucial role under
nutrient-limited circumstances, in which autophagosomes fuse with intracellular
vacuoles. Whether or not the above-mentioned glycosomal vacuoles are directly related
to cellular autophagy in mammals raises an interesting question of the roles of these
vacuoles and the purpose of compartmentalization of glycogen metabolism in cellular
function. Nonetheless, these findings suggest a role for glycogen as more than a storage
molecule and potentially indicate the parallel existence of glycogen degradation pathway
compartmentalized away from synthesis, an interesting metabolic behavior known to be
observed in neuronal and astrocyte biology that is later touched upon in this dissertation.
The studies of glycogen metabolism and its regulation in several species and a
number of organ/systems can be dated back to as early as the 1900’s (Young, 1957a, b).
However, due to the existence of different isoforms of enzymes involved in the glycogen
metabolic pathways, recent studies have newly identified distinct functional and
regulatory mechanisms at a subcellular level of several different tissues and systems.
These observations, indeed, alert the scientific community for the needs for more work to
better understand the exact role(s) of glycogen, its metabolism, and regulation in the
systems that have been previously overlooked in the past.
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1.4.1 Glycogen metabolism in Skeletal Muscles, Astrocytes, and Neurons
In addition to the liver glycogen metabolism, skeletal muscles and the brain are
two other major sites of active glycogen storage and metabolism. Skeletal muscle is wellknown to possess a large pool of glycogen stores in support of continuous muscular
contractile activities. Muscle cells actively engage in anaerobic glycolysis and
glycogenolysis for a rapid turnover of glucose and ATP. Similar to the skeletal muscle
system, the energy demand of the mammalian brain is immensely high and is fulfilled
primarily by glucose as the main fuel source. Glucose is also required for generation of
substrates, such as glutamate for neurotransmitter synthesis. Although the brain can use
ketones and lactate under particular circumstances, glucose functions as an indispensable
nutrient source. Hence, glycogen serves as the largest energy reserve in the brain. Both
tissues express GYS1 and tissue specific isozymes of glycogen phosphorylase, namely
PYGM in muscles and PYGB in the brain. Unlike the liver, the muscle and brain cells do
not express glucose-6-phosphatase; therefore, individual glucose molecules released from
these tissues are contributed towards their own metabolic needs and physiological
functions (Dashty, 2013). Regardless of differential isoform expressions of
glycogenolysis pathway, this subsection highlights a few interesting glycogen metabolic
characteristics shared by both systems.
The utilization of glycogen metabolism in the skeletal muscles depends on
muscular activities. Under resting or non-exercising conditions and the fed state, the
intracellular glycogen level increases and glycogen breakdown is inactive. However,
glycogen breakdown is initiated and muscular glycogen level is depleted rapidly after
medium to strenuous muscular activities. Interestingly, prolonged exercise reverts the
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glycogen level to a much higher content, coupling with a phenomenon termed
supercompensation, in which intracellular glycogen depletion is compensated with an
increased glycolytic activity (Nielsen et al., 2011; Prats et al., 2009). It is not clearly
understood why and how these cells accumulate more glycogen than even before the
energetic crisis in these cells. A potential mechanism is intracellular
compartmentalization in muscle cells (Prats et al., 2005; Prats et al., 2011; Prats et al.,
2009) that allows them to engage in parallel metabolic pathways of spatially defined
domains. Skeletal muscle undergoes actin cytoskeletal filament rearrangements after
exercise-induced glycogen depletion, resulting in the formation of distinct intracellular
compartments harboring glycogen resynthesis processes (Prats et al., 2005; Prats et al.,
2011; Prats et al., 2009). The idea of compartmentalization is closely related to a
phenomenon termed “glycogen shunt”, which refers to a continuous sequence of
synthesizing and simultaneous breakdown of glycogen regardless of abundant glucose in
the cellular microenvironment (Shulman et al., 2001; Shulman and Rothman, 2001).
While the glycogen shunt could be beneficial for millisecond muscular contractions by
sustaining required energy, the drawback is an excessive generation of lactate that
eventually results in muscle fatigue (Shulman and Rothman, 2001). Nevertheless, the
exact purpose and regulatory mechanisms of interrelation between compartmentation and
glycogen shunt are not clearly understood.
Astrocytes contain a comparatively larger quantity of glycogen than neurons,
although both cell types actively utilize glycogen metabolism for their functions (Hertz et
al., 2007). The fact that glycogenolysis still occurs in the brain even in the presence of
sufficient glucose strongly indicates the role of glycogen as more than a reservoir of
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energy storage (Brown et al., 2005; Brown et al., 2003a; Schousboe et al., 2010;
Swanson, 1992). Similar to skeletal muscle glycogen metabolism, glycogen shunt activity
is also observed in neurons and astrocytes (Shulman et al., 2001; Shulman and Rothman,
2001). While there are controversial reports on whether or not the glycogen shunt is
beneficial in light of short-term energy production (Obel et al., 2012), neuronal and
astrocytic cells could still take advantage of the glycogen turnover for glutamate
synthesis. Glutamate released from neurons to neuron-astrocytic synapses is taken up by
astrocytes, which then convert glutamate to glutamine via the glutamate-glutamine cycle.
Clearance of glutamate from these synapses is crucial for proper action potential
propagations (Hertz et al., 2007; Schousboe et al., 2010). Because the transport of
glutamate across the blood brain barrier and into the neurons is not as efficient as
glucose, the cells normally depend on glycolysis and glycogenolysis to generate
glutamate (Brown et al., 2005; Hertz, 2004; Hertz and Dienel, 2002; Rogers et al., 2005;
Sickmann et al., 2012). On this account, the glycogen shunt is proposed to serve this
purpose (Kreft et al., 2012), subsequently enhancing the rapid action potential firings
upon neuronal stimulation. The net ATP generated from a long-term cyclical turnover of
glycogen is also proposed to drive glutamate transporters (Walls et al., 2009). Although
functionally different, pioneering studies on the glycogen shunt and intracellular
compartmentation both in the brain and skeletal muscle systems underscore the complex
role of glycogen in fundamental homeostasis of cellular metabolic activities.
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1.4.2 Glycogen metabolism in cancer cells
Because cancer cells shift their metabolism to glycolysis, it is not surprising that
glycogen is also involved in cancer cell biology. The implication of glycogen metabolism
in certain cancer cells was examined as early as in the 1960’s. Earlier studies discovered
an accumulation of glycogen and increased glycogen synthesis in tumor and malignant
cells, particularly during the active phase of cell cycle (Huang et al., 1978; Rousset et al.,
1979; Rousset et al., 1981). Increased glycogen storage in actively proliferating cancer
cells is believed to be due to a survival mechanism in low glucose conditions (Pelletier et
al., 2012; Pescador et al., 2010), and such accumulation is found to be induced in hypoxic
environments, via hypoxia-induicble-factor-1 (HIF1-) (Favaro et al., 2012; Iida et al.,
2012; Pelletier et al., 2012; Pescador et al., 2010; Zois et al., 2014). One of the most
interesting findings from a recent study is that cancer cells display a temporal change in
glycogen metabolism under hypoxic conditions. Upon acute exposure to hypoxia, cancer
cells upregulate the transcription and translation of both GYS1 and PYGL, a
phenomenon similar to the “glycogen shunt” described in the brain and skeletal muscles,
with a subsequent accumulation of glycogen levels. A prolonged exposure of low oxygen
levels causes a decrease in GYS1 activity, along with a gradual increase in PYG,
resulting in a net breakdown of glycogen in cancer cells. Disruption of glycogen
breakdown by blocking PYGL with pharmacologic or genetic means increases the
cellular glycogen content and induces cell senescence (Favaro et al., 2012). This biphasic phenotype of temporal changes in glycogen metabolism sheds some light into why
cancer cells store glycogen. Intriguingly, the glycogen shunt observed in cancer cells
potentially serves as a homeostatic mechanism involving glycolysis, pentose phosphate
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pathway, and gluconeogenesis by maintaining G6P and other glycolytic intermediates
(Shulman and Rothman, 2017).

1.4.3 Glycogen metabolism in immune cells
Since the discovery of glycogen in the liver by Claude Bernard in the 1850’s
(Young, 1957b) preceeded by the establishment of glycogen metabolism in other tissues
such as muscles and the brain, the presence of glycogen in immune cells was not
examined until 1925 (Gibb and Stowell, 1949). The earliest studies identified glycogen as
uniformed “clusters of granules” present in the blood cells of the peripheral circulation
(Scott and Still, 1968). Due to technical challenges in isolating a pure population of
leukocytes, glycogen content was examined mostly in mixed polymorphonuclear
leukocytes or neutrophils (Wagner, 1946, 1947) although some studies later showed that
lymphocytes also contain glycogen, with a much higher content in younger cells (Gibb
and Stowell, 1949). More glycogen has been detected in lymphoproliferative diseases,
such as chronic lymphocytic leukemia or Hodgkin’s lymphoma (Quaglino and Hayhoe,
1959; Valentine et al., 1953). On the other hand, glycogen concentration in immune cells
of myeloid lineage has been shown to start at a relatively low level but increase upon
cellular maturity. Observations from earlier studies indicated a normal glycogen level in
leukocytes of myeloid leukemia (Wagner, 1946, 1947), whereas a higher content was
observed in polycythemia (Gibb and Stowell, 1949; Valentine et al., 1953; Wagner,
1947) or acute lymphoid leukemic patients (Cusso et al., 1975). Surprisingly, glycogen
synthase activity is reported to be consistently low in acute leukemic WBCs (Cusso et al.,
1975; Seitz, 1965). In all of these conditions, glycogen was measured in the total WBC
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population, rather than in specific cell types. Therefore, it is impossible to determine
which exact cell type has a faulty glycogen metabolic machinery directly attributable to a
particular disease condition. As opposed to the variations of leukocyte glycogen levels in
proliferative disorders, one consistent finding among endotoxin-induced inflammatory
leukocytes was an initial spike of glycogen in the leukocytes located within inflammatory
exudates (Gudewicz and Filkins, 1974; Scott and Cooper, 1974; Wulff, 1962), a
phenomenon proposed to be due to “pre-phagocytic” response, (Scott and Cooper, 1974)
most likely in preparation for phagocytosis and subsequent functional activities.
Unlike the structure of liver glycogen, the catalysis and synthesis of intracellular
glycogen in leukocytes takes place uniformly across all glycogen particles in the “first-in
last-out” behavior, characterized by the last glucose molecules being added to the
polymer to be released first (Scott, 1968; Scott and Still, 1968). Although the appearance
of glycogen particles in leukocytes is similar to and proposed as glycosome-like
organelles as observed in parasites, the definitive structures of such in immune cells are
yet to be proven.
As the fluctuation of leukocyte glycogen levels observed in various disease
conditions can be explained by enzymatic expression, glycogen phosphorylase (PYG)
was the first and only characterized enzyme in WBCs in earlier days. In the liver, the
inactive form of PYG, phosphorylase b, is not affected by AMP, whereas in the muscles,
the activity of phosphorylase b is strongly influenced by high AMP levels (Gella et al.,
1978; Yunis and Arimura, 1964). In this respect, some reports have indicated that
leukocyte PYG behaves similarly to the liver PYG, although other studies claimed the
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behavior of leukocyte PYG conforming to that of muscle PYG (Yunis and Arimura,
1968).
The functional aspects of glycogen metabolism were widely studied almost
exclusively in neutrophils possibly due to the fact that they are the most abundant cell
type in peripheral blood circulation. The energy expenditure during neutrophil
phagocytosis is shown to be fulfilled almost entirely by the breakdown of intracellular
glycogen rather than from free glucose (Borregaard and Herlin, 1982; Sbarra and
Karnovsky, 1959; Stossel et al., 1970). These findings were followed by the discovery of
an interesting metabolic phenomenon wherein granulocytes utilize free glucose exported
via glucose transporters to support chemotaxis and glycogen-derived glucose for
phagocytosis (Weisdorf et al., 1982). A recent study on the differential nutrient utilization
by neutrophils for neutrophil extracellular trap (NET) formation showed that exogenous
glucose is required during the later stage, but not in the earlier phase, of NET formation
(Rodriguez-Espinosa et al., 2015), implying the potential role that intracellular glycogen
plays during the initial stage. Macrophages, one of the most abundant phagocytes, were
also shown to use intracellular glycogen reserves for phagocytosis (Gudewicz and
Filkins, 1976). Of interest, macrophage ingestion of extracellular glycogen that is
originated from cellular debris, particularly from dead PMNs, in active inflammatory
tissue environments is suggested to serve as a fuel source during host defense or tissue
repair mechanisms (Gudewicz and Filkins, 1974). Very limited information regarding
lymphocyte utilization of glycogen was available until a recent study reported the
differential glycogen metabolism in T cells cultured in IL-2 versus IL-15 (Ma et al.,
2018). In that case, IL-15 cultured memory CD8+ T cells maintain cellular homeostasis
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and survival via a circuit of generating G6P from imported glucose, which in turn is
rapidly utilized for synthesizing glycogen. The resultant glycogen is immediately broken
down to regenerate G6P, which is then channeled into the PPP for NADPH and reduced
glutathione (Ma et al., 2018). Similar to the glycogen metabolic circuit described in T
cells, a majority of this dissertation focuses on continuous cycles of glycogen turnover in
LPS-activated DCs.

1.5.1 Major Metabolic regulatory mechanisms in DCs
1.5.1.1: PI3k/Akt/mTOR/HIF1-
With a growing interest in the immune cell utilization of metabolic pathways,
significant advances have been made within the past decades towards our understanding
of how these cells regulate their metabolic statuses. One major signaling pathway known
as phosphatidyl inositol 3 kinase (PI3k), Akt, and mammalian (mechanistic) target of
rapamycin (mTOR) - PI3k/Akt/mTOR- plays a crucial role in mediating a number of
cellular processes such as nutrient uptake, cellular proliferation, cell death, anaplerosis,
and cataplerosis. Conjugation of cognate ligands with PRRs activates PI3k, a conserved
family member of intracellular lipid kinases ubiquitously expressed in many cells, and
catalyzes the formation of PIP3, phosphatidyl inositol-3,4,5-triphosphate, from PIP2,
phosphatidyl inositol bisphosphate. PIP3, which acts as a second messenger,
phosphorylates PI3k-dependent-kinase-1 (PDK1) (Cao et al., 2016; Vanhaesebroeck et
al., 2010; Weichhart and Saemann, 2008). At the same time, PIP2 and PIP3 activation
recruits the serine threonine kinase Akt1 to the plasma membrane, where Akt is
phosphorylated on the amino acid T308 residue by activated PDK1 and on Ser473 by
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mTORC2, a kinase that is believed to be stimulated by PI3k via an unknown mechanism
(Weichhart and Saemann, 2008; Yu and Cui, 2016). This leads to the full activation of
Akt1 and subsequent Akt phosphorylation in many downstream proteins, such as
glycogen synthase kinase 3 (GSK3), tuberous sclerosis 2 (TSC2), and forkhead box
protein O1 (FoxO1). TSC2, a negative regulator of mTORC1, is inhibited upon its
phosphorylation by Akt1, leading to mTORC1 activation. Thus, the PI3k/Akt signaling
cascade ultimately leads to an activation of mTORC1 (Duvel et al., 2010; Weichhart and
Saemann, 2008; Xu et al., 2012; Yu and Cui, 2016).
This signaling activity is important in many respects because mTORC1 is a
conserved serine threonine kinase that plays a crucial role in nutrient sensing and
regulating cellular metabolism. Stimulation of mTORC1 induces the expression of a
number of genes and the synthesis of proteins involved in cellular proliferation, cytokine
secretion, and anabolic processes. Two major targets of mTORC1 are S6K and 4E-BP1,
and phosphorylation of these molecules leads to increased protein synthesis (Duvel et al.,
2010; Xu et al., 2012).
The PI3k-Akt-mTORC1 pathway is essential for the in vivo development of mouse
Langerhans cells and human pDCs (van de Laar et al., 2012) as well as in in vitro
differentiation of human monocyte derived DCs cultured with GM-CSF and IL-4
(Haidinger et al., 2010; Sukhbaatar et al., 2016). Inhibition of this pathway with the
mTOR inhibitor, rapamycin, or PI3k inhibitors causes deleterious effects on the
development, differentiation, and survival of these cells. While mTOR was demonstrated
to have negative effects on DC immune responses by downregulating pro-inflammatory
cytokine secretion, surface co-stimulatory molecule expression, and ultimately reduce
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DC ability in stimulation and differentiation of T cells (Amiel et al., 2012; Amiel et al.,
2014), recent studies have shown the opposing effects of mTOR on both immune and
metabolic phenotypes of immune cells (Amiel et al., 2012; Amiel et al., 2014). While the
PI3k-Akt-mTOR pathway is the core of development, differentiation, and immune
effector responses of dendritic cell, each of these components is vastly fundamental in
regulation of metabolic outcomes in response to a variety of stimuli. In regard to cellular
metabolism, PI3k-Akt-mTORC1 signaling pathway drives the LPS-activated DCs to fully
commit to aerobic glycolysis (Amiel et al., 2012; Krawczyk et al., 2010), a phenomenon
observed in mouse but not in human myeloid DCs (Amiel et al., 2012). Inhibition of
mTORC1 by rapamycin reverts this metabolic phenotype back to mitochondrial
respiration, by preserving the mitochondrial function and longevity, along with enhanced
survival and effector function (Amiel et al., 2014; Krawczyk et al., 2010). mTORC1
activation in TLR-activated macrophages has been illustrated to induce hexokinase-1
dependent glycolytic reprogramming in support of NLRP3 inflammasome assembly and
IL-1 production (Moon et al., 2015), an interesting metabolic phenotype presumed to be
shared by activated DCs, in which, however, has yet to be examined.
A more in-depth analysis of PI3k-Akt driven metabolic changes in DCs reveals a
spatio-temporal regulation, in which Akt is activated by TBK1-IKK, two kinases
directly downstream of TLR, leading to the Akt-driven translocation of hexokinase II to
the outer mitochondrial membrane and a resultant increase in glycolytic flux (Everts et
al., 2014). The TBK1-IKK-Akt-driven early glycolytic flux occurs independently of
mTOR or PI3K activation as evidenced by the fact that TBK1 and IKK are rapidly
phosphorylated in an PI3k/mTOR independent manner (Everts et al., 2014). Inhibiting
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either Akt or TBK1 phosphorylation disrupts the acute metabolic changes required for de
novo fatty acid synthesis, a process believed to be supported by the intermediates, citrate
and NADPH, produced from the TCA cycle and the PPP respectively. Newly synthesized
fatty acids are incorporated into the expansion of ER and Golgi organelles in support of
maximizing the protein and cytokine outputs required for acute DC activation. This
regulatory mechanism assures DCs to be able to replenish the TLR-driven rapid demand
of metabolic intermediates by generating carbon substrates via both glycolysis and the
TCA cycle (Everts et al., 2014). These findings present a new paradigm as to how we
should reconsider the metabolic reprogramming in DCs insofar as the metabolic
alterations are separated by temporally controlled signaling mechanisms. Regulations
involving PI3k-mTOR come into play after the first wave of rapid glycolytic
reprogramming (Amiel et al., 2012; Amiel et al., 2014; Everts et al., 2014; Krawczyk et
al., 2010). While PI3k-mTOR-mediated signaling plays a minimal role in early metabolic
reprogramming, this axis possesses a critical function in controlling the metabolic fate of
GM-CSF DCs via its regulation of activation-induced nitric oxide (NO) production
(Amiel et al., 2014; Krawczyk et al., 2010). The metabolic implication of NO-mediated
regulation in NO-producing DCs is discussed in the following subsection.
mTOR activation in DCs also promotes anabolic pathways and glycolysis via
induction of hypoxia inducible factor-1 (HIF-1) and sterol regulatory element binding
(SREB) to promote the synthesis of a cohort of nucleic acids, proteins, and amino acids
required for activation processes. Here, HIF-1 activation by mTOR is of particular
interest because its stimulation occurs in LPS-activated inflammatory DCs even under
normoxic conditions (Corcoran and O'Neill, 2016; Jantsch et al., 2008). Similar to the
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implications of mTOR in DC effector responses, activated HIF-1 enhances the survival,
ATP production, expression of key maturation-associated molecules, and antigen
presenting capability to T cells of LPS-activated DCs. Inhibition of HIF-1 causes
detrimental effects on DCs (Jantsch et al., 2008). The immune responses supported by the
activation of HIF-1 are directly coupled with the HIF-1-driven surface expression of
glut1 or generation of metabolic intermediates such as phosphoglycerate kinase1 (PGK1),
lactate, and succinate. For instance, although not yet proven in DCs, the generation of
succinate in support of IL-1 production in TLR-activated macrophages is dependent on
HIF-1 activation (Corcoran and O'Neill, 2016; Tannahill et al., 2013). The mTORC1HIF-1 axis also plays a crucial role in the trained immunity of Dectin-1-ligand (glucan) primed-monocytes by supporting aerobic glycolysis (Cheng et al., 2014), and this
regulatory mechanism is shown to be fundamental in epigenetic reprogramming in these
cells (Arts et al., 2016; Cheng et al., 2014).

1.5.1.2: Nitric oxide (NO)- mediated metabolic regulation
One of the downstream targets of mTORC1 upon TLR ligation in GM-CSF
cultured murine DCs is upregulation of inducible nitric oxide synthase (iNOS), an
enzyme responsible for catalyzing the generation of nitric oxide (NO) and citrulline from
arginine. iNOS upregulation is under the direct regulation of HIF-1, which in turn is
activated by mTORC1. In other words, iNOS expression is shown to be most entirely
dependent on PI3k-mTOR-HIF-1 signaling directly downstream of TLR activation
(Everts et al., 2012). Interestingly, the signaling network of iNOS, HIF-1, and mTOR
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seems to be more complex than what we have learned from previous studies. A recent
study elegantly demonstrated a feedback loop of iNOS expression by mTOR-mediated
induction of HIF-1, which in turn is stabilized by iNOS upregulation and NO
production. Therefore, the TLR-driven glycolytic switch is coordinated by this mTORHIF-1-iNOS circuit, the operation of which is again dictated by nutrient availability in
tissue microenvironments (Lawless et al., 2017). While the murine GM-CSF cultured
BMDCs upregulate iNOS a few hours after TLR activation, conventional DCs or human
myeloid DCs do not express iNOS at all (Bogdan et al., 2000; Bonham et al., 1997;
Bonham et al., 1996; Thwe and Amiel, 2018). A distinct subset of DCs, claimed to be
present in both mouse and human and capable of generating both TNF- and NO, is
called TNF-/iNOS producing DCs (Tip-DCs). Although human peripheral blood
monocyte-derived DCs do not produce NO nor express iNOS in in vitro culture systems,
several studies have identified the presence of diverse subsets of tissue resident DCs
capable of generating NO in certain disease conditions, such as psoriatic inflammation
(Haider et al., 2008; Lowes et al., 2005; Wilsmann-Theis et al., 2013).
NO displays multifaceted roles in several physiological functions, such as muscle
relaxation/contractility, neuronal activities, and immune responses. NO is also known to
impose anti-microbial effects on invading pathogens (Qualls et al., 2012). As diverse as
its role can be in normal and/or abnormal physiological responses in the body, NO is
largely implicated in DC metabolism and effector function. Among its pleotropic
functions, NO is notorious as a mito-toxic molecule that has an ability to reversibly Snitrosylate cytochrome C oxidase of the electron transport chain (ETC) (Clementi et al.,
1998). Therefore, in TLR-activated BMDCs, glycolytic metabolism is sustained through
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the course of activation as the mitochondrial OXPHOS respiratory chain is crippled from
NO intoxication. On an important note, the TLR-driven initial glycolytic burst, along
with a brief surge in mitochondrial activity during early activation, is believed to be
under the NO-independent phenotype, which, however, is converted to a NO-dependent
switch to aerobic glycolysis, characterized by a permanent damage to the mitochondria
(Everts et al., 2014; Everts et al., 2012; Pearce and Everts, 2015). Although NOproducing DCs that are fully committed to Warburg metabolism are thought to be
dependent on glycolytic ATP for their survival and activation, conflicting findings have
indicated that ATP can be dispensable (Everts et al., 2012). Additionally, as a result of
the NO-mediated mitochondrial inhibition, functional impairments of DCs manifest as
reduced co-stimulatory molecule expression and diminished capability to prime T cells
(Everts et al., 2012). Because NO is fairly permeable to phospholipid membrane bilayers
and can easily travel to target neighboring cells, it can cause detrimental effects on the
oxidative metabolism and function of bystander cells that do not produce NO. An
example is a decrease in the proliferation of T cells exposed to NO-producing DCs
potentially due to the fact that NO derived from DCs induces mitochondrial dysfunction
and a shortened lifespan of T cells (Xu et al., 2001). This dissertation work discusses the
impact of NO on DC utilization of glycogen metabolism during activation.
1.5.1.3: AMP-kinase (AMPK)
Another key metabolic sensor that acts in opposition to the mTOR regulatory
mechanism is AMP kinase (AMPK). AMPK is generally activated when the ratio of
cellular ATP to ADP drops (i.e., low energy status) although other mechanisms of
activation can be brought about by the phosphorylation action of its upstream kinase
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LKB1 or increased intracellular calcium (Hardie et al., 2012). With a primary purpose of
maintaining cellular energy status, AMPK is well known to antagonize the anabolic
events mediated by mTOR (O'Neill and Hardie, 2013). Thus, AMPK is recognized to
play a central role in catabolic metabolism (Hardie et al., 2012; O'Neill and Hardie,
2013). Since AMPK upregulates OXPHOS, its activity in DCs is most prominent in
resting/naïve conditions prior to encounter of pathogens. In line with this, TLR ligation of
DCs has been shown to downregulate AMPK phosphorylation. As activated DCs undergo
a rapid metabolic switch from OXPHOS to glycolysis, which is facilitated by the PI3kAkt-mTOR axis, AMPK is considered as an inhibitor of DC activation responses
(Krawczyk et al., 2010). In parallel with its role as an energy sensor, AMPK is also
recognized as a glucose sensor, even under normal energy statuses, and the activation of
AMPK via glucose sensing mechanism again antagonizes mTORC1 activities (Lin and
Hardie, 2018). Inhibition of AMPK not only promotes glycolytic metabolism but also
augments the production of inflammatory cytokines such as TNF-, IL-12p40, and IL-6,
along with decreased IL-10 secretion (Kelly and O'Neill, 2015; Krawczyk et al., 2010).
Because AMPK can also be pharmacologically activated by drugs, such as metformin
used as a first-line diabetes therapy, and multiple downstream targets of AMPK
demonstrate its signaling complexity, this dissertation work rather focuses on the
potential implications of AMPK on DC glycogen metabolism.

1.6: Perspective and scope of this thesis
Following the characterization that the Warburg phenomenon first described in
cancer cells also occurs in activated immune cells, carbohydrate metabolism became the
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most widely-studied topic in immune cells (Levene and Meyer, 1912; Newsholme et al.,
1986; Palsson-McDermott and O'Neill, 2013; Schwartz, 1976; Stossel et al., 1970;
Warburg, 1956; Warburg et al., 1927; Yunis and Arimura, 1964). As glucose is the
primary carbon fuel substrate for many cell types, including immune cells, there has been
a growing appreciation for the role of glucose metabolism in supporting the immune
responses and survival of DCs within recent years. While most of the metabolic studies
have focused on the TLR activation of DCs in the field, there has been a recent increasing
attention towards understanding the metabolic responses to stimulation with ligands for
other PRRs, such as C-type lectin receptors in fungal infections. While glucose
metabolism has been well-characterized to play a central role in metabolic regulations of
immune cell function, very few studies to date have investigated the role of glycogen
metabolism in regulating glucose homeostasis in immune cells. A large body of work on
liver, brain, muscle, and cancer cell glycogen metabolism has broadly demonstrated the
cell- or tissue-specific roles and regulatory mechanisms of glycogen metabolism.
Understanding cell-specific role for glycogen metabolism in cells of the immune system
can make a substantial contribution to our evolving understanding of the importance of
metabolic regulation of immunological processes. Therefore, we initially set out to
identify metabolic reprogramming broadly in non TLR-ligand stimulation of DCs, and
then advanced our research into how DC glycogen metabolism, and glycogen metabolism
regulation, is implicated in their immune effector responses.
Chapter 2 of this dissertation determines whether DC stimulation with molecules
extracted from fungal pathogens can alter glycolytic metabolism in a manner similar to
that observed in TLR-induced DCs. Using an array of ligands for Dectin-1, which is the
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most widely-used model in investigating C-type lectin receptor activation, we attempted
to compare the nuances of metabolic regulation in TLR- and Dectin-1 mediated DC
activation. On this account, Chapter 2 also establishes the glycolytic contribution to one
of the important effector signatures of early innate inflammatory responses –
inflammasome activation.
In the past decade, attention has been given towards comprehending glycolytic
reprogramming of immune cells, which was thought to be driven primarily by glucose
from the extracellular environment. One problem with this paradigm is that the inducible
glucose transporter-1 (Glut1), which has been widely invoked as the central regulator of
increased glycolytic flux in activated immune cells (Freemerman et al., 2014; Fu et al.,
2004), is not readily expressed in the early phase of immune activation and thus cannot
satisfy the acute glycolytic need of those cells undergoing the rapid metabolic demands
associated with activation. In trying to resolve this problem with the prevailing paradigm,
we were first interested in examining how DCs utilize intracellular fuel sources to drive
glycolysis, particularly focusing on the early activation period before the Glut1-mediated
glucose flux occurs. Chapter 3 of this dissertation describes our studies testing and
establishing the overarching hypothesis that DCs possess cell-intrinsic glycogen
metabolic machinery responsible for driving the early glycolytic reprogramming
associated with initial immune responses by these cells. To our knowledge, we are the
first to demonstrate that cell-intrinsic glycogen metabolism supports early glycolysis in
TLR-activated DCs and that inhibiting glycogen metabolism can significantly impair a
wide variety of DC immune effector functions.
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One interesting feature of glycogen metabolism observed in cancer cells, neurons,
astrocytes, and muscle is continuous cycles of glycogen synthesis and degradation, a
phenomenon termed the “glycogen shunt,” which was demonstrated in these systems to
serve cell- or tissue-specific functional purposes, such as supporting the action potential
firings in neurons and rapid muscular contractility in muscle. While, prior to this work,
there was no formal understanding of this unusual metabolic phenomenon in immune
cells, we formally demonstrate that the glycogen shunt phenomenon in TLR-activated
DCs exists using a metabolomics approach, and that this pathway critically supports
citrate generation in these cells, previously shown to be a signature metabolite of DC
activation. The findings from our work has highlighted the need for reassessment of the
role of cellular glycogen metabolism as more than a storage depot for their immune
responses, such as the potential role of maintaining metabolic homeostasis via the
glycogen shunt during immune activation.
Chapter 5 of this dissertation presents preliminary findings on the investigation of
some of the regulatory mechanisms on DC metabolism mediated by nitric oxide
production in these cells. A significant body of work has delineated the deleterious
effects of NO on immune cell metabolism, such as inhibition of mitochondrial oxidative
phosphorylation, enforcing the cells to permanently switch to glycolysis, and shortening
cellular lifespan (Corinti et al., 2003; Everts et al., 2012; Thwe and Amiel, 2018). The
divergent role of NO between murine and human models in regard to glycogen
metabolism has not been previously investigated. This is fundamentally important
because of the versatile roles that NO participates in, particularly pertaining to its ability
to both enhance and suppress immune outcomes during infection. Therefore, in Chapter
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5, we attempt to provide an overview of what is known about the pleiotropic effects of
NO on DC metabolism and then go on to elucidate a potential role for NO-mediated
regulation of glycogen metabolism in activated DCs.
In this body of work, we have embarked to investigate a more complex level of
understanding carbohydrate metabolism and regulation in DC activation and immune
effector function. Collectively, these studies have contributed to a novel understanding of
the complexity by which glucose homeostasis is regulated through glycogen metabolism
in DCs. Our findings have identified new pathways and metabolic regulatory checkpoints
that impact the functional aspects of DCs in response to infectious stimuli.
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CHAPTER 2
Syk-dependent Glycolytic Reprogramming in Dendritic Cells Regulates IL-1
production to Fungal-associated Ligands in a TLR-independent Manner.
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Abstract
Dendritic cells (DCs) activated via TLR ligation experience metabolic
reprogramming, in which the cells are heavily dependent on glucose and glycolysis for
the synthesis of molecular building blocks essential for maturation, cytokine production,
and the ability to stimulate T cells. Although the TLR-driven metabolic reprogramming
events are well documented, fungal-mediated metabolic regulation via C-type Lectin
Receptors such as Dectin-1 is not clearly understood. Here, we show that activation of
DCs with fungal-associated ligands induces acute glycolytic reprogramming that supports
the production of IL-1 via inflammasome formation. This acute glycolytic induction to
fungal-associated ligands is depending on Syk signaling in a TLR-independent manner,
suggesting now that different classes of innate immune receptors functionally induce
conserved metabolic responses to support immune cell activation. These studies provide
new insight into the complexities of metabolic regulation of DCs immune effector
function regarding cellular activation associated with protection against fungal microbes.

Introduction
Dendritic cells (DCs) are professional antigen presenting cells (APCs) of the
innate immune system. They play a critical role in initiating both innate and adaptive
immune responses by serving as a bridge between these two systems (1, 2). They express
a vast array of pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs),
C-type Lectin receptors (CLRs), and mannose receptors (3, 4). Recognition of microbial
stimuli through these receptors induces DCs to upregulate transcription and translation of
genes and proteins associated with their immune effector function, such as surface
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expression of co-stimulatory molecules, MHC class II, and production of proinflammatory cytokines and chemokines. Subsequent to activation, DCs migrate to
secondary lymphoid organs and present antigens to T cells, thereby initiating the adaptive
immune responses (1).
Among the PRRs, CLRs can recognize various lengths of carbohydrates through
binding of polysaccharide moieties in C-type lectin domains (CTLD) of the receptors.
Dectin-1 is a C-type lectin receptor expressed primarily on myeloid cells, such as
macrophages and DCs, and on a small subset of lymphocytes (5, 6). Among the complex
multilayers of fungal cell walls, O-linked mannosylated proteins and mannans in the thin
outermost layer are recognized by TLRs, whereas -glucan, the most abundant layer of
the fungal cell wall, is primarily recognized by Dectin-1 receptor (7). Innate immune
responses to fungal infection are orchestrated by the cooperative recognition of PAMPs
on the fungal cell wall via TLRs and CLRs. Previous studies have reported that fungal
activation of immune cells induces their activation via stimulation of TLR2 and/or TLR4,
in addition to Dectin-1 (8).
-glucans capable of stimulating Dectin-1 exist in 1,3- and 1,6- linkages. These
Dectin-1 agonists are commercially available from the preparation of yeast Saccromyces
cervisiae or Candida albicans; while the -glucan ligands such as zymosan (Z), a cell
wall component derived from Saccromyces cerevisiae, has been shown to elicit proinflammatory immune responses in macrophages and DCs (5, 9, 10), these responses are
mediated by both Dectin-1 and TLR2 activation (11, 12). However, studies have shown
that whole glucan particles or depleted zymosan (ZD), which is deprived of TLR
stimulatory capacity by treatment of Z with hot alkali, produce Dectin-1 specific
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inflammatory responses, such as ROS and cytokine production (13, 14). Furthermore,
Dectin-1 specific responses are non-redundant with TLR-mediated innate immune
responses, as Dectin-1-deficient mice display impaired immune responses against C.
albicans, resulting in compromised resistance to fungal infection (10).
Stimulation of PRRs by pathogen associated molecular patterns (PAMPs), such as
microbial pathogens, and/or danger associated molecular patterns (DAMPs), such as ATP
and uric acid crystals, results in the release of pro-inflammatory cytokines by DCs and
macrophages. Among these cytokines, IL-1 plays a crucial role in both local and
systemic inflammation as one of the earliest inflammatory mediators released by
activated innate immune cells. The secretion of biologically active IL-1 is mediated by
the cleavage of pro-IL-1 by active caspase-1, and is tightly controlled by two distinct
cellular signals. PRR activation for IL-1 expression serves as a first signal, which is
followed by the second signal that causes the cleavage of pro-IL-1 by active caspase-1.
Different forms of a heterogeneous group of multiprotein complexes, termed
inflammasomes, are responsible for activing caspase-1. These inflammasome complexes
consist of sensor proteins, such as NOD-like receptor family proteins (NLRs) that can
detect PAMPs and/or DAMPs, an adaptor protein apoptosis-related speck like protein
(ASC), a pyrin or caspase recruitment domain, and effector caspase-1. Inflammasome
activation gives rise to autocatalysis and activation of caspase-1, which then exerts a
catalytic activity on pro IL-1 (15-17). Among different types of NLR inflammasomes,
activation of the NLRP3 inflammasome is most abundantly studied in the field of
myeloid immune cells in response to various microbial pathogens, including fungi, and
plays a documented downstream role in Dectin-1-initiated innate immune responses (1878

20). Recent studies have reported that NLRP3 inflammasomes are required for immune
responses against C. albicans mediated by both Dectin-1 and TLR2; however, IL-1
secretion was completely ablated in Dectin-1 deficient mice compared to that in TLR2
knock out mice (19, 21, 22). Although the immune effector responses in these studies
have been reported to require both TLR2 and Dectin-1 to fight fungal infections, Dectin1–mediated effects on downstream NLRP3 inflammasome activation are much more
pronounced (21).
Activation through TLRs causes DCs to exhibit rapid changes in cellular
metabolism characterized most prominently by increased rates of aerobic glycolysis.
TLR-driven glycolytic reprogramming critically supports the survival and immune
function of DCs by satisfying both the energetic and nutrient substrate requirements
associated with the rapid anabolic synthesis of proteins and effector molecules during DC
activation (23-26). Pharmacologic or genetic approaches to inhibit the induction of
aerobic glycolysis during DC activation results in attenuation of DC maturation and leads
to subsequent adverse effects on DC effector functions, including inflammatory cytokine
secretion, antigen presentation, and T cell stimulation (25-27). A prominent recent study
has demonstrated that monocytes challenged with a β-glucan cell wall component of
Candida albicans can also upregulate aerobic glycolysis in these cells, albeit the
underlying mechanism for this process is epigenetically regulated after a long-term
fungal challenge (28). Although activation of the NLRP3 inflammasome in macrophages
is supported by aerobic glycolysis (18), and inhibition of glycolysis attenuates IL-1
release and inflammasome activation (18, 29), little is known about the dectin-1 specific
acute glycolytic induction for inflammasome formation in DCs, nor the role of Dectin-1
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in support of acute glycolytic reprogramming. Here, we report that DC stimulation with
Dectin-1 specific ligands drives aerobic glycolysis for inflammasome formation, in a
TLR-independent manner.
Upon activation of Dectin-1, the downstream adaptor motif of its cytoplasmic tail,
which is similar to immunoreceptor tyrosine-based activation motifs (ITAMs), serves as a
docking site for spleen tyrosine kinase (Syk) (30). Syk signaling plays an important role
in lymphocyte proliferation and survival. In macrophages and DCs, phosphorylation of
Syk induces inflammatory responses such as cytokine secretion (31), ROS production,
and NLRP3 inflammasome activation (30, 32). On the other hand, the PI3k/Akt axis
regulates the proliferation, survival, and metabolic activities in many cells (33-35). We
have shown the activation of PI3k and Akt signal transduction during the TLR-driven
glycolytic burst in DCs (24). However, whether the PI3k/Akt axis is associated with Syk
activity in Dectin-1 stimulated DCs is not quite understood. Additionally, TLR signaling
has been shown to depend on MyD88 (36, 37), which is an essential signaling adaptor
molecule in most TLR signaling pathways. While some reports indicate the involvement
of MyD88 in the immune responses to fungal pathogens (31, 38, 39), the role of MyD88
in Dectin-1 activation is still controversial (38, 40). In this report, we demonstrate that
inflammasome activation by a Dectin-1 specific ligand is mediated by a Syk-dependent
and PI3k/Akt-dependent glycolytic reprogramming that is independent of TLR-MyD88.
While the glycolytic reprogramming of DC effector function has been extensively
studied in TLR-driven activation, DC metabolic regulation in response to fungal
pathogens is understudied. In this study, we show that Dectin-1 driven glycolytic burst is
regulated by Syk-kinase activation in a TLR-independent manner. Syk inhibition
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abolished the Dectin-1 driven glycolytic burst and downstream IL-1 activation, while
sparing MyD88-dependent TLR stimulation. Collectively, our study suggests that DCs
engage in a Syk-dependent signaling mechanism responsible for driving the Dectin-1
specific glycolytic burst in support of IL-1 release. These findings show that CLRs, in
addition to TLRs, are sufficient for driving early glycolytic reprogramming in DCs, and
that this activity is important for sustaining the early inflammatory responses to fungalassociated ligands.

Materials and methods
Mice and reagents
C57BL/6J, TLR2-/-, and MyD88-/- mice were purchased from Jackson Laboratory and
bred in-house and maintained at the University of Vermont animals care facility under
protocols approved by Institutional Animal Care and Use Committee. Endotoxin free
LPS (Escherichia coli serotype O), Pam2Csk4, Zymosan (Z), Zymosan-depleted (ZD),
Curdlan, and Whole Glucan Particles (WGP) were purchased from Invivogen. was from
Selleckchem, 2-deoxy-glucose (2DG) was purchased from Sigma. Antibodies for flow
cytometry: 7-Aminoactinomycin D (7-AAD), anti-CD11c, anti-CD86, anti-CD40, and
anti MHC-II antibodies- were purchased from BD Biosciences and Biolegend. For
Western blot analysis, all antibodies were from Cell Signaling except for Il-1 and
Caspase-1antibodies which were from Santa Cruz. PI3K, Akt, and TBK1
pharmacological inhibtors (LY294002, Akti-1/2, and BX-795 respectively) were
purchased from Selleckchem.
Mouse DC culture and Activation
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Bone marrow derived DCs were generated as described in Lutz et al (Lutz et al., 1999).
Briefly, BM hematopoietic cells were differentiated in GM-CSF (20ng/uL; Peprotech) in
complete DC medium (CDCM), comprised of RPMI1640, 10% FCS, 2mM L-glutamine,
1IU/mL Pen-Strep, 1mM beta-mercaptoethanol, for 7 days. On day 7, DCs were washed
in CDCM and cultured at 2x10^5 cells per 200L of media For intracellular cytokine
staining, cells were activated for a total of 4 hours with an addition of Golgi plug
(Biolegend) after the first hour of stimulation.

Western Blot Analysis
DCs lysed using lysis buffer with Pierce Protease and Phosphatase inhibitors. Protein
levels were quantified using the Pierce BCA Assay kit prior to transfer to running on
12% SDS-PAGE gels and transfer to PVDF membranes.

Metabolism assays
Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were
measured with Metabolic Flux Analyzer (Seahorse Bioscience, North Billerica, MA
24XP and/or 96XP).

Flow Cytometry and Cytokine measurements
Above mentioned antibodies were used for flow cytometry. For intracellular staining of
TNF-  and IL-12 (Biolegend), cells were fixed in 4% Paraformaldehyde, permeabilized
in 0.2% saponin, and stained with the antibodies in FACS buffer (1%BSA in PBS).
Samples were analyzed on a BD LSRII flow cytometer. For cytokine levels, supernatants
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were collected as indicated time points and measured by Duo-set ELISA kits (R&D
Systems).

Quantitative Real-time PCR of Il-1 expression
RNA was isolated with an RNAeasy Kit (Qiagen) and cDNA was synthesized with an
iScript cDNA Synthesis Kit (Biorad). Il-1 Taqman primer probes (Applied Bioscience
system) and AB7500 sequence detection system or QuantStudio 3.0 were used for
relative mRNA expression. mRNA relative quantitative values were calculated based on
2(-CT) and were normalized to untreated DCs.

Statistical Analysis
Data were analyzed with GraphPad Prism software (version 6.0). Samples were analyzed
using Paired t-test, One-way and Two-way ANOVA. ANOVA tests were post-calculated
by Tukey’s multiple comparison test. Results are means +SD or +SEM, and statistical
values are represented significant when p values were below 0.05.

Results
Dectin-1 mediated activation drives glycolytic reprogramming
TLR activation in DCs leads to acute glycolytic reprogramming, which is an
essential process to generate metabolic intermediates for the synthesis of biomolecules
required for DC effector responses. We have previously characterized that this glycolytic
burst occurs in response to agonists across the TLR family of receptors (24). In contrast,
relatively little is known about metabolic changes in DCs response to fungal pathogens
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and fungal-associated ligands. Although studies with human monocytes activated with glucan from Candida albicans demonstrate a long-term switch from oxidative
phosphorylation to aerobic glycolysis in these cells, this study delineates a long-term
metabolic reprogramming associated with epigenetic regulation of myeloid cell
metabolism and does not explicitly address acute metabolic regulation in these cells (28).
While previous reports have described that cooperative activation of TLRs and Dectin-1
play an important role in innate immune responses to fungal-associated ligands, rapid
metabolic changes in response to Dectin-1 -specific ligands have yet to be elucidated (8,
12, 13). In order to identify Dectin-1 -specific acute metabolic reprogramming in DCs
and to determine the contribution of these metabolic changes to early immune responses
by these cells, we utilized an array of ligands specific to TLRs alone (LPS), Dectin-1
alone (ZD, Curdlan, WGP), or ligands that interact with both simultaneously (Zymosan).
We first characterized the ability of these different agonists to induce acute
glycolytic reprogramming, termed ‘glycolytic burst’, in GM-CSF-differentiated BMDCs
by metabolic extracellular flux analysis (Agilent, Seahorse Biosciences). By stimulating
the cells with LPS (TLR agonist), Zymosan (Z, TLR and Dectin-1 agonist), or Zymosan
depleted (ZD, Dectin-1 –specific agonist), we were able to determine the ability of these
receptors in mediating acute glycolysis induction. Consistent with our previous work in
which TLR4 stimulation with LPS induced a rapid glycolytic burst, we observed a similar
metabolic response to both Z and ZD stimulation (Figure 2 -1A). 2-deoxy-glucose
(2DG), a synthetic molecule structurally similar to glucose that functions as an inhibitor
of glycolysis, dramatically attenuated glycolytic burst induced by all three ligands,
suggesting that Dectin-1 activation drives the aerobic glycolytic burst (Figure 2 -1B). To
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verify that each member of our agonist panel was able to induce DC maturation
comparably, we next characterized the induction of surface co-stimulatory molecule
expression in BMDCs stimulated for 24 hours with each ligand (Figure 2 -1C).
Futhermore, we observed a requirement for glycolytic metabolism to support activationassociated TNF- and IL-12 production in response to each ligand (Figure 2 -1D).
Consistent with our metabolic data (Figure 2 -1A and Figure 2 -1B), proper DC
maturation by all ligands, including Dectin-1 specific ligand, ZD, requires glycolytic
reprogramming (Figure 2 -1C and Figure 2 -1D).

Dectin-1 –dependent glycolytic burst and maturation requires Syk signaling
Dectin-1 -driven immune responses are documented to be mediated by both Sykdependent and -independent mechanisms (5, 41). Based on this, we were interested in
testing the requirement for Syk signaling in supporting Dectin-1-mediated glycolytic
burst and effector function in DCs. We examined acute glycolysis induction in BMDCs
stimulated with TLR and/or Dectin-1 ligands in the presence or absence of the Syk
inhibitor, PRT. Interestingly, PRT completely ablated glycolysis induction in the cells
stimulated by the Dectin-1 specific ligand, ZD, while only a partial inhibition was
observed for the TLR-specific agonist LPS and dual agonist Z (Figure 2 -2A).
Upregulated surface expression of the costimulatory molecules CD40 and CD86 in
response to Dectin-1–specific ligands (ZD, Curdlan, WGP) was strongly attenuated by
Syk inhibition, while TLR-driven maturation (LPS) was unimpaired, and dual-agonist
maturation (Z) was only partially impaired, by Syk inhibition (Figure 2 -2B). These data
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indicate Syk-dependent signals are sufficient to regulate Dectin-1-mediated glycolytic
reprogramming and maturation in DCs.

Dectin-1 –mediated metabolic reprogramming is independent of TLR/MyD88 signals
In order to confirm that Dectin-1 specific metabolic reprogramming and
activation was independent of TLR-signaling, we stimulated DCs from TLR2 -/- and
MyD88-/- mice and assessed their ability to induce acute glycolytic burst in response to
Dectin-1–specific activation (Figure 2 -3A). We next activated WT, MyD88-/- and TLR2/-

BMDCs with ZD in the presence or absence of PRT and found that DCs exhibited

comparable levels of glycolysis induction to ZD even in the absence of TLR2 or MyD88
expression (Figure 2 -3B). Syk inhibition completely ablated Dectin-1–mediated
glycolysis induction in all genotypes (Figure 2 -3B). Furthermore, TLR2-/- BMDCs were
unresponsive to canonical TLR2 agonist Pam2Csk4, and MyD88-/- BMDCs did not
mature to both TLR2 and TLR9 agonists as expected, while all genotypes matured
properly to LPS (presumably via the MyD88-independent TRIF/TRAM signaling
pathway) and Dectin-1-specific ligands (Figure 2 -3C). These data confirm that Dectin1/Syk mediated signals are necessary to drive DC metabolic reprogramming even in the
absence of the TLR2/MyD88 signaling axis that is also well-documented to regulate
innate immune responses to fungal-associated ligands.

Dectin-1 mediated glycolytic reprogramming requires a PI3K/TBK-1/Akt signaling axis
Syk signaling is known to play a crucial role in Dectin-1-mediated innate immune
responses (22, 30, 31, 42). In previously published work, we have identified that
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phosphorylation of Akt T308 is required for Hexokinase association with the
mitochondria and glycolytic reprogramming in TLR-stimulated DCs (24). We thus
hypothesized that similar signaling pathways may regulate acute metabolic responses to
Dectin-1-specific activation of DCs. To test this, we first examined expression of total
and T308-phosphorylated Akt in BMDCs stimulated with Z or ZD (Figure 2 -4A). We
observed that Dectin-1 activation by both ligands induces the phosphorylation of Akt
T308, suggesting that similar signaling mechanisms are likely involved in Dectin-1
mediated glycolytic reprogramming (Figure 2 -4A). PI3K inhibition resulted in reduced
phosphorylation of Akt T308, suggesting that PI3K is involved in regulating Dectin-1–
dependent signaling that leads to Akt T308 phosphorylation (Figure 2 -4B). This is in
contrast to previously published data showing that PI3K is not required for acute
glycolytic reprogramming to TLR stimulation in DCs (24). However, inhibition of TBK1
completely ablated the phosphorylation of Akt T308 in ZD activation (Figure 2 -4C),
which is consistent with previously published data for TLR-mediated acute activation.
Consistent with these data, Akt inhibition attenuated acute glycolytic reprogramming in
both Z- and ZD–stimulated DCs, whereas PI3K inhibition significantly impacted
glycolysis induction only in ZD-stimulated cells (Figure 2 -4D). In TLR-stimulated DCs,
TBK1 phosphorylation of Akt has been demonstrated to regulate acute glycolytic burst
independent of PI3k signaling, whereas the PI3k/Akt axis plays a major role in
maintaining long-term glycolytic activity in these cells (24, 26). In contrast to these
findings for acute glycolytic induction to TLR-mediated stimulation, our data suggest that
Dectin-1–dependent Akt T308 activation is mediated by both PI3k and TBK-1.
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Dectin-1 –mediated acute glycolytic reprogramming is required for NLRP3
inflammasome activation
In macrophages, glycolytic reprogramming has been demonstrated to drive
NLRP3 inflammasome activation initiated by two signal components, LPS as a first
signal and ATP or Nigericin as a second (18). While Cheng et al. have shown that human
monocytes challenged with -glucan components of C. albicans upregulate aerobic
glycolysis, these studies emphasized the long-term stimulatory effect of -glucan-treated
monocytes and the metabolic changes described in these cells have been documented to
be regulated by epigenetic changes (28, 43). However, the requirement for Dectin-1
driven acute metabolic regulation for NLRP3 inflammasome activation has not been
explicitly characterized in DCs. We hypothesized that the aerobic glycolysis observed in
Dectin-1 activated BMDCs (Figure 2 -1 and Figure 2 -2) is required to support NLRP3
formation and IL-1 production in a Syk-dependent manner. To test this, we activated
BMDCs with LPS, Z, and ZD in the presence or absence of 2DG for 6 hrs and examined
the transcriptional expression of IL-1 (Figure 2 -5A). Interestingly, mRNA expression
of IL-1 did not change regardless of glycolysis inhibition, indicating that IL-1
production is not regulated by glycolysis at the transcriptional level, a finding consistent
with the lack of a glycolytic requirement for transcription of inflammatory genes in
response to TLR stimulation of DCs (24). However, the levels of IL-1 in both culture
supernatants (Figure 2 -5B) and cellular lysates (Figure 2 -5C) of Dectin-1-activated
BMDCs stimulated with nigericin were significantly attenuated by 2DG-mediated
glycolysis inhibition. Furthermore, Syk inhibition completely ablated IL-1 release from
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Dectin-1–stimulated cells, further supporting the requirement of Syk-dependent signals
for both glycolytic induction and NLRP3 inflammasome activation in these cells (Figure
2 -1B). These data suggest that Dectin-1 -mediated IL-1 production is regulated at the
translational level in a Syk and glucose -dependent manner (Figure 2 -5C). In addition,
NLRP3 induction was notably inhibited by 2DG during Dectin-1–mediated activation but
not TLR activation (Figure 2 -5D).
Discussion
Stimulation of myeloid immune cells with fungal ligands induces metabolic
reprogramming (28, 44). Several studies have also shown that fungal pathogen activation
causes inflammasome formation (17, 32, 42, 45) and induces the Syk-kinase signaling
pathway (22, 30, 31, 42). While these studies add significant value to the understanding
of host immune responses against fungal pathogens, an integrated understanding of
fungal-mediated metabolic changes in the regulation of specific immune outcomes in
DCs, such as inflammasome activation, has not been previously described. In this study,
we demonstrate that the Dectin-1-specific activation of DCs induces glycolysisdependent IL-1 production via the Syk-mediated signal transduction pathway, which
drives activation of the PI3K/TBK1/Akt axis. By activating BMDCs with Dectin-1specific ligands, we have been able to discriminate between Dectin-1-specific glycolytic
burst and effector responses from TLR-mediated effects. We show that the Dectin-1
specific ligands induce rapid glycolytic reprogramming in DCs, and DC maturation by
Dectin-1 specific ligands is dependent on glucose in a TLR2 and MyD88–independent
manner.
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In this study, we have taken a reductionist approach using purified ligands to
interrogate the contribution of specific receptors to anti-fungal metabolic responses.
However, the composition of fungal cell walls is complex, and understanding the
contribution of a single receptor to innate immune cell metabolism is a challenge. Recent
work by Netea’s group has elegantly shown that activation of monocytes with hyphae or
yeast cells results in a differential utilization of metabolic pathways, in which yeastactivated immune cells are dependent on both glycolysis and TCA metabolism, while
hyphae activation induces the cells to rely solely on glycolysis (44). Earlier studies have
reported that C.albicans hyphae are primarily recognized via Dectin-2 receptors (46),
suggesting that metabolic responses to nuanced components of fungal cell walls by
different PRRs could initiate utilization of distinct metabolic pathways.
The TLR-driven early glycolytic reprogramming is mediated by Akt-dependent
TBK1/IKK signaling (24), and a long-term commitment to aerobic glycolysis is
facilitated by PI3k/Akt/mTOR signaling (25). While MyD88, an upstream adaptor
molecule of TLR-mediated signaling pathways, is central to TLR-driven effector
responses, conflicting reports exist regarding the role of MyD88 in non-TLR signaling
pathways such as Dectin-1-driven responses (22, 38). However, whether MyD88 is
involved in Dectin-1-specific ligand recognition or a crosstalk between cooperative
ligand recognition by TLRs and Dectin-1 is not clear. To address this, we examined if
MyD88 is involved in Dectin-1-specific metabolic regulation of DCs. We found that the
Dectin-1-specific ligand, ZD, specifically triggers rapid glycolytic burst independent of
TLR2 or MyD88. These data indicate that Dectin-1-specific signals, via a Syk/PI3K/Akt
signaling axis, are sufficient to initiate both DC glycolytic reprogramming and maturation
90

in response to activation by fungal-associated ligands (modeled in Figure 2 -6). These
findings are consistent with the recent work of Ding et al. in which they showed that
PI3k/Akt signaling regulates the proliferation of cytotoxic T cells activated by human
monocytes induced with Dectin-1 specific -glucan molecules (34).
The pioneering work of Sousa et al. highlighted that Syk plays a central role for
cytokine production by Dectin-1 activation (31). Syk phosphorylation is also crucial for
Dectin-1-mediated inflammasome formation and IL-1 production (22, 32). Although the
TLR-MyD88 axis is not essential for Dectin-1-mediated inflammasome formation in
BMDCs, clear distinctions between Dectin-1- and TLR-mediated signaling components
have not been fully established (22). This could be potentially due to the complex nature
of fungal cell wall composition and the challenge of experimentally isolated single
receptor-specific responses. Here, we show that Dectin-1 activation of BMDCs requires
Syk signaling for glycolysis induction. Interestingly, we also show that Dectin-1mediated Syk-dependent IL-1 production in BMDCs is heavily reliant on glucose and
glycolytic reprogramming.
Glucose metabolism in TLR-mediated activation has been widely studied in DCs
and innate myeloid immune cells alike (47, 48), while few studies delineate the glycolytic
requirement during cell activation via CLRs such as Dectin-1. This work helps illustrate
that glucose metabolism plays a central role in DC activation via distinct families of
PRRs and that the upregulation of glycolysis is a classic metabolic hallmark in both TLR
and CLR-mediated activation. Interestingly, recent studies suggest that there may be
nuanced differences in cellular metabolic responses to distinct types of microbialassociated ligands. For instance, activation of human monocytes with Pam3Csk4 and
91

LPS induces differential metabolic responses, in which Pam3Csk4 upregulates both
glycolysis and OXPHOS, whereas LPS induces aerobic glycolysis but not OXPHOS
(49). Differential functional outcomes could also arise from cellular participation in
divergent glucose metabolism. In an example of monocytes stimulated with TLR2
ligands, phagocytic activity of these cells is preferentially supported by OXPHOS
whereas cytokine production is facilitated by glycolysis and OXPHOS (49). In parallel to
TLR-mediated metabolic changes, recent work has highlighted the differential metabolic
outcomes from dimorphic stages of C. albicans, leading to diverse functional responses
(44). Of note, since we have recently shown that TLR-mediated DC activation relies on
alternative metabolic pathways such as glycogen metabolism (50), it is tempting to
hypothesize that Dectin-1 mediated responses may participate in similar aspects of
activation-assoicated glucose metabolism.
In summary, our findings identify Dectin-1-specific acute glycolytic
reprogramming events that support DC effector responses to fungal-associated ligands.
However, the complex and redundant nature of the metabolic networks demands
additional work at an organism level to better understand the regulatory mechanisms
implicated in particular anti-fungal immune responses. With a rising interest in metabolic
regulation and consequent immune outcomes from various pathogenic stimuli, our work
adds to an increasingly nuanced understanding of metabolic regulation of DCs in
response to different microbial stimuli. These studies, as well as those by others in the
field, underscore the need for additional research to elucidate the complexity of metabolic
regulation of innate immune cell responses to different pathogens.
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Figures

Figure 2 -1. Dectin-1 mediated activation drives glycolytic reprogramming.
(A) BMDCs were stimulated with LPS, Z, ZD for 24hours and extracellular acidification
rate (ECAR) is measured in real time using a Seahorse Extracellular Flux Analyzer
(Agilent, Seahorse Biosciences). (B) Relative ECAR of BMDCs stimulated with 2DG
followed by media or corresponding ligands (LPS, Z, or ZD). (C) Surface expression of
CD40 and CD86 on BMDCs stimulated for 24 hours with LPS, Z, ZD, Curdlan, or WGP.
(D) Intracellular cytokine staining of TNF and IL-12 of BMDCs stimulated for 6 hours
with LPS, Z, ZD in 5mM glucose in the presence or absence of 2DG. Blue peaks
represent unstimulated. Representative of n=3.
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Figure 2 -2. Dectin-1 dependent glycolytic burst and maturation requires Syk signaling.
(A) Real-time Relative ECAR of BMDCs stimulated in the present or absence of Syk
inhibitor (PRT) followed by LPS, Z (Zymosan) or ZD. (B) CD40 and CD86 surface
expression of BMDCs stimulated for 24hours with LPS, Z, ZD, Curdlan, or WGP in the
presence or absence of Syk inhibitor.
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Figure 2 -3. Dectin-1 mediated glycolytic reprogramming is independent of
TLR2/MyD88 signals.
(A) Relative ECAR of BMDCs from WT, TLR2-/-, and MyD88-/- stimulated in real time
response to ZD. (B) Relative ECAR of BMDCs from WT, TLR2-/-, and MyD88-/stimulated in real time response to PRT followed by ZD. (C) CD40 and CD86 surface
expression of BMDCs WT, TLR2-/-, and MyD88-/- stimulated for 24 hours with
Pam2CSK4 (TLR2 ligand), CpG (TLR9 ligand), LPS (TLR4 ligand), Z (TLR2 and
Dectin-1 ligand), ZD, or Curdlan (Dectin-1 ligands).

95

Figure 2 -4. Dectin-1 mediated glycolytic reprogramming requires a PI3k/TBK1/Akt
signaling axis.
(A) Protein expression of pAkt (T308), pan Akt, and -actin in BMDCs stimulated with
Z and ZD for 5, 15, and 30 minutes. (B) Protein expression of pAkt (T308) in BMDCs
stimulated for 5, 15, and 30 minutes with ZD in the presence or absence of PI3k inhibitor
(LY). (C) Protein expression of pAkt (T308) in BMDCs stimulated with ZD in the
presence or absence of TBK1 inhibitor (BX) for 5, 15, and 30 minutes. (D) Relative
ECAR of BMDCs stimulated in real time response to Z and ZD in the presence or
absence of PI3k or Akt inhibitors. Data represents n=4; * p<0.05 student t test.
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Figure 2 -5: Dectin-1 mediated acute glycolytic reprogramming is required for NLRP3
inflammasome activation.
(A) Relative mRNA expression of IL-1 in BMDCs stimulated for 6 hours with LPS, Z,
ZD in the presence or absence of 2DG. (B and C) Protein expression of active IL-1 from
culture supernatant (B) and pro-IL-1 from cell lysates (C) of BMDCs stimulated with
LPS, Z, and ZD in the presence or absence of 2DG or PRT for 4 hours with an addition
of nigericin in the last hour. (D) Protein expression of IL-1 and NLRP3 from culture
supernatant of BMDCs stimulated with LPS and WGP particles in the presence or
absence of 2DG for 4 hours with an addition of nigericin in the last hour.
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Figure 6
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Figure 2 -6: Model of Dectin-1 -mediated glycolytic reprogramming and IL-1
production
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CHAPTER 3

Cell-intrinsic glycogen metabolism supports early glycolytic reprogramming
required for dendritic cell immune responses
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Summary
Dendritic cell (DC) activation by toll-like receptor (TLR) agonists causes rapid
glycolytic reprogramming that is required to meet the metabolic demands of their
immune activation. Recent efforts in the field have identified an important role for
extracellular glucose sourcing to support DC activation. However, the contributions of
intracellular glucose stores to these processes have not been well characterized. We
demonstrate that DCs possess intracellular glycogen stores and that cell-intrinsic
glycogen metabolism supports the early effector functions of TLR-activated DCs.
Inhibition of glycogenolysis significantly attenuates TLR-mediated DC maturation and
impairs their ability to initiate lymphocyte activation. We further report that DCs exhibit
functional compartmentalization of glucose and glycogen –derived carbons, where these
substrates preferentially contribute to distinct metabolic pathways. This work provides
novel insights into nutrient homeostasis in DCs, demonstrating that differential utilization
of glycogen and glucose metabolism regulates their optimal immune function.

Introduction
Dendritic cells (DCs) are canonical “professional antigen presenting cells” of the
immune system and play a central role in coordinating both innate and adaptive immune
responses (Banchereau and Steinman, 1998; Lee and Iwasaki, 2007; Lipscomb and
Masten, 2002). DCs recognize microbial pathogens and other inflammatory stimuli
through the expression of innate immune receptors including the Toll-like receptor (TLR)
family (Akira and Takeda, 2004; Amati et al., 2006; Barton and Medzhitov, 2002). DC
104

activation by TLR signaling initiates a complex set of transcriptional and translational
events that are characterized by the up-regulation of surface co-stimulatory molecule
expression, inflammatory cytokine secretion, and the ability to stimulate T lymphocytes
via antigen presentation by major histocompatibility (MHC) molecules.
TLR stimulation initiates a shift in DC metabolism characterized by upregulation
of aerobic glycolysis, which plays a vital role in supporting the immune effector function
and survival of both human and mouse DCs (Amiel et al., 2012; Amiel et al., 2014;
Everts et al., 2012; Krawczyk et al., 2010). Rapid glycolysis induction supports the
metabolic requirements associated with the high levels of protein synthesis that
contribute to DC immune activity. The TLR-mediated “glycolytic burst” drives de novo
fatty acid synthesis via glucose-dependent citrate metabolism, which supports the
synthesis and secretion of inflammatory cytokines (Amiel et al., 2014; Rehman et al.,
2013). Interrupting the glucose-to-citrate pathway significantly impairs DC maturation,
cytokine secretion, and T cell stimulatory capacity (Amiel et al., 2014; Everts et al.,
2012; Krawczyk et al., 2010).
Immune cells are thought to primarily support activation-associated glycolysis via
increased expression of glucose transporters (Everts and Pearce, 2014; Fox et al., 2005;
Pearce and Everts, 2015; Pearce and Pearce, 2013). Consistent with this, the role of the
inducible glucose transporter, GLUT1, in regulating activation-associated glucose flux in
both myeloid and lymphoid immune cells has been a major focus in the field
(Freemerman et al., 2014; Macintyre et al., 2014). In DCs however, GLUT1 upregulation
occurs several hours after TLR stimulation, while TLR-mediated glycolytic
reprogramming happens within minutes of activation. Thus, the source of glucose
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supporting the earliest events in DC activation, namely whether glucose is sourced from
the extracellular environment or from intracellular pools, has not been fully defined. We
propose that the DCs utilize intracellular glycogen reserves to fuel their metabolic needs
during early immune activation and that glycogen metabolism is required by these cells
to initiate proper immune effector responses.
Glycogen, a large branch-chained glucose polymer, has been extensively
characterized in hepatocytes, muscle cells, and neuronal tissue where it serves as an
intracellular carbon reservoir (Adeva-Andany et al., 2016; Roach et al., 2012; Voet et al.,
2013). By expressing tissue-specific enzymes for glycogen synthase (GYS) and glycogen
phosphorylase (PYG), rate-limiting enzymes of glycogen synthesis and break down
respectively, cells in the liver, muscle, and brain store glucose in the form of glycogen to
be utilized according to their specific metabolic demands (Adeva-Andany et al., 2016;
Roach et al., 2012; Voet et al., 2013). During glycogenolysis, PYG isozymes break down
glycogen into glucose-1-phosphate (G1P), which is subsequently converted into glucose6-phosphate (G6P) and can serve as a direct substrate for further catabolism via
glycolysis. In this manner, glycogen-storing cells, such as those in muscle and brain
tissue, can maintain intracellular glycogen reserves for cell-intrinsic metabolic
requirements (Adeva-Andany et al., 2016; Voet et al., 2013). The significance of cellintrinsic glycogen metabolism in immune cells has not been well-characterized.
We demonstrate that DCs express specific isoforms of enzymes essential for
glycogen synthesis and breakdown and that these cells require glycogen metabolism to
support their immune function. Although the presence of glycogen in DCs has been
previously implicated (Maroof et al., 2005), the direct role for glycogen in DC
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metabolism and immune function has not been described. We propose that DCs use
intracellular glycogen reserves to support early glycolytic metabolism that accompanies
their activation. We show that disruption of glycogen metabolism significantly impairs
DC maturation and immune effector function, particularly at early stages of activation
and in glucose-restricted conditions. We further show that glycogen-derived carbons
preferentially contribute to the TCA-dependent citrate pool compared to glucose
catabolized directly by the cell. These findings elucidate a novel metabolic regulatory
pathway in DCs, and provide new insights into energy and nutrient homeostasis in these
cells in support of their immune activation.

Results and discussion
DCs express glycogen metabolic machinery and utilize cell-intrinsic glycogen
metabolism upon activation
TLR stimulation drives DCs to undergo glycolytic reprogramming in order to
meet cellular anabolic demands associated with activation (Amiel et al., 2014; Krawczyk
et al., 2010). We performed a nutrient screening assay using single-carbon-source defined
media and found that DCs can catabolize both short- and long-chain glucose polymers
(Figure 3 -1A). The ability of DCs to generate NADH from glycogen (Figure 3 -1A) is
of particular interest given its role as the predominant form of glucose macromolecule
storage in normal physiology. While cells are unlikely to encounter extracellular
glycogen in vivo, these assays demonstrate that DCs exhibit the capability to catabolize
glycogen and are likely to express the key enzymes of glycogen metabolism.
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We analyzed mRNA levels of glycogen phosphorylase (PYG) and glycogen
synthase (GYS), the rate-limiting enzymes of glycogen breakdown and synthesis
pathways, respectively in DCs. Glycogenolysis is executed by three different tissuespecific PYG isozymes in mice and humans: PYGL in the liver, PYGM in muscle, and
PYGB in brain tissue. Glycogen synthesis is controlled by two different tissue-specific
GYS isozymes: GYS1 in muscles and other peripheral tissue, and GYS2 in the liver.
Both mRNA and protein analysis in BMDCs (Figure 3 -1B, Figure 3 -1C) and moDCs
(Figure 3 -1D) showed that DCs express PYGL and GYS1 isozymes. These enzymes
were not appreciably regulated following 6hr stimulation with LPS (Figure 3 -1B,
Figure 3 -1D). Detection of intracellular glycogen in freshly isolated human CD14+
monocytes and CD1a+ dendritic cells (Figure 3 -1E) indicates a physiological role for
glycogen in these cells. Unactivated DCs contain intracellular glycogen pools that are
fully depleted when cells are cultured in glucose-free media (Figure 3 -1F), and partially
depleted by LPS stimulation in BMDCs (Figure 3 -1G) and moDCs (Figure 3 -1H).
TEM images of BMDCs show distinct glycogen deposits by tannic acid stain that are
absent in cells grown without glucose (Figure 3 -1I) (Afzelius, 1992).
To validate the efficacy and specificity of the PYG inhibitor, CP91149 (CP), we
incubated BMDCs with CP in the nutrient screening assay (as in Figure 3 -1A) and
assessed inhibition of glucose or glycogen catabolism. Glycogen-dependent NADH
levels were fully attenuated in the presence of CP, while glucose-dependent NADH
levels were unaffected (Figure 3 -1J), demonstrating the specificity of this inhibitor.
PYG inhibition caused a reduction in basal glycolysis rates in unactivated BMDCs
(Figure 3 -1K), indicating that DCs utilize intracellular glycogen to support basal
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glycolytic demands. Importantly, the effect of glycolysis inhibitor 2-deoxyglucose (2DG)
was non-redundant with CP, showing that free glucose and intracellular glycogen stores
make distinct contributions to DC metabolism (Figure 3 -1K).

PYGL inhibition impacts DC survival in hypoglycemic conditions

Glycogen metabolism supports cancer cell growth, proliferation, and cellular
lifespan (Favaro et al., 2012). We tested the effect of PYG inhibition on the survival of
BMDCs at early (6hrs) and late (24hrs) time points after LPS activation. PYG inhibition
resulted in modest increases in cell death at early time points under low-glucose
conditions (Figure 3 -2A). This phenotype was increased after 24hrs of inhibition
(Figure 3 -2B). In contrast, the viability of human moDCs was not impacted at all
glucose concentrations tested (Figure 3 -2C).

Glycogen metabolism preferentially supports early DC maturation
TLR-driven early glycolytic burst is a metabolic hallmark of activated DCs
(O'Neill, 2014), and both lymphoid and myeloid cells depend heavily on extracellular
glucose for glycolysis-dependent effector responses (Everts et al., 2012; Krawczyk et al.,
2010; Pearce and Pearce, 2013; Pearce et al., 2009). This may pose a limitation on the
abundance of glucose in highly inflamed tissues and secondary lymphoid organs where
DCs likely experience nutrient competition with proliferating lymphocytes (Lawless et
al., 2017). We hypothesized that glycogen metabolism supports early TLR-mediated
glycolysis and activation in DCs by providing an intracellular source of glucose carbons.
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We examined the surface expression of CD40 and CD86 in BMDCs stimulated with LPS
for 6 and 24hrs in the presence or absence of PYG inhibitor over a range of glucose
concentrations representing both hyper- and hypoglycemic states. CD40 and CD86
expression was attenuated by CP treatment (Figure 3 -2D and S1a), with a more
pronounced effect at 6hrs and in hypoglycemic conditions (Fig 2D and S1a). PYG
inhibition with an alternative inhibitor, DAB, at 6hrs after stimulation gave similar
outcomes (Fig S1b). Reduced CD40 and CD86 expression was observed both in BMDCs
starved of intracellular sugar (Figure 3 -2E) and in moDCs inhibited by CP (Figure
3 -2F) further suggesting a role for glycogen pools in sustaining DC maturation. In
addition, PYG-targeted siRNA was used to silence PYG expression in moDCs. As
mRNA expression data indicated that both PYGB and PYGL isoenzymes are expressed
in human moDCs (Fig S1c), both isoforms were silenced simultaneously in moDCs using
targeted siRNA (Fig S1d). Genetic silencing of PYG in moDCs resulted in attenuation of
LPS-induced expression of maturation markers (Figure 3 -2G).
While the importance of GLUT1 has been conclusively delineated in both
myeloid and lymphoid immune cells (Amiel et al., 2014; Freemerman et al., 2014;
Macintyre et al., 2014; Wieman et al., 2007), the kinetics of GLUT1 regulation do not
account for the acute glycolytic reprogramming that occurs in activated DCs. GLUT1
upregulation in activated DCs is not detected before 6 hours of LPS stimulation (Fig
S1e), which correlates with the finding that extracellular glucose is depleted only after
6hrs of stimulation (Figure 3 -2H). To confirm that the cells are less dependent on
imported glucose for early activation, we assessed DC maturation at 6 and 24hrs after
LPS stimulation while blocking GLUT1 activity with inhibitor STF31 (Figure 3 -2I and
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S1f). In contrast to PYG inhibition, GLUT1 inhibition had a significant impact on the
maturation at 24hrs but not 6hrs after activation. These data provide strong evidence that
cell-intrinsic glycogen metabolism plays a central role in driving DC maturation,
particularly during early time points and in glucose-restricting conditions.

PYG inhibition impacts DC immune effector function
Blocking glycolysis in TLR-activated DCs impairs their ability to produce
inflammatory cytokines and stimulate T cells (Amiel et al., 2014; Krawczyk et al., 2010).
We tested whether these responses are also affected by PYG inhibition. Intracellular
cytokine staining for TNF- and IL-12 after 4hrs of LPS stimulation showed that PYG
inhibition attenuates inflammatory cytokine production, with a larger effect in lowglucose conditions (Figure 3 -3A-B, S2a). Multiplex cytokine analysis of LPS-stimulated
DCs showed reduced pro-inflammatory cytokines and chemokine production in PYGinhibited cells compared to controls in both BMDCs (Figure 3 -3C) and moDCs (Figure
3 -3D). CP did not globally impact all LPS-mediated protein production as other
cytokines were unaffected (Fig S2b-c). siRNA-mediated knockdown of PYG expression
in moDCs recapitulated the inhibitor data, as LPS-driven IL-12 production was
attenuated in PYG-silenced moDCs (Figure 3 -3E).
To examine the ability of DCs to take up and process antigens, we stimulated
BMDCs with LPS plus OVA-AF488 or OVA-DQ for 3 hours (Figure 3 -3F). OVAAF488 allows tracking of antigen uptake, while OVA-DQ only fluoresces upon antigen
uptake and processing. PYG-inhibited DCs showed reduced antigen uptake regardless of
LPS stimulation (Figure 3 -3F while antigen processing was unexpectedly enhanced by
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PYG inhibition. We next tested the effect of PYG inhibition or silencing on DC ability to
stimulate CD4+ T cells. PYG-inhibited BMDCs exhibited significantly reduced capacity
to stimulate T cells (Figure 3 -3G and H). PYG-silenced moDCs exhibited similar
impairments in CD4+ T cell stimulation (Figure 3 -3I). These data demonstrate that cellintrinsic glycogen metabolism contributes to the regulation of the multifaceted
dimensions of DC immune effector function.

Glycogen-derived carbons fuel both glycolytic reprogramming and mitochondrial
respiration in activated DCs
We proposed that glycogen-derived glucose drives early glycolytic flux in TLRactivated DCs prior to GLUT1 upregulation. To test this, we performed a real-time
extracellular flux analysis on BMDCs and moDCs. LPS-driven glycolytic burst was
significantly attenuated by PYG inhibition in both BMDCs (Figure 3 -4A, S3a) and
moDCs (Figure 3 -4B). We further tested whether cell-intrinsic glycogen metabolism
also contributes to mitochondrial respiration during early activation. Concomitant with
glycolysis reduction, PYG inhibition attenuated the oxygen consumption rate (OCR) in
BMDCs regardless of activation (Figure 3 -4C). These data suggest that pre-existing
glycogen pools contribute metabolic substrates for mitochondrial respiration. Consistent
with this, PYG inhibition accelerates LPS-mediated ATP depletion during early
activation in a time-dependent manner (Figure 3 -4D). The synergistic effect of
combined CP and ATP-synthase inhibitor oligomycin in reducing ATP production
(Figure 3 -4E) indicates that glycogen catabolism contributes to both cytosolic and
mitochondrial ATP generation. These findings indicate the intriguing possibility that
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there may be distinct roles for glucose and glycogen-derived carbon molecules in DC
metabolism.
Since PYG inhibition resulted in reduced intracellular ATP levels (Figure 3 -4D
& E), we assessed the effect of PYG inhibition on the activation of AMPK, a key
metabolic sensor of intracellular nutrient and ATP levels (Hardie et al., 2012). PYG
inhibition resulted in increased phosphorylation of AMPK (Fig S3b), which is reported to
antagonize BMDC activation (Krawczyk et al., 2010). This is consistent with reports
showing that inhibition of glycolysis induces compensatory activation of AMPK (Wang
et al., 2011; Wu et al., 2015). However, PYG inhibition had no impact on LPS-mediated
GLUT1 upregulation (Fig S3c), suggesting that AMPK regulation of glucose transport is
not a significant mechanism at play in our model. Nevertheless, LKB1 deficient BMDCs,
which are incapable of activating AMPK, show decreased sensitivity to PYG inhibition
during maturation at normal glucose concentrations, suggesting that AMPK
compensatory activation during PYG inhibition may be involved in regulating maturation
in these conditions (Fig S3d).
Previous work has demonstrated that glucose consumed by activated DCs enters
the TCA cycle to generate citrate, which is preferentially translocated from the
mitochondria into the cytosol via the citrate shuttle to support de novo fatty acid
synthesis. This process is linked to ER and Golgi membrane expansion, which is
hypothesized to enhance the production of effector molecules central to DC activation
(Amiel et al., 2014; Rehman et al., 2013). To examine the role of glycogenolysis in
citrate metabolism explicitly, we performed metabolic tracing experiments in which
BMDCs were differentiated in 13C-labeled glucose to label all intracellular metabolites.
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Cells were subsequently switched to normal glucose at the time of LPS stimulation in the
presence or absence of CP for 1 and 3hrs. As previously published, LPS stimulation
induces substantial metabolic flux through glycolysis and TCA citrate production
((Everts et al., 2014) and data not shown). PYG inhibition significantly reduced 13Clabeled citrate while no statistically significant impact on hexose phosphate, pyruvate,
lactate, and post-citrate metabolites fumarate and malate was observed (Figure 3 -4F and
S3e). Hexose phosphate refers to any 6-carbon sugar since our metabolite tracing
approach could not distinguish individual sugars among this group. These data indicate
that intracellular glycogen reserves preferentially support the generation of citrate
following LPS stimulation.
Glutamine can also serve as an important carbon source for the TCA cycle.
However, the findings that nearly the entire glutamine pool is derived from 12C-labeled
sources (Fig S3f) and that CP has very little effect on glutamine levels (Fig S3f), suggests
that glutamine metabolism is not directly impacted by PYG inhibition. This is further
supported by observations that: 1) CP attenuates the maturation of BMDCs stimulated in
the presence or absence of glutamine (Fig S3g); and 2) glutaminolysis inhibitor DON has
no significant impact on glycolytic burst or OCR (Fig S3h).
To identify the role of glycogen metabolism in regulating extracellular glucose
flux, the reverse metabolomics experiment was performed in which BMDCs
differentiated in normal glucose were switched to 13C-glucose at the time of LPS
activation and analyzed at 3 and 6 hours post stimulation (Figure 3 -4G). PYG inhibition
minimally affected the 13C-glucose contribution to cytoplasmic hexose phosphate, lactate,
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and pyruvate, while it severely attenuated both 12C and 13C-glucose contributions to
citrate production (Figure 3 -4G).
The metabolite tracing data are consistent with previously published work (Everts
et al., 2014), in which extracellular glucose contributes heavily to cytoplasmic glycolytic
metabolites and citrate production from the TCA cycle (Figure 3 -4F-G). However, these
data also uncover two previously unappreciated aspects of glucose metabolism in DCs: 1)
glycogen-derived carbons from basal glycogen stores (CP-sensitive 13C metabolites in
Figure 3 -4F) preferentially support initial glycolytic intermediates and citrate synthesis;
2) a significant amount of glucose imported from the extracellular environment gets
rapidly converted into glycogen (CP-sensitive 13C metabolites in Figure 3 -4G). The
finding that extracellular 13C-glucose incorporation into citrate (Figure 3 -4G), succinate,
fumarate, and malate (Fig S3i) is sensitive to PYG inhibition suggests that a significant
portion of extracellular glucose destined for mitochondrial oxidation is metabolically
routed via a glycogen-dependent pathway during DC activation. The routing of glucose
carbons via a rapid sequence of glycogen synthesis and glycogenolysis is characteristic of
a metabolic pathway described in astrocytes and muscle cells as the “glycogen shunt”
(Shulman et al., 2001; Shulman and Rothman, 2001). Our metabolic profiling studies
support a model where glucose processing in TLR-stimulated DCs undergoes three
functionally distinct pathways: 1) the catabolism of pre-activation intracellular glycogen
stores; 2) the catabolism of imported glucose directly; 3) the incorporation of imported
glucose into synthesis and breakdown of glycogen via the glycogen shunt (modeled in
Fig S4).
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While the glycogen shunt is clearly inefficient from an energetic perspective,
others have argued that glycogen breakdown and synthesis may occur in separate spatial
pools within brain and muscle cells to fuel rapid bursts of metabolic activity required in
these cells that override the total energetic cost of this process (Calder and Geddes, 1992;
Elsner et al., 2002; Obel et al., 2012). DCs may employ a similar strategy of
compartmentalized glycogen metabolism in order to fuel early immune activation.
However, how this occurs and how it may be regulated in DCs remains an important
question. Precedent for distinct and parallel sugar metabolism has been previously
reported, whereby granulocyte phagocytic capability is driven by glycogen-derived
carbons, while their chemotaxis is fueled by catabolism of free glucose carbons
(Weisdorf et al., 1982). We propose that the source of carbons in activated DCs, namely
whether it is glucose or glycogen –derived, may dictate differential functional responses.
We speculate that spatial compartmentalization of these processes in the cytoplasm may
be an important component of how glycogen metabolism is regulated.
While glycogen metabolism has been previously implicated in myeloid cells of
the immune system (Maroof et al., 2005; Scott, 1968; Weisdorf et al., 1982; Yunis and
Arimura, 1964, 1966), the role of glycogen metabolism in specific immune effector
functions of DCs has not been previously defined. We show here a definitive role for
glycogen metabolism in regulating immune effector functions of both human and mouse
DCs. We further demonstrate that glucose- and glycogen-derived carbons exhibit distinct
metabolic fates, a phenomenon that we suspect is not DC-specific and likely occurs in
other cells that utilize cell-intrinsic glycogen metabolism. Ongoing studies are focused on
elaborating the mechanistic details of how glycogen-dependent compartmentalization of
116

metabolic pathways occurs in response to different immune stimuli. With a growing
interest in understanding how metabolic regulation controls the functional effector
responses of immune cells, this work delineates an intricate and novel layer of
complexity to how metabolic pathways operate at a subcellular level, which may be
exploited in cell-based therapeutic applications in the future.
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Experimental Procedures
Mice
C57/Bl6J and OT-II (B6.Cg-Tg (TcraTcrb)425Cbn/J mice were purchased from
Jackson Laboratory and bred in-house and maintained at the University of Vermont
animals care facility under protocols approved by Institutional Animal Care and Use
Committee.
Itgaxcre LKB1fl/fl mice PubMed: 21124450 were housed and bred at the LUMC,
Leiden, Netherlands, under SPF conditions. All animal experiments were performed in
accordance with local government regulations, and the EU Directive 2010/63EU and
Recommendation 2007/526/EC regarding the protection of animals used for experimental
and other scientific purposes and approved by the CCD, animal license number
AVD116002015253.
Mouse DC culture and Activation
Bone marrow-derived DCs (BMDCs) were generated as follows: BM cells were
flushed from femurs of 9-18-week-old mice and the cells were differentiated in GM-CSF
(20ng/mL; Peprotech) in complete DC medium (CDCM), comprised of RPMI1640, 10%
FCS, 2mM L-glutamine, 1IU/mL Pen-Strep, 1mM beta-mercaptoethanol, for 7 days, with
a medium change every 2 days. On day 7, DCs were washed in CDCM and cultured at
2x10^5 cells per 200L of media alone, STF31 (12.5 M), CP91149 (75-100M), DAB
(1mM), LPS (100ng/mL), LPS plus STF31 or CP91149, or DAB, or OVA (from whole
egg white) at indicated time points. Where appropriate, DCs were stimulated in CDCM
containing 0mM, 1.25mM, 2.5mM, or 5mM glucose.
Glucose starvation experiment
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BMDCs were starved for glucose overnight, with a non-starved group as a
control. On the next day, DCs from both groups were washed with sugar free RPMI and
stimulated with LPS in glucose free medium CP for 6hours. CD40 and CD86 expression
was analyzed by Flow cytometry.
Human DC culture and activation
Human monocyte-derived DCs (moDCs) were differentiated from peripheral
blood monocytes as follows: Blood filters from de-identified blood donors were provided
by CVPH Medical Center Blood Bank in Plattsburgh, NY. Filters were reverse-flushed in
sterile PBS, and PBMCs were prepared by Ficoll-Paque (density gradient of 1.0772)
centrifugal separation using LSM media (MP biochemical; Fisher). Resulting monocytes
were enriched using CD14 positive selection beads per manufacturer instructions
(Miltenyi Bioscience) and cultured in complete DC medium (CDCM) supplemented with
human recombinant GM-CSF (20ng/mL) plus human recombinant IL-4 (20ng/mL)
(Peprotech) for 7 days. On day 7, moDC were harvested, stimulated as indicated, and
analyzed by FACS for maturation and by multiplex panels (Life Technologies) for
cytokine production.
Quantitative Real-time PCR of pygl, pygm, gys1, and gys2 expression
RNA was isolated with an RNAeasy Kit (Qiagen) and cDNA was synthesized
with an iScript cDNA Synthesis Kit (Biorad). pygl, pygm, gys1, gys2, and slc2a1 Taqman
primer probes (Applied Bioscience system) and AB7500 sequence detection system or
QuantStudio 3.0 were used for relative mRNA expression. mRNA relative quantitative
values were calculated based on 2(-CT) and normalized to untreated samples.
Glycogen phosphorylase knockdown by siRNA transfection of moDC
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For knockdown of glycogen phosphorylase isoforms, moDCs were generated as
mentioned above. At day 4 of the culture, the cells were harvested, washed with PBS,
brought to a concentration of 1x10^6 cells / 100 µL resuspension buffer, and finally,
transfected by electroporation with either 10 nM anti-PGYL siRNA in combination with
10 nM anti-PYGB siRNA or 20 nM scrambled siRNA (Dharmacon). Electroporation was
performed using a Neon Transfection System (Invivogen) with the following settings:
1600 V, 20 ms and one pulse. Immediately after electroporation, 1x10^6 cells were taken
up in 5 mL 10% HI-FCS basal media, containing no antibiotics, and plated at 200 cells /
µL. The next morning, the media was re-supplemented with penicillin, streptomycin,
rGM-CSF and rIL-4. At day 6, the cells were harvested, stimulated as indicated, and
analyzed by FACS for maturation and by ELISA for cytokine production. Silencing
efficiency was determined by qPCR on 6 day-old cells. The transfection efficiency was
routinely greater than 80%.
Antigen Uptake, Processing, and in-vitro T cell responses
BMDCs were stimulated LPS with OVA-AF488 (5g/mL) and OVA-DQ
(5g/mL) for antigen uptake and processing, respectively. For in vitro T cell responses, T
cells were generated using mouse CD4 positive selection beads from spleens of 6-10week-old transgenic OT-II mice and age-matched Wild-type B6 mice. BMDCs were
pulsed with whole Ovalbumin protein (OVA), extracted from egg white, and LPS in the
presence or absence of CP for 6 hours, washed 3 times, and co-cultured with CFSElabeled OT-II T cells at a 1:5 ratio for 72 hours. T cell proliferation (CFSE dilution) was
analyzed by flow cytometry.
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For alloreaction studies of siRNA transfected moDC, the cells were washed 2
times, and co-cultured with CellTrace Violet-labelled human naïve CD4+ T cells, which
were isolated using a naïve pan T cell isolation kit (Miltenyi) followed by negative
selection using CD8 MicroBeads (Miltenyi), at a 1:4 ratio for 4 days. T cell proliferation
was analyzed by flow cytometry.
Metabolism assays
Extracellular glucose and intracellular glycogen levels were measured with a
Glucose assay kit (Eton Biosciences) and a Glycogen assay kit (Biovision), respectively.
For Biolog assays, (Metabolic phenotypic screening assays), IFM-1 reagent, Biolog MA
redox dye, and Biolog plates were purchased from Biolog Inc. Fully differentiated
BMDC were plated overnight at 50,000 cells per well in specified nutrient sources in
basal MC-0 medium (IFM1 media with 5%FCS, 0.3mM L-glutamine, 100I/U Pen Strep).
20L of Biolog MA dye was added to each well the next morning plates measured at 592
nm absorbance as indicated. Data were normalized to the readings at time 0. Extracellular
acidification rate (ECAR) and oxygen consumption rate (OCR) were measured with
Metabolic Flux Analyzer (Seahorse Bioscience, North Billerica, MA 24XP and/or 96XP).
ATP concentrations were measured with an ATP Determination Kit (Invitrogen)
according to the manufacturer’s instructions.
BMDC cultures and activation for metabolomics
For metabolomics tracing in Fig 4F, BMDCs were differentiated in

13C -glucose
6

containing CDCM. On day 7, the cells were switched to 12C6-glucose medium, with LPS
and LPS+CP added at the time of media switch and stimulated for 1 and 3 hours. At each
time point, cells were harvested, counted, pelleted, and frozen for the UHPLC-MLS
121

metabolomics processing below. For inverse metabolomics in Fig 4G, BMDCs normally
differentiated in regular CDCM were switched to

13C -glucose
6

medium at the time of

stimulation, with and without CP for 3 and 6 hours. Cells were harvested and processed as
above. Supernatant from the 6 hour stimulation groups was collected for Multiplex
Cytokine analysis.
UHPLC-MS metabolomics
Frozen cell pellets were extracted at 2x10^6 cells/mL in ice cold lysis/extraction buffer
(methanol:acetonitrile:water 5:3:2). Samples were agitated at 4 °C for 30 min followed by
centrifugation at 10,000 g for 10 min at 4 °C. Protein and lipid pellets were discarded, and
supernatants were stored at -80 °C prior to metabolomic analysis. Ten µL of extracts were
injected into an UHPLC system (Vanquish, Thermo, San Jose, CA, USA) and run on a
Kinetex C18 column (150 x 2.1 mm, 1.7 µm – Phenomenex, Torrance, CA, USA) at 250
µl/min (phase A: Optima H2O, 0.1% formic acid; phase B: acetonitrile, 0.1% formic acid).
The autosampler was held at 7 oC and the column compartment at 25 oC. The UHPLC
system was coupled online with a Q Exactive mass spectrometer (Thermo, Bremen,
Germany), scanning in Full MS mode (2 µscans) at 70,000 resolution in the 60-900 m/z
range in negative and then positive ion mode (separate runs). Eluate was subjected to
electrospray ionization (ESI) with 4 kV spray voltage, 15 sheath gas and 5 auxiliary gas.
Metabolite assignments and isotopologue distributions were determined using the software
Maven (Princeton, NJ, USA)1, upon conversion of .raw files into .mzXML format through
MassMatrix (Cleveland, OH, USA). Chromatographic and MS technical stability were
assessed by determining CVs for heavy and light isotopologues in a technical mixture of
extract run every 10 injections. Relative quantitation was performed by exporting the
122

values for integrated peak areas of light metabolites and their isotopologues into Excel
(Microsoft, Redmond, CA, USA) for statistical analysis including t-test and ANOVA
(significance threshold for p-values < 0.05).
Electron Microscopy
Samples were fixed in Karnovsky’s Fixative for 1hr at 4C, washed in 0.1M
Cacodylate Buffer, and post-fixed in 1% OsO4 for 1hr at 4C followed by an extensive
rinse with Cacodylate buffer. Samples were then dehydrated in a graded series of ethanol,
and embedded in Spurr. Sections were cut with a Reichert Ultracut Microtome and
stained with toluidine blue. For contrast, 1% tannic acid was added to the cut sections of
the grids for 10 minutes, followed by 6 minutes of uranyl acetate and 4 minutes of lead
citrate. Cells were examined with a JEM1400 transmission electron microscope (JEOL
USA).
Immunoblot analysis
Cell lysates were prepared using 2X NP-40 lysis buffer. 20g protein was loaded
into each well of a 12.5% polyacrylamide gel, transferred onto activated nitrocellulose
membrane (BioRad). Electrophoretic transfer was performed using Trans-Blot Turbo
RTA mini Nitrocellulose transfer kit. Membranes were blocked in 2%milk in 1xTBST at
RT for 1hr, and incubated in indicated antibody at 4C overnight. Blots were washed 3x
in 1xTBST at RT, probed with secondary antibodies at RT for 45-60 minutes, and
washed 3-4x with 1xTBST. Proteins were visualized by SuperSignal West Pico
Chemiluminescent substrate and exposed with GeneXpert System imager. Trans-Blot
Turbo Transfer system and secondary antibodies for Western blots were generously
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provided by Dr. Paula Deming, Medical Laboratory and Radiation Science Department,
UVM.
Flow Cytometry and Cytokine measurements
The following fluorescently labeled antibodies were used for flow cytometry:
anti-CD11c (N418), anti-CD40 (3/23), anti-CD86 (GL1), IA-b (AF6-120.1), anti-CD1a
(HI149), anti-CD40 (5C3), anti-CD86 (IT2.2), anti-TNF (MP6-XT22), anti-IL-12p40
(C15.6). Stimulated cells as indicated were harvested and washed in 1% FACS buffer
(PBS plus 1% FBS), stained with specific antibodies, and incubated on ice for 30
minutes. All samples were acquired using a LSRII flow cytometer (BD Biosciences). For
intracellular cytokine expression, cells were activated with indicated treatment groups for
a total of 4 hours with an addition of Golgi plug (1:1000) (Biolegend) after the first hour
of stimulation. For intracellular staining of TNF- and IL-12 (Biolegend), cells were
fixed in 4% Paraformaldehyde, permeabilized in 0.2% saponin, and stained with
antibodies in FACS buffer (1%FBS in PBS). Samples were analyzed on a BD LSRII flow
cytometer. For cytokine levels of BMDCs and moDCs, supernatants were collected as
indicated time points and measured with Mouse Cytokine Magentic 20-Plex and Human
Cytokine Magnetic 30-Plex panels (Life Technologies) per manufacture instructions
using Bio-Plex array suspension system.
Statistical Analysis
Data were analyzed with GraphPad Prism software (version 6.0). Samples were
analyzed using Student’s t-test, One-way, and Two-way ANOVA where appropriate.
ANOVA tests were post-calculated by Tukey’s multiple comparison test or Sidak test.
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Results are means +SD as indicated, and statistical values are represented significant
when p values were equal or below 0.05.
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Figures

Figure 3 -1: DCs utilize intracellular glycogen metabolism upon LPS stimulation.
(A) BMDCs were cultured in the indicated substrates as the sole nutrient sources and
measured for ability to produce NADH as described in the methods. Data indicate
relative NADH production at 6 hrs normalized to no carbon source controls, n=3. (B)
Relative mRNA expression of pyg and gys isoforms in naive BMDCs. (C-D) PYGL,
GYS1, and -actin protein expression in unactivated and 6hr LPS-stimulated BMDCs (C)
and 24hr LPS-stimulated moDCs (D). (E-H) Intracellular glycogen levels of: human
peripheral blood CD14+ monocytes and CD1a+ DCs (E), untreated BMDCs cultured
overnight in glucose (F), BMDCs (G) and moDCs (H) stimulated LPS in 5mM glucose
(n=3-6, mean SD, student’s t-test, *P<0.05, ** P=0.0021, nd= not detected). Glycogen
levels were normalized to 10^5 cells. (I) TEM images of unactivated BMDCs in 5mM
glucose (left) and 0mM glucose (right), with arrows indicating intracellular glycogen
deposits identified by tannic acid staining. (J) NADH levels over time in BMDCs
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cultured in glucose or glycogen containing media (as in A) CP (n=4, meanSD, ***P
<0.0001). (K) Basal ECAR of resting BMDCs treated with CP, 2DG, or both (treatment
introduced at dotted line), representative of at least 3 replicates.
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Figure 3 -2: Glycogen metabolism supports survival and early maturation of TLRactivated DCs.
(A-B) 7AAD viability staining of BMDCs stimulated with LPS  CP for 6hrs (A) and
24hrs (B) at 5mM glucose. (C) 7AAD viability staining of moDCs stimulated with LPS 
CP for 24hrs. (D) BMDCs were stimulated for 6 and 24 hours and analyzed for CD40
and CD86 surface expression. (E) CD40 and CD86 expression of BMDCs stimulated for
6 hrs in free glucose medium with and without glucose starvation. (F) CD86 and HLADR expression of moDCs stimulated with LPSCP for 24hrs in 5mM glucose. (G) CD86
and HLA-DR surface expression of 24hr LPS-stimulated moDCs silenced with control
(scrambled) or PYG-targeted siRNA. (H) Glucose measurements from supernatant of
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BMDCs stimulated with LPS for 3, 6, and 24 hrs. (I) CD40 and CD86 surface expression
of BMDCs stimulated GLUT1-inhibitor in normal glucose for 6 and 24hr. (A-F, H-I)
n=3-6, meanSD, Two-way ANOVA with Tukey Post-test, *P0.05 ***P=0.0006
****P<0.0001. (G) n=5, Paired t-test, *P=0.04, **P=0.0093.
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Figure 3 -3: PYGL inhibition attenuates immune effector functions of DC.
(A-B) Intracellular staining of TNF- and IL-12 of BMDCs stimulated with LPS for 4
hrs in 5mM glucose. (C-D) Multiplex panels of cytokine and chemokine measurements
from the supernatant of BMDCs (C)and moDCs (D)activated with LPS for 6 hrs. Dotted
lines represent unstimulated levels. (E) Relative IL-12 production by moDCs LPSstimulated for 24hrs transfected with control or PYG-targeted siRNA. (F) BMDCs treated
with LPS CP plus OVA-AF488 or OVA-DQ for 3 hours and analyzed by flow
cytometry for antigen uptake and processing. (G) BMDCs were pulsed for 6 hours with
indicated treatments and subsequently co-cultured with CFSE-labeled OT-II Tcells.
CFSE dilution was measured on day 3 post co-culture. (H) Measurements of proliferation
of OT-II T cells (from (G)) stimulated by BMDCs pre-treated with indicated conditions.
(I) si-RNA transfected moDCs were co-cultured with CellTrace Violet –labeled human
naïve CD4+T cells for 4 days. Data were normalized to scrambled siRNA. Proliferation
was measured after 4 days. (A-I) n=3-5, meanSD, (B, F) 2-way ANOVA Tukey
Posttest. (C-E, H-I) student’s t-test, *P0.05, **P<0.001, ***P=0.0004, ****P<0.0001.
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Figure 3 -4: Glycogen-derived carbons fuel early glycolytic reprogramming and
mitochondrial respiration in activated DCs
(A-B) Real-time changes in ECAR of BMDCs (A) and moDCs (B). (C) Real-time
changes in OCR of BMDCs. (A-C) treatments introduced at dotted lines (1st injection: 2nd
injection). (D-E) ATP levels of BMDCs in 30 minute intervals (D) and at 2 hrs (E) after
stimulation with indicated treatments. (F) BMDCs cultured and differentiated in 13C6glucose were switched to normal glucose at the time of stimulation with LPSCP for 1
and 3 hours and 13C-labeled metabolites were detected by LC-MS spectrometry. (G)
Inverse metabolomics of F, where BMDC were differentiated in normal 12C glucose and
switched to 13C6-glucose at the time of stimulation with LPSCP for 3 and 6hrs. Data
represent n=4, mean SD, (A-B) paired students t-test. (D-G) n=5, Two-way ANOVA,
Tukey Posttest. *P<0.05, **P<0.005, ***P<0.0005, ****P<0.0001. (F-G) Statistical
significance of each color * represents color-coded 13C6- or black * for 12C groups. White
bars indicate l2C-glucose and all color bars denote 13C6-glucose.
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Supplemental Figures

Supplemental Figure 1: (Related to Figure 3.1 and Figure 3.2)
(a) BMDCs stimulated with LPS+/-CP for 6 and 24hours in indicated glucose
concentrations were analyzed for CD40 and CD86 surface expression. (b) CD40 and
CD86 expression of BMDCs stimulated with LPS+/-DAB for 6hours in normal glucose
concentration. (c) Intracellular stain of Glut-1 expression in BMDCs stimulated for 1, 6,
and 24hrs. (d) CD40 and CD86 surface expression of BMDCs stimulated with LPSGlut1ib for 6 and 24hours in normal glucose concentration. (e) mRNA expression of 3 PYG
isoforms; data normalized to PYGL; n=6. (f) Relative mRNA level for confirmation of
knockdown of pygl and pygb by si-RNA transfection of moDCs. (a, c-d) representative
of more than 3 experiments. (b) n=4, mean+/-SD, One-way ANOVA with Sidak Posttest, **P=0.0038.
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Supplemental Figure 2: Related to Figure 3.3
(a) Intracellular staining of TNF- and IL-12 of BMDC stimulated with LPS  CP for 4
hours, with the last 3.5 hours in Golgi plug reagent, in 2.5 and 0mM glucose. Data are
from one experiment representative of four. (b-c) Multiplex panel of cytokine and
chemokine measurements from the supernatant of (b) BMDC and (c)moDC activated
with LPS  CP for 6 hours. n=4, meanSD, student’s t-test.
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Supplemental Figure 3: (Related to Figure 3.4)
(a) Real-time changes in ECAR of BMDCs using an alternate PYGL inhibitor, DAB;
treatments introduced at dotted lines (1st injection: 2nd injection). Representative of 3
experiments. (b, c) BMDCs differentiated in 13C6-glucose were switched to normal
glucose for stimulation with LPS+/-CP for 1 and 3hrs and detected by LC-MS
spectrometry. Color bars denote 13C6-glucose whereas white bars represent light
glucose. (d) CD40 and CD86 expression was analyzed in BMDCs stimulated for 6hours
with LPSCP in the presence or absence of glutamine in the medium. n=6 (e) Real-time
OCR and ECAR with CP, glutaminolysis inhibitor (DON), and combination; treatment
injected at dotted lines (1st injection: 2nd injection). (f) Protein expression of AMPK and
pAMPK in BMDCs stimulated with LPS+/-CP for 30 minutes and 24hours in normal
glucose. (g) Protein expression of Glut1 in BMDCs stimulated with LPS CP for 3, 6, and
24hours in normal glucose. (h) Surface expression of CD40 and CD86 of BMDCs from
WT or LKB1-/- mice stimulated with LPS+/-CP for 6 hrs. (i) Inverse metabolomics of b
and c, where BMDCs were stimulated in 13C6-glucose medium for 3 and 6hrs and
selected TCA intermediates were shown. Data represents n=4, mean+/-SD, Two-way
ANOVA with Tukey-Posttest. *P=0.019, **P<0.0039, and ****P<0.0001
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Supplemental Figure 4:
Pathway 1 (red) represents the catabolism of basal glycogen stores primarily driving
citrate generation. Pathway 2 (blue) represent the catabolism of free glucose which
primarily supports the formation of intracellular lactate. Pathway 3 (green) represents
glycogen shunt activity, which primarily supports citrate production and a full TCA
cycle. PPP=Pentose phosphate pathway
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CHAPTER 4
The role of Nitric Oxide in Metabolic Regulation of Dendritic Cell Immune
Function
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Abstract
Dendritic cells (DCs) are canonical antigen presenting cells of the immune system
and serve as a bridge between innate and adaptive immune responses. When DCs are
activated by a stimulus through toll-like receptors (TLRs), DCs undergo a process of
maturation defined by cytokine & chemokine secretion, co-stimulatory molecule
expression, antigen processing and presentation, and the ability to activate T cells. DC
maturation is coupled with an increase in biosynthetic demand, which is fulfilled by a
TLR-driven upregulation in glycolytic metabolism. Up-regulation of glycolysis in
activated DCs provides these cells with molecular building blocks and cellular energy
required for DC activation, and inhibition of glycolysis during initial activation impairs
both the survival and effector function of activated DCs. Evidence shows that DC
glycolytic upregulation is controlled by two distinct pathways, an early burst of
glycolysis that is nitric oxide (NO) –independent, and a sustained commitment to
glycolysis in NO-producing DC subsets. This review will address the complex role of NO
in regulating DC metabolism and effector function.

Introduction
Dendritic cells (DCs) are professional antigen presenting cells of the immune
system and play a central role in coordinating both innate and adaptive immune responses
[1]. In their unactivated state, DCs continuously sample the tissue microenvironment for
foreign material and are equipped to react to inflammatory stimuli by expressing a wide
variety of innate immune receptors including the Toll-like receptor (TLR) family [2-4].
These TLRs recognize multiple forms of pathogen-associated molecules, and recognition
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of cognate ligands via TLRs cause DCs to become highly activated. Activated DCs
undergo a process of “maturation”, which is characterized by the upregulation of costimulatory molecule expression, the ability in vivo to migrate from the site of
inflammation to secondary lymphoid organs, the synthesis and secretion of immunemodulating cytokines and chemokines, and the processing and presentation of antigens to
T lymphocytes. In this manner, DCs play a fundamental role in initiating and maintaining
both innate and adaptive immune responses [1, 5, 6]. A number of studies in recent years
have identified that DC activation is accompanied by distinct metabolic changes,
highlighted by significant upregulation of aerobic glycolysis, that regulates the survival
and immune effector function of both human and mouse DCs [7-13]. The microbicidal gas
nitric oxide (NO) is among the activation-induced compounds synthesized and secreted by
activated DCs and plays a complicated role in regulating DC immune responses as well as
their cellular metabolism. TLR-mediated glycolysis induction in DCs occurs in two distinct
phases (modeled in Figure 1, upper right panel). Shortly after activation, DCs experience
an early phase of TLR-driven glycolytic burst that is NO-independent [8], which is
subsequently followed by a sustained phase of glycolytic metabolism that is contingent
upon NO production in subsets of these cells [8-10]. The focus of this review is to highlight
and discuss the current understanding in the field regarding the role of NO in regulating
DC immunometabolism and effector function.

NOS Expression and NO production
Cellular production of NO is catalyzed by three distinct nitric oxide synthase
(NOS) enzymes. Endothelial NOS (eNOS, NOS1) and neuronal NOS (nNOS, NOS3) are
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constitutively expressed and were originally named for their primary tissue distribution,
although the expression of these enzymes by a wide variety of cell types is now
appreciated [14-17]. Of highest relevance to this review, inducible NOS (iNOS, NOS2) is
the primary NO-synthesizing enzyme expressed by immune cells and is often not
constitutively expressed but is potently induced during stimulation by inflammatory
signals [18, 19]. All NOS enzymes catalyze the reaction that converts substrates Larginine, NADPH, and O2 to L-citrulline, NADP+, and NO [19]. As a membrane
permeable volatile compound, NO participates in a variety of cellular processes that can
extend beyond cell-intrinsic impacts on the cells that produce it [20-22]. The NO radical
can influence cellular processes through a number of distinct mechanisms (reviewed in
[20]), including: 1) the formation of toxic compounds such as peroxynitrite (ONOO -)
when combined with superoxide (O2-) [23]; 2) S-nitrosylation of proteins leading to
altered cellular activity [24, 25]; 3) deamination of nucleic acids leading to genetic
mutation [26].

Heterogeneity of DC Subsets
DCs refer to a broadly heterogeneous family of immune cells that include cells
derived from both myeloid and lymphoid lineage progenitors (reviewed in [27]). These
cells are specialized in their ability to acquire and process antigen, their expression of
MHC-II antigen presentation machinery, their ability to travel to secondary lymphoid
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organs after activation, and their capacity to initiate antigen-specific T cell activation in
these compartments [27]. So called “classical DCs” found in secondary lymphoid organs
can be subdivided into two major subsets: CD11b+ DCs, which are thought to specialize in
cytokine production and CD4+ T cell activation [28, 29]; and CD8+ DCs which specialize
in cross-presentation of exogenous antigen and are potent activators of CD8+ T cells [3032]. In addition, there exist a number of non-classical DC subsets that play an important
role in peripheral immune surveillance and infection response. These include the
circulating and tissue-resident plasmacytoid DCs (pDCs) that are potent producers of Type
I interferons [33, 34], skin-resident Langerhans cells [35, 36], and monocyte-derived
“inflammatory DCs” (iDCs) [37-39]. With technological advances, different subsets of
cDCs and pDCs in both mouse and human have been newly identified based on their tissue
localization, surface markers, and ontogeny [40-42]. In the vast majority of in vitro –
differentiated DC studies in both mouse and human systems, myeloid precursors (typically
bone-marrow stem cells or circulating monocytes) are differentiated in the presence of the
cytokine GM-CSF (with or without IL-4) to generate relatively pure populations of DClike cells that are thought to most closely resemble iDCs both genetically and functionally
[43, 44].

Variability of iNOS Expression in DC Subsets
In evaluating the physiological role of NO in DC biology, it is important to note
that iNOS is expressed only by specific subsets of DC populations, whether these be in
vivo subsets or in vitro DC models, and that there exist notable differences in iNOS
regulation between mice and humans DCs. Early studies determined that LPS and IFN-
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can induce iNOS expression in mouse GM-CSF –differentiated bone marrow-derived
DCs (GM-DCs) [45]. In addition, mouse skin-derived DCs express iNOS and produce
NO in response to LPS [46, 47] and a role for NO production by thymic DCs in T cell
differentiation has also been reported [48]. As originally defined, monocyte-derived iDCs
(originally coined TNF-a/iNOS-producing-DCs, or “TipDCs”) express iNOS and are
potent producers of NO that are required to control a number of different types of both
bacterial and viral infections [39, 49, 50]. Nevertheless, unlike infection-associated iDCs
and in vitro –cultivated GM-DCs, classical DC subsets in secondary lymphoid organs do
not readily express iNOS nor produce detectable amounts of NO [9, 51, 52].
Conventional GM-CSF and IL-4 –differentiated monocyte-derived human DCs (moDCs)
also do not readily express iNOS, which is in stark contrast to their murine GM-DC
counterparts [9, 53]. Despite this, the conditions for in vitro differentiation of human
iDCs expressing iNOS have been reported [54], suggesting that the right environmental
conditions can elicit a monocyte-derived iDC population in human cells. One possible
explanation for the mouse/human species difference with regard to iNOS expression is
the observation that the iNOS gene promoter region in human cells is more heavily
methylated than in mice and possibly controlled by negative epigenetic regulation [55].
Despite these differences, there is ample evidence to suggest that some in vivo human DC
populations can express iNOS, ranging from blood circulating CD1a+ DCs [56] to DC
infiltrates in psoriatic skin lesions [57-59]. Given the significant heterogeneity in iNOS
expression described above, it is critical to take into account the population of DCs being
studied with regard to NO-mediated immune regulation, particularly given the
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understanding that NO-production will significantly impact the duration and nature of
metabolic reprogramming in these cells.
While acute induction of glycolysis has been implicated in the immune responses
of most of these DC subsets, it is worth noting that tolerogenic DCs exhibit a reduced
commitment to glycolysis compared to conventional DC subsets [60], highlighting the
correlation between glycolysis induction and inflammation in DC populations. In
addition, it has become evident that, even within a single DC subset, cellular origin may
impact the different metabolic requirements of these cells [61, 62], highlighting the
difficulty in fully understanding metabolic regulation in such a diverse and complex
cellular family. Given the functional heterogeneity of the subsets described, it is not
surprising that the production and function of NO in these cells varies as well

The Role of NO in DC Metabolic Reprogramming
The early foundation for the current interest in myeloid immune cell metabolism
was established decades ago with the observation that increased glucose metabolism
accompanies macrophage activation [63, 64]. Within the last decade, several studies
established the existence of a similar requirement for increased glycolytic metabolism
during DC activation and immune function [10, 12]. Subsequent to these studies, in the
last several years researchers have intensely focused on attempting to understand the
mechanisms behind metabolic regulation of DC activity with the aid of sophisticated
technology and research approaches that were not available when glycolytic
reprogramming was first discovered in macrophages. While a number of reports have
identified a critical role for the mTOR/HIF1/iNOS signaling axis in driving activation145

associated glycolysis induction in DCs [12, 22, 65-67], we now appreciate that metabolic
reprogramming in DCs is driven by two distinct temporal events regulated by distinct
signaling axes delineated below.

Early Glycolytic Reprogramming in DCs is NO-independent
Within minutes of TLR stimulation, DCs exhibit a rapid two-fold increase in their
glycolytic rate that is sustained for several hours and mediated by a TBK1/IKK/Akt
signaling axis [68]. This acute “glycolytic burst” is independent of mTOR/HIF1/iNOS
signaling. It also promotes rapid translocation of Hexokinase 2 (HK2) to the outer
mitochondrial membrane leading to the rapid flux of glucose metabolism, which is
required for proper DC activation and immune effector function [68]. Metabolite tracing
studies have shown that this early glycolytic flux supports pentose phosphate pathway
(PPP) activity and the preferential generation of citrate [68, 69]. While the explicit
contribution of citrate metabolism in supporting DC activation is not fully understood,
citrate production supports fatty acid synthesis, which in turn contributes to endoplasmic
reticulum and Golgi body expansion associated with DC maturation and DC effector
function [68-71]. In addition, citrate metabolism supports acetyl-CoA production
necessary for epigenetic regulation of glycolysis enzymes including, HK2 [72, 73]. While
epigenetic reprogramming is not likely involved in acute glycolytic reprogramming, it
may play an important role in long-term metabolic reprogramming to inflammatory
stimuli, as has been notably reported in monocytes [74, 75].
In DCs that do not express iNOS as a consequence of their activation, the rapid
induction of glycolysis is transient, lasting approximately 4-6 hours, after which activated
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DCs return to a metabolic state that more closely resembles their pre-activation
metabolism (modeled in Figure 1, upper right panel). The early and transient glycolytic
reprogramming occurs in both in vitro –derived DC subsets and ex vivo populations
regardless of iNOS expression [68]. Interestingly, while the conventional paradigm in the
field has focused on glycolytic reprogramming as a downstream consequence of innate
immune signaling, a recent study reported that hexokinase itself can serve as an innate
immune receptor [76], adding a startling layer of complexity to the interplay between DC
metabolism and microbial recognition by these cells.

Sustained Glycolytic Reprogramming in DCs is NO-dependent
In DCs that express iNOS, a second wave of glycolytic induction is mediated by
mTOR/HIF1/iNOS that commits these cells to glycolytic metabolism for the duration of
their post-activation lifespan in an NO-dependent manner [8, 9] (modeled in Figure 4 -1,
upper right panel). It is this phenomenon that has led many researchers to conclude that
HIF1 is critically required for DC glycolytic reprogramming [12, 22, 65-67], when in
fact this is only the case for the sustained commitment to glycolysis observed in NOproducing DCs [8, 9]. While mTOR plays a multifaceted and complex role in immune
cell activation (reviewed in [67]), mTOR–dependent HIF1 activity drives iNOS
expression in TLR-activated DCs [22, 77]. iNOS protein expression is detectable at
around 6-8 hours following DC activation and is concomitant with NO-mediated
suppression of DC mitochondrial activity and oxidative phosphorylation [8, 9].
Reversible inhibition of mitochondrial cytochrome c oxidase activity [78, 79] and
persistent inhibition via S-nitrosylation by NO has been well documented [79], and iNOS
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inhibitors are able to rescue the mitochondrial defect in NO-producing DCs [9]. The net
result of NO production in DCs is the near-complete loss of mitochondrial function and
the associated catabolism of fatty acids through oxidative phosphorylation. The
functional consequences of this loss of mitochondrial function is the requirement for a
sustained commitment to glycolysis in these cells to meet both their bioenergetic (ATP
production) and biosynthetic demands [7, 13, 68]. While glycolysis can help extend the
lifespan of NO-producing DCs in the face of altered mitochondrial activity, the lifespan
of these cells is still largely regulated by their NO production [8, 9, 22]. Thus, NOproduction represents a critical cellular event in DC activation that initiates a chain of
events that fundamentally shapes the immune activity and survival of these cells.

The Impact of NO-inhibition in DC immunometabolism
As mentioned above, iNOS-deficient DCs and DC subsets that do not upregulate
iNOS engage in an early glycolytic burst followed by a return to a less-glycolytic
metabolic state [9] (Figure 4 -1). To try and assess the regulatory impact of NOdependent metabolic reprogramming in DCs, a number of studies have investigated the
impact of iNOS-inhibition on DC immune activation and effector function. There is a
strong consensus among these studies that inhibition of NO production or its upstream
signaling elements attenuates sustained glycolytic commitment and significantly
enhances many DC activation parameters including costimulatory molecule upregulation,
inflammatory cytokine production, T cell stimulatory capacity, and post-activation DC
survival [8, 9, 22]. These effects can also be seen by perturbation of upstream regulatory
elements controlling iNOS expression. For example, mTOR inhibition by rapamycin,
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which reduces but does not completely ablate iNOS expression and NO production in
DCs, rescues mitochondrial respiration in these cells, leading to enhanced activation and
T cell stimulatory capacity [7, 8]. Additionally, a recent study reported that the
mTOR/HIF1a/iNOS signaling axis serves as a glucose-sensing pathway in DCs that
limits DC activation and T cell stimulatory capacity [22]. Interestingly, there appears to
be significant crosstalk between NO-independent and –dependent glycolytic
reprogramming in DCs. HIF1 induces upregulation of the glucose transporter Glut1,
which is required for sustained commitment to glycolysis [67, 80]. In addition, citrate
metabolism from early glycolytic programming generates NADPH, which is a substrate
for iNOS and may contribute to NO synthesis [71, 81, 82]. These findings support a
model in which NO-production critically regulates the long-term metabolic
reprogramming in DCs and plays a central role in regulating the immune activity of these
cells. In systems where NO production is not produced by DCs directly, exogenous
sources of NO can still contribute to changes in DC metabolism [83] as well as the
function of other immune cells [84, 85]. To this effect, NO from iNOS-expressing DCs or
exogenous sources can impair the immune responses of DCs [7, 9, 85], and exogenous
NO is reported to regulate monocyte-derived DC immune responses. In addition, NO
production by macrophages can induce HIF1 expression in DCs that do not express
iNOS [22], and cDCs from the spleen that do not express iNOS exhibit attenuated
mitochondrial activity, possibly due to NO exposure from other NO-producing cells in
the spleen such as macrophages [86].
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The Role of DC NO Production in Disease States
Historically, NO has been attributed a primary role as a microbicidal compound
that can directly disrupt bacterial structural proteins, lipids, and nucleic acids (reviewed
in [87]). In support of this, iNOS expression is induced in immune cells during infection
and contributes a protective role in variety of microbial infections [39, 88-92]. The
identification of a monocyte-derived iDC subset, then termed TNF/iNOS –producing DC
(TipDCs), that is induced by and controls systemic Listeria monocytogenes infection,
helped establish a role for NO-producing iDCs in bacterial defense [39, 93]. Since their
original discovery, NO-producing iDCs have been further reported to play important
roles in other bacterial infections such as Leishmania major [21, 50] as well as viral
influenza infections where they help limit viral replication but also contribute to immunemediated pathology [49]. Interestingly, NO-producing iDCs have been shown to be both
necessary and sufficient to promote T cell –dependent IgA class switch recombination in
mucosa-associated lymphoid tissue, suggesting that this DC subset may have a
specialized role at these sites [94]. Examples in which NO production by iDCs can also
regulate non-infectious disease states are documented for atherosclerosis [95], murine
models of autoimmune disease [96], and cancer. The presence of tumor-infiltrating iDCs
is required for efficacy of cyototoxic T cells in eliminating tumors via a NO-dependent
mechanism [97]. In vitro activated BMDCs have been reported to induce tumor cell death
by NO and/or peroxynitrite -dependent mechanisms [98, 99]. Notably, DCs generated
from cancer patients exert tumoricidal activities via peroxynitrite and enhance tumorspecific antigen presentation to T cells [100]. NO has also been shown to be released by
tumor cells [101] and infection-induced granulomas [102], which may have immune150

modulatory activity on immune cells within the tumor milieu. It is probable in these
systems, that NO influences on cellular metabolism regulate the types of immune
responses not only of the NO-producing DCs themselves, but also the function of
bystander cells in the local tissue microenvironment.

NO Regulation of DC Immune Activation
Predating the recent focus in the field on the metabolic regulation of immune
cells, there exists a substantial literature delineating the complexity of NO-mediated
regulation of DC immune function. While a few studies have shown a role for NO in
augmenting DC immune activity from enhancing MHC-II surface expression [103, 104],
promoting CCL19-directed chemotaxis [105], and driving proper activation and T cell
stimulatory capacity [106], the majority of studies have reported an inhibitory role for
NO on DC-mediated inflammation. iNOS inhibition during activation leads to significant
enhancement of GM-DC costimulatory molecule expression and inflammatory cytokine
production, indicating that NO production by these cells limits their activation [8, 9, 107].
In support of this, exogenous NO stimulation (through chemical NO-donors) significantly
reduces costimulatory molecule expression and IL-12 production in human moDCs and
shapes the CD4+ T cell polarization by these cells [108, 109]. In addition, iNOS
expression in differentiating moDCs negatively impacts both moDC differentiation and
activation [25, 110]. NO additionally inhibits IL-12, IL-6, and TNF cytokine production
in human pDCs [84]. The inhibitory role of DC-produced NO is further underscored by
studies showing the suppressive function of “inhibitory DCs” induced by phagocytosis of
apoptotic cells is at least partially dependent on NO production in these cells [111]. In
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addition, NO production suppresses the migratory capacity and limits the survival of
cutaneous Langerhans cells in mice [112]. While work remains to explicitly delineate the
multiple ways by which NO may be contributing to impaired DC function, it is clear that
NO-mediated mitochondrial inhibition and the compensatory long-term commitment to
glycolysis imparts a metabolic crisis in these cells that impacts activation and survival [810, 22].

DC-produced NO Limits T Cell Activation
The impact of NO on DC function is not restricted to DC cell-intrinsic effects but
also negatively regulates DC-mediated T cell activation [45, 113, 114]. This is at least in
part due to the membrane permeable nature of NO as NO-producing DCs are able to
inhibit mitochondrial activity in co-cultured cells that do not express iNOS [8]. The
presence of NO-producing DCs significantly attenuates T cell proliferation in mixed
lymphocyte reactions in both mouse and human studies [51, 115]. In addition, iDCs are
reported to limit antigen-specific T cell expansion through an NO-dependent mechanism
[116]. We believe that the existing literature supports a model whereby DC NO
production restricts T cell activity through two separate mechanisms: 1) DC stimulatory
capacity is reduced in a cell-intrinsic manner by attenuation of maturation parameters as
described above; 2) DC-derived NO can promote mitochondrial respiratory crisis and cell
death in T cells directly [96]. Of particular relevance to both of these points, a recent
study has elegantly delineated an mTOR/HIF1/iNOS glucose-sensitive signaling axis
that functionally restricts the ability of DCs to stimulate T cells [22]. This study further
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showed that disruption of any component of this signaling axis can enhance T cell
activation by NO-producing DCs [22].

NO and DC Cell Death
In addition to its role in regulating DC activation, NO has a well-documented role
in the regulation of immune cell survival. While low-levels of NO have been reported to
induce cGMP-dependent cytoprotection in a RAW264 macrophage cell line [117], most
studies on this topic have reported a cytotoxic effect of NO, particularly during prolonged
exposure and at high concentrations [118, 119]. One possible mechanism for this effect is
the ability of NO to upregulate caspase activity [119] and to directly induce cytochrome c
release from mitochondria [118]. In addition, NO derivatives such as peroxynitrite,
nitrogen dioxide, and nitrosothiols can irreversibly inhibit enzymes of the electron
transport chain in mitochondria at high concentrations, leading to metabolic crisis and
cell death (reviewed in [120]). In DCs specifically, NO production has been identified as
a principal cytotoxic factor during post-activation death in these cells [8, 9]. Furthermore,
iNOS -deficient DCs exhibit greater metabolic flexibility than NO-producing cells and
are able to more easily survive metabolic stress, such as culture in glucose-limiting
conditions [9]. In further support of these findings, mTOR inhibitors, which reduce NO
production in DCs below the threshold required for complete mitochondrial disruption,
augment post-activation DC lifespan and immune function [7, 8].
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Concluding Remarks
The emergent focus on the study of the metabolic regulation of DCs and the role
of NO in DC metabolism has helped clarify and re-focus much of the historical literature
regarding the effect of NO on DC immune function and cell survival. Because NO plays
such a fundamental role in determining the long-term immunological and cellular fate of
DCs (Figure 1), we anticipate that future studies in the field of DC immunometabolism
will judiciously consider the source of DCs being examined, with particular focus on the
iNOS expression status of the DCs and the production of NO in the tissue
microenvironment. Because of the inherent complexity of both metabolic regulation in
general and the pleiotropic effects of NO and its derivative compounds, further work on
explicitly defining the NO-dependent and –independent aspects of DC metabolic
regulation is needed. Ongoing efforts on these topics will provide new insights in how
DC immune activity is controlled at the metabolic level and will help distinguish those
aspects of DC immunometabolism that are universal across DC subsets (and from
different species) from those that are restricted to NO-producing cells.
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Figures

Figure 4 -1: Model of NO-mediated impacts on DC metabolism and function.
Upper right panel, kinetics of NO-dependent and –independent glycolytic induction is
illustrated. Main figure, the pleiotropic effects of NO on DC metabolism and function are
modeled.
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CHAPTER 5
Nitric oxide regulates glycogen metabolism utilization in LPS-activated dendritic
cells.
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Introduction
Dendritic cells (DCs) are canonical antigen presenting cells (APCs) of the
immune system and play a crucial role in orchestrating the innate and adaptive immune
responses. Through the expression of a broad array of pattern recognition receptors
(PRRs), such as toll-like receptors (TLRs), DCs recognize a variety of microbial
pathogens and inflammatory stimuli (1, 2). TLR stimulation of DCs initiates a series of
activation events characterized by the upregulation of a number of genes and proteins
required for surface co-stimulatory molecule expression, pro-inflammatory cytokine and
chemokine secretion, the ability to migrate to secondary lymphoid tissues, and present
antigens to T lymphocytes via antigen presentation by MHC molecules (1). These events
are collectively termed “maturation” and coupled with a rapid change in metabolism,
featured by the upregulation of aerobic glycolysis. TLR-driven aerobic glycolysis is
essential in supporting DC effector function and survival (3-6), and inhibition of
glycolysis has detrimental effects on the immune outcome.
Nitric oxide (NO) is a functionally versatile gas implicated in many physiological
and patho-physiological processes. NO is generated from amino acid arginine by a
catalytic reaction of three distinct enzymes – endothelial nitric oxide synthase (eNOS,
NOS1), inducible NOS (iNOS), and neuronal NOS (nNOS, NOS3). eNOS and nNOS are
constitutively expressed in a broad number of cells, whereas iNOS expression is induced
upon exposure to infection or inflammatory stimuli (Bogdan, 2001; Bogdan, 2015;
Förstermann and Sessa, 2012; Thwe and Amiel, 2018). Although iNOS is expressed in
many different cell types, its role is widely appreciated in the context of infection
responses in immune cells, such as DCs and macrophages. While NO has anti-microbial
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properties (7-10), it can also alter cellular functions by a number of distinct mechanisms,
including: formation of toxic compounds, such as superoxide and peroxy nitrite (11); post
translational modification of proteins and nucleic acids via S-nitrosylation (12-19) or
deamination (20), respectively. One of the deleterious effects of NO on the metabolism of
activated DCs is impaired mitochondrial respiratory function due to S-nitrosylation of
cytochrome C oxidase of the electron transport chain (ETC) (21), thus forcing cells to
switch to aerobic glycolysis.
A large body of work has reported that GM-CSF cultured bone marrow-derived
DCs (BMDCs), which is a classic mouse model of inflammatory DCs, and a few subsets
of mouse tissue resident DCs express iNOS and produce NO. On the other hand, neither
iNOS expression nor NO production is observed in GM-CSF and IL-4 cultured
monocyte-derived human DCs (moDCs), a conventional model of human DCs commonly
used in the field. Regardless of the functional similarities between BMDCs and moDCs,
fundamental differences in NO-mediated immuno-metabolic effects between these two
cell types are not clearly understood.
Previous studies have shown that murine DCs experience TLR-mediated
glycolytic reprogramming in two distinct phases: an early glycolytic burst that is
independent of nitric oxide (NO) and a later phase of activation that is supported by a
long-term commitment to aerobic glycolysis in NO-producing DCs (4, 6, 10). The two
phases of glycolytic reprogramming are also regulated by two different signaling
mechanisms: the early phase, which happens immediately after TLR stimulation, is
regulated by TBK1/IKKe/Akt signaling (4); and the NO-dependent glycolysis is largely
controlled by the PI3k/mTOR/HIF-1a/iNOS axis (5, 22). DCs that do not make NO, such
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as moDCs, engage in a TLR-driven early glycolytic burst for a brief period, lasting for
about 4-6 hours, followed by a metabolic reversion back to pre-activation metabolism (4).
In NO-producing DCs, activation of the PI3k/mTOR/HIF-1/iNOS axis forces the cells to
commit to aerobic glycolysis that is sustained throughout the post-stimulation lifespan (4,
5).
While several studies have demonstrated the effect of NO on glucose metabolism,
including the aforementioned findings of NO on DCs, such as NO-mediated inhibition of
aerobic respiration, little is known about the implication of NO on cellular glycogen
metabolism. In liver glycogen metabolism, iNOS expression and NO production has been
shown to induce insulin resistance by reducing glycogen synthase activity (23, 24). On
the other hand, iNOS expression is coupled with a rise in glycogen levels in stimulated
astrocytes (25). Given that NO has a substantial impact on immune cell metabolism, we
hypothesized that NO is likely involved in regulating glycogen utilization in DCs.
Here, we show that NO influences glycogen utilization in BMDCs and moDCs
via distinct mechanisms and that PI3k-mTOR signaling is most likely regulating this
process in mouse DCs. Our data altogether suggest a potential regulatory mechanism of
DC glycogen utilization, by which NO affects TLR-activated DCs via modulating their
glycogen metabolic pathways.

Materials and Method
Mouse DC culture and activation
Bone marrow-derived DCs (BMDCs) were generated from 6-12-week-old
C57/Bl6J mice as follows: bone marrow cells were flushed from femurs and the cells
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were differentiated in murine recombinant GM-CSF (20ng/mL; Peprotech) in complete
DC medium (CDCM), comprised of RPMI1640, 10%FBS, 2mM L-glutamine, 1IU/mL
Pen-Strep, 1mM beta-mercaptoethanol, for 7 days, with a medium change every 2 days.
On Day 7, DCs were harvested, washed in CDCM and cultured at 2x10^5 cells/well (96well plate) per 200L of total volume per well in indicated treatment conditions.

Reagents
These reagents were purchased from given companies: SEITU (iNOS inhibitor)
(500M): Tocris; NO donor, SNAP: Cayman chemical; LPS (100ng/mL): Invivogen;
Oligomycin (1M): Sigma-Aldrich; and Rotenone (100nM): Sigma-Aldrich.

In vitro differentiation and isolation of human monocyte-derived DCs
Leukocyte Filters of de-identified donors were provided by CVPH medical center
blood bank in Plattsburgh, NY. Filters were reverse-flushed with sterile 1xDPBS
(without calcium and magnesium) and peripheral blood monocytes (PBMCs) were
extracted by Ficoll-plaque centrifugal separation (density gradient of 1.0772) using LSM
(lymphocyte separation medium, MP Biochemical). Monocytes were enriched using
CD14 positive magnetic selection beads per manufacturer protocols (Miltenyi
Bioscience) and resulting monocytes were cultured in complete DC medium containing
human recombinant GM-CSF (20ng/mL) and human recombinant IL-4 (20ng/mL)
(Peprotech) for 7 days. On day 7, monocyte-derived dendritic cells (moDCs) were
harvested, stimulated as indicated, and intracellular glycogen levels were assessed from
prepared lysates, using Biovision hydrolysis enzyme and Eton Glucose reagent kit.
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BMDC and moDC co-culture
BMDCs were pre-stimulated with LPS, with and without SEITU (500M), at
0.5x10^6 cells per well for the first 6 hours in Transwell inserts. moDCs were stimulated
for 24 hours with and without LPS at 0.5x10^6 cells/well in lower chambers of a
transwell plate. After 24hours total, moDCs were harvested for analysis of intracellular
glycogen contents.

Western blot
Cell lysates were prepared using 2X NP-40 lysis buffer. 20g protein was loaded
into each well of a 12.5% polyacrylamide gel, transferred onto activated nitrocellulose
membrane (BioRad). Electrophoretic transfer was performed using Trans-Blot Turbo
RTA mini Nitrocellulose transfer kit. Membranes were blocked in 2% milk in 1xTBST at
RT for 1hr, and incubated in indicated antibody at 4C overnight. Blots were washed 3x
in 1xTBST at RT, probed with secondary antibodies at RT for 45-60 minutes, and
washed 3-4x with 1x TBST. Proteins were visualized by SuperSignal West Pico
Chemiluminescent substrate and exposed with GeneXpert System imager. Trans-Blot
Turbo Transfer system and secondary antibodies for Western blots were generously
provided by Dr. Paula Deming, Medical Laboratory and Radiation Science Department,
UVM.

Metabolism assays
Glycogen assay
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Intracellular glycogen was measured using a modified protocol that consists of the use of
hydrolysis enzyme from Biovision Inc. and glucose assay reagents from Eton Bioscience
as briefly described: Diluted cell lysates were incubated with and without hydrolysis
enzyme (Biovision Inc.) for 30 minutes at room temperature, followed by addition of
glucose assay reagents (Eton Bioscience) and subsequent incubation for 15 minutes at
370-C in a non-CO2 incubator. Color development was measured at 490nm.

Nitrite assay
Supernatants collected from indicated culture conditions were assayed for nitrite
using Griess nitrite assay kit (Life Technology Inc.) per manufacturer instructions.

Statistical analysis
Data were analyzed using Graphpad Prism (version 7) and statistical analyses
were calculated using paired student’s t test and one-way ANOVA test.

Results
BMDCs but not human monocyte-derived DCs accumulate more glycogen within
24hours of LPS stimulation
We demonstrated that the stimulation of BMDCs and moDCs with LPS for 6
hours results in a partial depletion of intracellular glycogen in BMDCs (Figure 5 -1A), a
finding consistent with our previously published work (26), and a minimal change in the
glycogen levels of moDCs (Figure 5 -1B). We also showed that DCs utilize intracellular
glycogen to support the TLR-driven early effector responses and that glycogen-carbons
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contribute directly to fuel acute glycolytic reprogramming required for DC activation
(26). Although our recent work has shown that DCs require glycogen for the expression
of key maturation-associated surface proteins within 24 hours of LPS stimulation, their
glycogen metabolic utilization during this late activation stage has not yet been
elucidated.
Thus, we were interested in examining DC utilization of glycogen metabolism
beyond 6 hours of activation. To test this, we stimulated BMDCs and moDCs for 24
hours and measured the intracellular glycogen content. Because DCs partially utilize their
stored glycogen within the first 6 hours of LPS activation (26), we predicted that
stimulation with LPS for 24 hours would deplete the entire stock of intracellular glycogen
in both cell types. As expected, the glycogen level in moDCs is significantly reduced
although it is not completely exhausted (Figure 5 -1C). To our surprise, LPS-stimulated
BMDCs accumulate glycogen to levels higher than their resting counterparts (Figure
5 -1D), and this is not affected by the in vitro culture differentiation in cytokine GMCSF, the glycogen levels of which were compared with those of splenic tissue-resident
DCs (data not shown). This rise in glycogen content is observed only in murine BMDCs,
but not in human moDCs, and raises two major questions: 1) why do BMDCs utilize
glycogen in early activation but increase their storage in late activation? and 2) why is
there a difference in glycogen utilization between mouse and human DCs in the late
activation phase?
Previous work by us and others has shown that mouse GM-CSF cultured BMDCs
are capable of upregulating inducible nitric oxide synthase (iNOS) and generating nitric
oxide (NO) a few hours after TLR-activation, and that human DCs do not express nor
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produce NO (6). Therefore, it is plausible that NO is a common solution to both questions
described above. Because iNOS upregulation in BMDCs only occurs a few hours after
TLR activation prompted us to examine the effect of NO on BMDC glycogen
metabolism during the late activation phase. Therefore, we hypothesized that TLR-driven
glycogen accumulation in 24 hour-activated BMDCs is mediated by NO production in
these cells. Additionally, the fact that moDCs did not display a similar phenotype might
be attributed to their lack of NO production. Therefore, we next set out to test the
hypothesis that NO is the underlying cause of glycogen accumulation in BMDCs during
their later activation stages.

Glycogen accumulation in BMDCs is mediated by NO
To determine whether iNOS upregulation and NO induction in BMDCs elevates
intracellular glycogen contents, we stimulated BMDCs with LPS for 24 hours in the
presence or absence of the potent and highly specific iNOS inhibitor, SEITU, and
measured nitrite and intracellular glycogen levels. Consistent with our previously
published data (6), nitrite production from activated BMDCs was attenuated to baseline
levels in the presence of SEITU (Figure 5 -2A). In support of our hypothesis, SEITU
also abolished the intracellular glycogen accumulation in activated BMDCs (Figure
5 -2B), suggesting that NO is potentially at play in glycogen accumulation beyond 6
hours of activation in the murine DC model, thereby resulting in the increased synthesis
or decreased consumption of glycogen by these cells.
Next, we questioned whether we would observe a similar NO-induced glycogen
buildup in moDCs. Because moDCs do not make NO in response to LPS stimulation, we
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introduced exogenous NO to the cultures. We specifically employed two different
approaches to induce NO into the moDC culture media. First, to attain a constant level of
NO from the NO-donor SNAP, we added SNAP into the culture medium every 5 hours
for a total of 15 hours. Contrary to our expectation, glycogen utilization in moDCs was
accelerated in the presence of the NO-donor in both resting and LPS-activated conditions,
with a more pronounced effect in the resting cells (Figure 5 -2C). In parallel, we cocultured BMDCs, that were pre-stimulated with LPS for the first 6 hours to serve as a
source of NO, with LPS-activated moDCs in a transwell assay plate and examined the
glycogen content of moDCs (Figure 5 -2D). NO generated from the LPS-activated
BMDCs caused no effect on the intracellular glycogen level of moDCs (Figure 5 -2D).
Interestingly, the acute induction of exogenous NO to moDCs for 6 hours caused a much
faster depletion of glycogen (Figure 5 -2E) than the prolonged exposure to NO shown in
Figure 5 -2C. Despite a relative difference in the rate of glycogen depletion in the NOcontaining media in Figure 5 -2C and E, the NO-mediated rapid depletion of glycogen in
moDCs was consistent across any time course in both unstimulated and LPS-activated
conditions. The fact that NO-exposed moDCs display a different phenotype in consuming
their intracellular glycogen, a finding opposite from BMDC glycogen utilization,
indicates that the glycogen metabolism is differentially regulated by NO in BMDCs and
moDCs.

PYGL/GYS1 Protein expression by iNOS inhibitor
Glycogen accumulation observed in activated BMDCs (Figure 5 -1C and Figure
5 -2B) is potentially due to the inhibitory effect of NO on the rate-limiting enzyme
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glycogen phosphorylase (PYG), perhaps via S-nitrosylation reaction of NO, thereby
preventing the cells from utilizing intracellular stores of glycogen. It is also plausible that
NO can promote the activity of glycogen synthase (GYS), rate-limiting enzyme of
glycogen synthesis, resulting in a net buildup of glycogen in BMDCs. Or in the case of
moDCs, it is also likely that the activity of GYS is inhibited by NO, possibly resulting in
a metabolic imbalance towards over-utilization of glycogen. To determine the impact of
NO on the expression of these two enzymes, we determined the protein expression levels
of GYS1 and PYGL of BMDCs stimulated with LPS for 24 hours in the presence or
absence of SEITU. GYS1 expression is increased with LPS stimulation but its level is
relatively similar in the presence of the iNOS inhibitor (Figure 5 -3A). In contrast to
GYS1 expression, PYG expression does not change regardless of LPS activation (Figure
5 -3B). To our surprise, GYS1 expression in moDCs showed no differences regardless of
any treatment conditions (data not shown).

Glycogen accumulation/depletion is due to NO-induced mitochondria toxicity
Among the multifaceted effects of NO on cellular physiological functions, the
detrimental impact on cellular metabolism is its ability to block oxidative
phosphorylation (OXPHOS) by reversible S-nitrosylation of cytochrome C oxidase of the
electron transport chain (ETC), resulting in a collapse of mitochondrial function (13).
Therefore, we were interested in examining whether the NO-mediated mitochondrial
impairment induces the cells to accumulate intracellular glycogen in DCs. To test this, we
stimulated moDCs with LPS for 24 hours in the presence or absence of mitochondrial
toxins, Oligomycin (ATP synthase inhibitor) and Rotenone (ETC transport inhibitor) and
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measured intracellular glycogen content. Intriguingly, the inhibition of mitochondrial
function in resting moDCs forced the cells to rapidly deplete their intracellular glycogen
stores, a phenomenon not observed in the LPS-activated cells (Figure 5 -4A). Forcing the
cells to switch to aerobic glycolysis via the introduction of mitochondrial toxins,
Oligomycin and Rotenone, accelerates the moDC utilization of intracellular glycogen,
which is likely to fuel glucose-carbons directly to the glycolytic pathway. While these
effects shown here were not mediated by NO, the fact that these phenotypes were similar
to their exogenous NO-mediated effects shown in Figure 5 -2C and E suggested a
possible link between NO and the mitochondrial dysfunction, both of which result in the
increased glycogen utilization in resting moDCs.

NO-mediated glycogen accumulation is regulated by PI3k-mTOR axis
TLR-driven metabolic changes in BMDCs have been demonstrated to be
mediated by two distinct temporally regulated signaling axes: the NO-independent early
activation phase mediated by TBK1/IKK-Akt; and the NO-dependent late activation
stage mediated by PI3k/Akt/mTOR signaling. Based on this, we were interested in
finding out whether the observed increase in DC glycogen level is under mTOR
regulation. We first measured the total glycogen levels of BMDCs stimulated with LPS
for 24 hours in the presence of PI3k inhibitor (Ly), mTORC1 inhibitor (Rapamycin) and
iNOS inhibitor (SEITU). Inhibition of mTORC1 or PI3k dramatically attenuated the
glycogen levels regardless of activation (Figure 5 -5A). iNOS inhibitor, SEITU, also
knocked down the glycogen content, even much more dramatically than the former two
inhibitors, suggesting the PI3k-mTOR-iNOS axis, the same signaling pathway for NO
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production, is implicated in the regulation of glycogen metabolism in activated BMDCs.
As expected, iNOS inhibition of activated BMDCs resulted in the attenuation of nitrite
levels to the baseline (Figure 5 -5B), a phenotype similar to the reduced glycogen levels
upon iNOS-inhibition shown in Figure 5 -5A. Interestingly, PI3k or mTORC1 inhibition
resulted in the minimal reduction of nitrite levels (Figure 5 -5B) as opposed to the
dramatic decrease in glycogen content observed in Figure 5 -5A. Of note, the fact that
PI3k inhibitor, Rapamycin, and iNOS-inhibitor reduced the glycogen levels in untreated
cells suggested the basal signaling activity of the PI3k/mTOR axis. These data implied
that the regulation of BMDC glycogen utilization is not necessarily dependent on the
presence of NO although it appears to be mediated by iNOS upregulation via the PI3kmTOR-iNOS axis.
Next, we were interested in determining whether the master regulatory protein
GSK3, which is also a regulatory kinase protein of canonical glycogen synthesis
pathway, regulates TLR-driven BMDC utilization of glycogen metabolism. GSK3
canonically acts as a negative regulator of glycogen synthase GYS and inhibition of
GSK3 generally results in active glycogen synthesis. Interestingly, GSK3 inhibition
had very little impact on glycogen accumulation in BMDCs (Figure 5 -5A). The protein
expression of GYS1 dramatically increased in the un-stimulated BMDCs compared to
that of activated counterparts (Figure 5 -5C), suggesting that the GSK3-mediated
signaling pathway for glycogen synthesis in BMDCs seems to be different from the
canonical glycogen metabolic regulation.
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Discussion
Multiple lines of evidence have shown the pleotropic effects of iNOS-derived NO
on immune responses. NO originated from tissue macrophages has potent anti-microbial
activity against intracellular pathogens, such as Salmonella (27), Mycobacterium
tuberculosis (8) and Leishmania major (28-30). In line with its anti-microbial effects, NO
plays an important role in promoting TH-1 polarization by mature DCs (31), enhancing
pro-inflammatory cytokine responsiveness, and increasing NK cell cytotoxic ability (32).
In contrast to its ability in enhancing immune responses and clearing microbial
pathogens, inhibition of iNOS activity in NO-generating cells is associated with reduced
responsiveness to IL-12 in inflammatory environments, increased pathogen burdens, and
impaired NK-cell activity (28, 32). Other studies have also reported the immunosuppressive effects of NO, such as reduced proliferation of T cells that are exposed to NO
from NO-producing cells (33, 34). While NO is shown to induce inflammatory cytokine
responses of innate immune cells (28, 35), certain cytokines such as IFN- and/or LPS
stimulation of DCs can induce the expression of iNOS and generation of NO (33, 34, 36),
indicating that NO production can be induced by non-microbial stimuli.
Despite its protective actions against invading pathogens, NO is known to cause
detrimental effects on immune cell longevity and certain aspects of immune responses (6,
28, 35, 37). A significant body of work has demonstrated that NO significantly impairs
the antigen presentation ability of TLR-stimulated NO-producing DCs and that inhibition
of iNOS rescues their effector function (6, 33, 34). iNOS suppression in LPS-activated
macrophages is also shown to inhibit the polarization of macrophages to proinflammatory M1 macrophages (38).
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DCs are highly specialized in antigen recognition, capture, and stimulation of T
cells, thus serving as a critical link between innate and adaptive immune responses (1,
39). Activation of GM-CSF cultured murine BMDCs is coupled with a rapid metabolic
reprogramming, which is characterized as the initial NO-independent burst of glycolysis,
lasting for a few hours, followed by the NO-mediated sustained aerobic glycolysis.
Although these NO-driven metabolic effects in DCs were shown to arise from an
endogenous source of NO, a recent study has established that NO originated from other
cells impairs the mitochondria activity of iNOS deficient DCs (22). NO-mediated
impaired effector responses are also observed in non-NO-producing immune cells that
are exposed to exogenous NO present in tissue micro-environments (33, 34, 36, 40),
suggesting the serious functional outcomes inflicted by NO can still happen regardless of
the cell’s ability to produce NO.
Previous studies have identified the implication of NO in cellular ability to utilize
glucose and mitochondria in DCs (3, 5, 6, 41). In addition, the impact of NO production
and iNOS expression in regard to glycogen metabolism has been widely investigated in
non-immune systems (23-25, 42). In this study, we have demonstrated the link between
NO and glycogen utilization of activated DCs. We have also attempted to establish a
fundamental difference in glycogen utilization between mouse BMDCs and human
moDCs and found that these two types of DCs respond differently to iNOS upregulation
or exogenous NO. Here, we show the increased intracellular glycogen levels in iNOSupregulated BMDCs and the NO-driven acceleration of glycogen consumption in moDCs
(Figure 5 -2). These findings reveal that iNOS upregulation and exogenous NO can
differentially regulate the glycogen utilization of BMDCs and moDCs, respectively.
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NO production in BMDCs is regulated by the canonical signaling axis, PI3kmTOR-iNOS (5, 6, 43, 44), and our findings in Figure 5 -5A&B suggest that BMDCs
undertake the similar signal transduction mechanism in regulation of their glycogen
metabolism. Since PI3k-mTOR signaling is responsible for glycolytic upregulation in
TLR-activated BMDCs, inhibition of this axis would force the cells to depend heavily on
the mitochondrial respiration for bioenergetics purposes (5, 43). On this account, the
reduction of intracellular glycogen in the PI3k- and mTOR-inhibited BMDCs is possibly
due to the direct contribution of glycogen into mitochondrial functions. This notion is
further supported by the increased glycogen levels upon iNOS upregulation in these cells
(Figure 5 -1 and Figure 5 -2), strongly suggesting that there is a potential link between
NO-induced mitochondrial toxicity and increased glycogen accumulation in BMDCs.
As the long-term commitment to aerobic glycolysis in TLR-activated BMDCs is a
survival and metabolic adaptation mechanism due to NO-induced mitochondrial
dysfunction (5, 10, 43, 44), we have tried to understand our data on NO-mediated
regulation of glycogen metabolism within this framework. We reason that a large pool of
glycogen induced by NO would provide a continuous supply of glucose carbons for
aerobic glycolysis induced in conditions of NO-mediated mitochondrial stress in
BMDCs. While we have not formally tested this concept in the murine model of BMDCs,
we examined the effect of mitochondrial inhibition on moDC glycogen utilization
(Figure 5 -4A). Inhibition of mitochondrial OXPHOS induced by the mitochondrial
toxins forces the cells to switch to aerobic glycolysis. This metabolic switch is coupled
with the acceleration of glycogen utilization in moDCs, suggesting that glycolysis is
directly fueled by the glucose-carbon derived from glycogen. In this framework, we have
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yet to establish this phenotype in correlation with NO-mediated regulatory mechanisms
in moDCs. In light of this, it appears that both mouse and human models of DCs in this
study differentially respond to the induction of NO in the inflammatory environments.
A major question still remains as to how these TLR-stimulated BMDCs can
continuously build their glycogen stock during the time of metabolic crisis because
glycogen synthesis is an energetically costly process. One possibility is that those
glycogen pools are not static in nature, but constantly turning over by engaging in the
“glycogen shunt,” as shown in our recent publication and other work in brain and muscle
(26, 45-52). Because G6P derived from the glycogen shunt can theoretically enter the
hexose monophosphate shunt, which is also known as pentose phosphate pathway (PPP),
and generate energy in the form of NADPH, DC participation in the glycogen shunt can
potentially protect the cells from energetic crisis. On the other hand, continued
expenditure on building intracellular glycogen stocks can possibly trigger “metabolic
exhaustion.” Similar to the concept of “exhaustion” in T effector cell function (53),
metabolic exhaustion can arise from bioenergetic insufficiencies and prolonged metabolic
stress (54). One of the contributing factors for metabolic exhaustion is shown to be
directly associated with chronic mTOR signaling during T cell receptor activation (55).
While our data suggest the TLR-mediated accumulation of glycogen is under regulation
of PI3k-mTOR signaling, we suspect these DCs would undergo metabolic exhaustion
perhaps due to two reasons. The first is that unlike the early and prolonged activation of
mTOR in T cells, mTOR-mediated transcriptional and translational events in TLRactivated DCs can take several hours (55). Secondly, it is likely that the cellular energy
sensor AMP kinase (AMPK) could become activated at a much later stage of TLR
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stimulation presumably due to the fact that the cellular energetic payloads for
synthesizing such a large pool of glycogen in BMDCs can trigger AMPK activation that
antagonizes mTOR activities.
One of the potential mechanisms for a rise in intracellular glycogen in activated
BMDCs and the opposite phenotype observed in moDCs is post-translational
modification (PTM) of NO on glycogen phosphorylase enzyme. NO has been historically
known to modulate the activities of a majority of metabolic proteins and enzymes
through the reversible S-nitrosylation at their cysteine residues (12, 14, 56, 57), and
glycogen phosphorylase is one of those enzymes susceptible to S-nitrosylation reaction
(15, 58-60). Although the activity of PYG in brain and hepatocytes is shown to be
enhanced upon reversible S-nitrosylation, further aspects of S-nitrosylated PYG function
has not been identified in any other systems (58, 61). In light of this, it is likely that the
regulatory activities of S-nitrosylated PYG may be opposite in NO-producing BMDCs
and NO-non-producing, thereby resulting in their differential utilization of intracellular
glycogen in these two models. The information acquired from identification of PYG Snitrosylation in DCs would be immensely helpful in better understanding of regulatory
and signaling mechanisms implicated in cellular functional aspects. This necessitates
further work including the investigation of whether or not PYG is S-nitrosylated in TLRactivated DCs.
Overall, we believe that we have discovered an intriguing behavior of glycogen
metabolism in both mouse and human models of TLR-activated DCs, which is potentially
regulated by NO (a proposed model illustrating this mechanism shown in Figure 5-6).
Despite the fact that moDCs do not express iNOS nor produce NO, a number of studies
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demonstrated that NO is generated in human patients of tuberculous granuloma,
granulomatous infections, and psoriasis (62-64), strongly implying the tremendous sideeffects of NO-mediated metabolic regulation on infiltrating immune cells, such as
inflammatory monocyte derived DCs from the peripheral circulation. Given that NO
functions as a “double-edged sword” in its ability to both enhance and suppress immune
responses during infections, elucidating this novel regulatory mechanism in the near
future will definitely provide valuable insights into how we can harness the desired
effects mediated by NO, without harming the host cells, to elicit optimal immune
outcomes.

183

Figures

Figure 5 -1: BMDCs, but not human monocyte-derived DCs (moDCs) accumulate more
glycogen.
(A and B) BMDCs (A) and moDCs (B) were stimulated with LPS for 6 hours.
Intracellular glycogen levels were then measured from the cellular lysates. For (A), n=5
and p **<0.005 for. For B, n=3. (C and D) moDCs (C) and BMDCs (D) were stimulated
with LPS for 24 hours, and then intracellular glycogen levels were measured from cell
lysates. For C, n=3 and **p <0.005. For D, n=3 and **p<0.005. Data were analyzed
using student’s t test.
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Figure 5 -2: Glycogen accumulation in LPS-activated BMDCs is mediated by NO
(A and B) BMDCs were stimulated with and without LPS for 24 hours in the presence or
absence of iNOS inhibitor (iNOS-ib). Unt=untreated (A) Supernatants were collected
from the culture media and Griess Nitrite assay was performed. n=4; **p<0.005. (B) Cell
lysates were prepared from the media and glycogen levels were measured. Data were
normalized to LPS-only group; n=4; and ***p<0.0005. (C) moDCs were stimulated with
LPS and NO-donor (SNAP) was added to the media every 5 hours, for a total of 15
hours. Cell lysates were then prepared and glycogen levels were measured. n=3;
**p=0.0095. (D) BMDCs were pre-activated with LPS, with and without iNOS inhibitor
185

(SEITU) for 6 hours before co-culturing with moDCs for the next 18 hours. At the time
of co-culture, moDCs were stimulated with and without LPS in the lower chambers of a
transwell plate, and pre-activated BMDCs were incubated in transwell inserts.
Supernatants were collected for Griess nitrite assay, and glycogen levels were measured
from the cell lysates of moDCs. n=3. (E) moDCs were stimulated with and without LPS
in the presence or absence of NO-donor for 6 hours, and glycogen levels were measured
from the lysates. n=3; *p=0.05. Statistical analyses were calculated with student’s t test.
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Figure 5 -3: PYG and GYS1 expression in iNOS-inhibited BMDCs.
(A) Glycogen synthase 1 (GYS1) expression of BMDCs stimulated with and without LPS
for 24 hours in the presence or absence of iNOS-inhibitor (SEITU). -tubulin was used as
loading controls. (B) Liver Glycogen phosphorylase (PYGL) protein expression of
BMDCs stimulated with LPS for 24 hours. -tubulin was used as loading controls. (A
and B) Representative of n=5.
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Figure 5 -4: Mitochondrial toxicity induces glycogen depletion in moDCs.
(A) moDCs were stimulated with and without LPS for 24 hours in the presence or
absence of Oligomycin and Rotenone and glycogen levels were assessed from cellular
lysates.
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Figure 5 -5: NO-mediated BMDC glycogen accumulation is mediated by PI3k-mTOR
axis.
(A and B) BMDCs were stimulated with and without LPS for 24 hours in the presence or
absence of mTOR inhibitor (Rapamycin), PI3k-inhibitor, iNOS inhibitor (SEITU), and
GSK3-inhibitor. (A) Griess nitrite assay from culture supernatant; n=4. (B) Cell lysates
were prepared and glycogen content was assessed. n=3. (C) Expression of GYS1 from
cell lysates of BMDCs stimulated similarly as in A. -actin was used as loading controls.
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Figure 5-6: Model Illustration of NO/iNOS regulation in BMDC and moDC
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CHAPTER 6
CONCLUDING REMARKS AND FUTURE DIRECTIONS
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The discovery of glycogen metabolism by Claude Bernard in the 1800’s opened
up many avenues for investigation into cellular utilization of glucose at different levels.
Since then, glycogen metabolism has been studied sporadically in immune cells,
particularly in total mixed leukocyte populations, with very few studies in isolated or
purified phagocytes specifically. Prior to this work, the functional aspects of glycogen
metabolism in DCs has not been clearly defined. Preceding knowledge on the importance
of glycogen metabolism in maintaining energy and metabolite homeostasis in
metabolically active tissues, such as brain, liver, and muscle, coupled with the already
established importance of glucose metabolism in supporting DC immune responses,
prompted us to elucidate the roles of glycogen metabolism in DC effector function.
While the bulk of this work primarily focuses on DC-intrinsic glycogen
metabolism in the TLR4-activation model discussed in Chapter 3 and chapter 5, the work
in Chapter 2 compares the metabolic regulation between TLR and non-TLR activation by
fungal ligand Dectin-1 stimulation. We have demonstrated the fundamental link between
cellular glycolytic reprogramming responses and Dectin-1-ligand specific activation of
Syk-dependent NLRP3 inflammasome formation. Because Syk signaling has been shown
to be coordinated with another signaling molecule, CARD9, in many instances (Gross et
al., 2006; Jia et al., 2014), we think that examining the potential implication of CARD9 in
association with Syk regulation may better elucidate whether CARD9 is also required for
Dectin-1 specific activation of glycolytic reprogramming. This is an important area of
investigation because of the complexity of fungal cell wall composition that can trigger
distinct metabolic responses and diverse signaling mechanisms. On an important note,
future work worthy of further exploration is the role for glycogen metabolism in
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regulating fungal ligand-mediated immune responses, in line with the overarching theme
of this dissertation.
In Chapter 3, we have examined the role and metabolic behavior of DC glycogen
metabolism in 3 different parts: 1) establishing the presence of DC-intrinsic glycogen
metabolic machinery; 2) defining its role in supporting DC effector function; and 3)
defining the contribution of glycogen to the activation-associated DC “metabolome”. One
interesting feature of DC expression of glycogen metabolic enzymes, demonstrated in
this Chapter, is that DCs express both liver and brain isozymes of glycogen
phosphorylase (PYG). However, one recent report showed that T lymphocytes express
the muscle isoform of PYG and that the stimulation of PYGM is required for IL-2stimulated T cell proliferation (Arrizabalaga et al., 2012). These data imply that the
immune cells of myeloid and lymphoid origins seem to differentially express distinct
PYG isoforms. More interestingly, PYG activity appears to be more complex than its
canonical function of glycogen degradation. Studies in NIH3T3 cell lines demonstrate
that PYG activity contributes to caspase-independent cellular necroptosis (Zhang et al.,
2009). In contrast, PYG is shown to be essential in cancer cell proliferation and survival
(Favaro et al., 2012; Iida et al., 2012). The pleiotropic functions of PYG in these
scenarios suggest additional roles in which PYG can be implicated in DC metabolism.
One situation would be its potential role as an energy and metabolic sensor in
coordination with GYS in DC glycogen shunt described in Chapter 3, given that the
continuous breakdown and synthesis of glycogen in the shunt is a metabolically costly
process that could upset the overall energy balance of the cells. The implications of this
were described in Chapter 3, in which we showed a drop in ATP and crucial metabolites
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upon inhibition of PYG. In addition, the fact that inhibition of PYG in low glucose
conditions impairs BMDC survival plus maturation as well as induces AMPK activation
suggests an interesting mechanism by which PYG perhaps can act in parallel with both
mTOR and AMPK -mediated pathways, particularly during nutrient starvation. A need
for the comprehensive understanding of how these molecules work together in
maintaining cellular energy and metabolite homeostasis, particularly during active
inflammatory reactions, necessitates further work in the future. Further questions also
remain as to whether PYG and/or the overall glycogen metabolism is involved in DC
longevity.
One prominent metabolic phenomenon that our work demonstrated in Chapter 3
is the ability of DCs to engage in a relatively obscure metabolic pathway termed the
glycogen shunt. Compared to the glycogen shunt observed in neuronal and muscle
systems, several questions arise in regard to the biological relevance and the purpose of
this shunt in DCs. As this continuous cycle of glycogen turnover is a seemingly wasteful
process from an energetic standpoint, one key question is how this process is sustained or
regulated in activated DCs without disturbing the cellular metabolic balance. One
possible explanation could be through the geospatial localization of the two parallel
pathways of glycogen metabolism. A few early studies suggested the potential existence
of spatial regulation of glycogen metabolism in immune cells (Scott, 1968; Scott and
Still, 1968). A few pieces of recent evidence, such as the rapid translocation of
hexokinase-II (HK-II) to the mitochondrial outer membrane in TLR-activated DCs, and
the observation of clusters of “vacuole-like” glycogen-containing compartments shown in
Chapter 3, corroborate the notion of spatially compartmentalized localization of glycogen
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and thus perhaps also glycogen metabolic pathways (Everts et al., 2014; Thwe et al.). It is
highly plausible that some of the glycogen clusters that are potentially designated for
degradation can locate in close proximity to mitochondria so that those glycogen
molecules can easily funnel the metabolic intermediates such as G6P into the glycolytic
pathway and the TCA cycle. This hypothetical projection strongly correlates with the
previous finding of HK-II translocation to mitochondria (Everts et al., 2014) and our
metabolomics data in Chapter 3, suggesting a need to explore this aspect of DC cellular
biology for a better understanding of the nature of spatial compartmentalized regulation
of glycogen metabolism that supports the downstream metabolic pathways.
Another question with respect to the glycogen shunt is the exact purpose(s) of
DCs for participating in the glycogen shunt activity. As we have learned from the nonimmune system, the glycogen shunt in astrocytes and neurons helps support their action
potential firing activities and glutamate production (Obel et al., 2012; Schousboe et al.,
2010; Shulman et al., 2001; Shulman and Rothman, 2017; Walls et al., 2009; Walls et al.,
2008). Similarly, muscle cells take advantage of the glycogen shunt for rapid contractile
functions (Jakobsen et al., 2017; Shulman and Rothman, 2001). As demonstrated by a
previous study, in which phagocytes differentially utilize G6P derived from intracellular
glycogen breakdown for phagocytic activities and from free glucose for chemotactic
function (Weisdorf et al., 1982), it is likely that the carbons derived from the glycogen
shunt may support differential functional activities in activated DCs. This area will be of
significant value for pursuit in our laboratory because a comprehensive understanding of
nutrient sourcing from a specific carbon pool for differential effector function would be a
powerful tool in the future to fine-tune the immune responses in these cells.
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Our metabolomics findings on the glycogen shunt activity and the differential
utilization of glycogen and free glucose metabolism by DCs suggest the possibility that
these phenotypes are not DC-specific and are likely to be observed in other cell types. For
example, a recent study following our publication of this work demonstrated that a
constant turnover of glycogen metabolic reprogramming is essential in formation and
maintenance of the memory CD8+ T cell population (Ma et al., 2018), thus corroborating
our opinion that examination of these pathways in other lineages of the immune system
would be of significant interest.
One of the fundamental metabolites of interest that is frequently mentioned
throughout this dissertation is citrate, and Chapter 3 describes the generation of citrate
from DC glycogen shunt. Citrate plays a crucial role in anabolic processes during the
activation responses of both myeloid and lymphoid immune cells. Our previous work,
delineating the extracellular glucose-driven early glycolytic reprogramming of TLRactivated DCs, as well as our current work focusing on DC-intrinsic glycogen
metabolism, have demonstrated that both free glucose-derived and glycogen-derivedglycolytic pathways are primarily enriched in the citrate pool (Everts et al., 2014; Thwe
et al.). In this regard, one of the metabolites worthy of further investigation is acetylCoA. Acetyl-CoA is generated from citrate for de novo fatty acid synthesis to support the
TLR-driven DC maturation. This metabolic process, in which citrate is transported into
the cytosol and converted to acetyl-CoA for the generation of downstream metabolites
and proteins, has been broadly studied in other immune cell types, such as macrophages
and effector T cells (Everts et al., 2014; Galván-Peña and O’Neill, 2014; Kelly and
O'Neill, 2015; O'Neill, 2011) . Given the fact that trained monocytes, primed to recognize
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specific pathogens in their secondary infections, elicit innate immune memory responses
upon experiencing epigenetic reprogramming events (Cheng et al., 2014), it is also
possible that DCs may undergo epigenetic rewiring directly relevant to the glycogen
shunt activity, thereby modulating the immune outcome. Among the several mechanisms
of epigenetic reprogramming, histone modification by acetylation and/or deacetylation is
one of the common mechanisms cells undertake to regulate protein and gene expressions,
and the cellular availability of acetyl-CoA has been proposed to be directly associated
with epigenetic changes (Cameron et al., 2016). While acetyl-CoA is not included in our
metabolomics data, it would be relevant to begin by examining the levels of acetyl-CoA
indirectly generated from the glycogen shunt. In light of a growing appreciation of
epigenetic regulatory mechanisms in immune cell function, identifying the possibility of
histone modification via glycogen shunt-derived acetyl-CoA is one of the fundamental
questions to be answered in the near future.
Since the work presented in Chapter 5 is not yet ready for publication, more
studies are needed to fully comprehend the NO-mediated regulatory mechanisms and
signaling pathways involved in the glycogen metabolism of both mouse and human
models of DCs. Intriguingly, we identified that NO-producing TLR-activated BMDCs
accumulate more glycogen than their resting counterparts, a phenomenon found to be
opposite in the human monocyte-derived DCs (moDCs), which deplete their intracellular
stores of glycogen more rapidly upon exogenous NO exposure. While the NO-induced
glycogen accumulation in NO-producing mouse DCs is an interesting phenotype, the
physiologically relevant findings on the NO-mediated glycogen depletion in moDCs are
substantiated by a few studies stating that the endotoxin-challenged hepatocytes display a
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decrease in synthase activity and an increase in phosphorylase (PYG) activity in response
to iNOS upregulation in those cells (Shinozaki et al., 2011; Sugita et al., 2002).
Given that PYG can be reversibly S-nitrosylated by NO, which is one of the posttranslational mechanisms of NO in modulating cellular function, we were interested in
whether PYG in our experimental models undergoes the S-nitrosylation reaction.
Although we have not had the opportunity to test this in Chapter 5 yet, it is possible that
an increased level of glycogen in BMDCs is likely due to the inhibitory effect of NO on
PYG. Similarly, increased glycogen utilization in moDCs could be also mediated by the
activity of nitrosylated-PYG. Considering NO as a “double-edged sword” in its effects on
immune responses, we would gain valuable insights into how we can harness the NOmediated positive immune outcomes without harming the host cells.
Importantly, there are a few major points to consider in an attempt to elucidate the
NO regulation of glycogen metabolism in both mouse and human DCs. The first question
is whether the rapid depletion of glycogen in moDCs is due to the universal effect of
exogenous NO observed only in non-NO-producer human DCs, but not in NO-producing
BMDCs. Because there are several distinct subsets of tissue-resident DCs in humans that
have been claimed to upregulate iNOS, which we described in Chapter 4 (Haider et al.,
2008; Lowes et al., 2005; Wilsmann-Theis et al., 2013), how do these distinct DC subsets
utilize their glycogen metabolism in response to their autocrine production of NO? Will
they behave as the NO-producing mouse model of BMDCs or the monocyte-derived in
vitro model of DCs that are induced by exogenous NO? Overall, these details are
definitively worthy of further pursuits for a better understanding of DC glycogen
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utilization that would have potentially consequent effects on the functional activities of
immune cells localized in the NO-enriched environment in most microbial infections.
One of the interesting aspects of glycogen metabolism in Chapter 5 is the
signaling pathway involving PI3k-mTOR-iNOS, the regulatory pathway for induction of
NO in BMDCs, which we believe is also possibly regulating the glycogen utilization in
NO-producing BMDCs. Our data showing the activity of GYS1 that is modulated upon
the activation of PI3k-mTOR-iNOS in BMDCs are relatively preliminary. However, one
of the critiques is the lack of information on other effector proteins downstream to PI3kmTOR that are likely to be impacted by this signaling axis. Therefore, in addition to the
expression of total GYS1 we have shown in Chapter 5, we acknowledge the need to
identify the expression of PYG and phosphorylated GYS1, which is the inactive form of
GYS1, so that it would help us fully understand this regulatory mechanism. Of interest,
another major signaling molecule highly relevant to this pathway is hypoxia inducible
factor-1 (HIF-1), which is one of the regulatory proteins directly downstream of
mTOR. Because HIF-1 canonically induces the upregulation of aerobic glycolysis and
iNOS expression in immune cells and also modulates glycogen synthesis in cancer cells
(Corcoran and O'Neill, 2016; Iida et al., 2012; Jantsch et al., 2008; Pelletier et al., 2012;
Pescador et al., 2010), it is of great relevance to examine the implication of HIF-1 in
this signaling mechanism.
Following our studies on the elucidation of TLR versus Dectin-1-driven glucose
metabolism, we uncovered a novel understanding of intracellular glucose reserves in
DCs. Using a pharmacological and genetic approach in Chapter 3, we established the
glycogen-driven early glycolytic reprogramming responses. In particular, we have
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acquired a more profound understanding of the role of DC-intrinsic glycogen storage in
supporting the TLR-driven early metabolic responses associated with their effector
function, and DC utilization of differential metabolic pathways driven by free glucoseand glycogen-derived carbons. We have also shown that inhibition of DC glycogen
metabolism causes detrimental effects on their activation responses. With respect to the
regulatory mechanisms of glycogen metabolism utilization in DCs, our preliminary
reports strongly implicate nitric oxide in this process. We found a drastic difference
between NO-mediated effects on the mouse and human DC models, explicitly illustrated
in Chapter 5. Namely, mouse DCs stockpile their intracellular glycogen upon iNOS
upregulation whereas human DCs accelerate their glycogen usage upon exposure to
exogenous NO. This intriguing phenotype opens up many questions to be answered in the
future, especially because NO is frequently involved in a variety of microbial infections,
in addition to its versatile regulatory roles in many physiological and metabolic
processes.
With a rising appreciation of the fundamental roles of cellular metabolism in
regulating immune cell responses to various inflammatory stimuli, there has also been an
increasing interest in targeting immune cell metabolism for immuno-therapeutic
applications. In light of this, a growing effort has been contributed towards the
development of metabolism-targeted approaches to enhance the immune functional
outcomes. In the studies described in this dissertation, we have established how DCs
maintain nutrient homeostasis to support their metabolic requirements during activation
responses, giving particular attention towards DC utilization of nutrients from their
intracellular glycogen stores, and the potential regulatory mechanisms governing these
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processes. We believe that the experimental evidence exhibited in this dissertation has
significantly contributed to the field for an enhanced understanding of the intricacies of
carbohydrate metabolism in DCs of the immune system, which may be further exploited
in metabolic interventions towards the development of cell-based therapeutic applications
in the future.
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APPENDIX A
Analysis of Glycogen Metabolic Pathway Utilization by Dendritic Cells and T Cells
Using Custom Phenotype Metabolic Assays
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Abstract
In the field of immunology, there is an increasing interest in cellular energy
metabolism and its outcome on immune cell effector function. Activation of immune
cells leads to rapid metabolic changes that are central to cellular biology in order to
support the effector responses. Therefore, the need for user-friendly and dependable
assay technologies to address metabolic regulation and nutrient utilization in immune
cells is an important need in this field. Redox-dye reduction-based Phenotype
MicroArray (PM) assays, which measure NADH reduction as a readout, developed by
Biolog Inc., provide a wide screening of metabolites both in bacteria and mammalian
cells. In this study, we delineate a detailed protocol of a customized Biolog assay for
investigation of a specific metabolic pathway of interest. The option to be able to easily
customize this technology offers researchers with a convenient assay platform to
methodically examine specific nutrient substrates or metabolic pathways of interest in a
rapid and cost-effective manner.

Introduction
There is a growing appreciation in the field of immunology that immune cell
activation is accompanied by dramatic shifts in cellular metabolism, often highlighted by
increased cellular uptake of glucose (1-9). Cellular utilization of specific metabolic
pathways has traditionally been assessed by radioisotope labeling of metabolites and/or
indirect measurements of enzymatic activities. While the techniques like carbon isotopic
labeling, such as LC-MS approaches, provide reliable snapshots of cellular metabolic
fluxes, they demand specialized expertise from the execution of experiments to data
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analysis. In this work, we outline an experimental method using Biolog Inc. Phenotype
MicroArray (PM) technology to perform simple and rapid screenings of cellular energyproducing metabolic pathways that provides fast, cost effective, and clear results.
The Biolog PM assay technology was originally developed for microbial
metabolic screening, based on assaying the ability of microorganisms to metabolize
distinct nutrient substrates. This assay platform was subsequently developed for a variety
of eukaryotic cell applications including assays for evaluating cancer cell drug targets,
metabolic disorders, cancer cell metabolism, drug toxicity testing, and general metabolic
pathway analyses. For these assays, cells are plated in a 96-well format where each well
is pre-loaded with a single distinct metabolic substrate. After allowing cells to equilibrate
to their nutrient environment and metabolism to occur, cells are then co-incubated with a
colorimetric dye that is reduced in the presence of NADH. If cells are capable of
metabolizing a substrate, NADH will be produced resulting in proportional reduction of
the dye. This assay is based on the premise that the amount of NADH produced directly
correlates to the cell’s ability to utilize a particular substrate as an energy source (10).
Although it is similar to the principle of MTT assays, the Biolog tetrazolium redox dye
mix is specifically optimized to measure cellular NADH production. It is also water
soluble and readily adapted for metabolic rate measurements. This eliminates the
solubility issues and the precipitation of formazan, thereby reducing the high background
noise that is a typical obstacle for data interpretation in standard MTT methodologies
(10). The intensity of color formation that results from dye reduction directly correlates
with the amount of cellular NADH production driven by metabolism of a given substrate.
In addition, cells can be assayed over time to provide kinetic analysis of substrate usage.
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Figure A-1 provides a simple illustration of NADH production during glycolytic and
mitochondrial metabolism, which is read as dye reduction of the Biolog Inc. Dye Mix in
these assays.
One of the major advantages of this assay, from the perspective of larger-scale
screening assays, is that it can be accomplished with relatively few cells in a total volume
of 100 L (see procedure for details) in each well of a 96-microwell plate. Cells are
originally plated in a minimal nutrient media (MC-0) for overnight incubation. During
this incubation, the cells will utilize residual glucose provided in MC-0 before they adapt
and switch to the saturating single nutrient source in each well of a PM plate. Cellular
utilization of metabolic substrates and their kinetics can be simply measured by
colorimetric readings of purple formazan formation from Biolog redox dye reduction.
The advantage of this technology is that it not only allows an individual to perform a
broad screening of multiple metabolites using pre-designed PM plates, but also provides
the flexibility to customize the assay for a thorough investigation of a single
metabolite/metabolic pathway of interest, specifically tailored to individual’s research
needs. Below, we delineate an illustrative example of how researchers can adapt this
technology to screen for the efficacy of metabolic-inhibiting drugs for a specific research
question.
In a recently published research article, we originally identified that dendritic cells
(DCs) of the immune system can use glycogen as an energy substrate from screening a
wide number of carbon substrates using Biolog Inc. PM assay plates (11). In this screen,
we identified that DCs can utilize not only single units of glucose but also various lengths
of glucose polymers including the long-chain glucose polymer known as glycogen (11).
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To systematically examine glycogen usage by DCs, we customized this technology to
allow us to specifically screen for the efficacy of drugs that targeted glycogen
metabolism in our assay system (Figure A-2). In this case, we built our custom assays
using our substrates of interest, glycogen and glucose. Because of the extreme flexibility
of the assay, we were also able to use this approach to simultaneously examine cellular
nutrient utilization in both resting and activated DCs. With this customized approach, we
have successfully identified a metabolite of our interest, glycogen, and validated the
specificity of multiple inhibitors of glycogen metabolism in DCs as well as other immune
cell types at different activation stages. Because of a growing interest in the metabolic
pathway utilization of immune cells in response to stimuli, we believe that this assay
platform will be attractive to researchers in the field based on the flexibility to customize
this technology to query a wide range of metabolic parameters in a quick and costeffective way.

Materials
1. *a96-well micro plates (Biolog Inc.); Other 96-well flat bottom plates can be
substituted. Please see discussion for more information.
2. *bBiolog dye mix MA (6x) (Biolog Inc.) (for some cell types dye mix MB may
work better)
3. *cIFM-1 (Biolog Inc.); This can be substituted with phenol red free, glucose and
glutamine free RPMI.
4. Glutamine 2mM
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5. 5% Fetal Bovine Serum (FBS) (or dialyzed FBS if limiting exogenous glucose is
desired)
6. Bovine pancreatic glycogen, 5mg/mL concentration (Sigma aldrich)
7. CP91149 (CP) glycogen phosphorylase inhibitor I (Selleckham)
8. DAB, 1,4-Dideoxy-1,4-imino-D-arabinitol hydrochloride, glycogen
phosphorylase inhibitor II (Santa Cruz)
9. Glucose 10mM
10. Multi-channel pipette and reservoir (optional)
11. Plate reader at 590nm wavelength
*These reagents/supplies are obtained from Biolog Inc.; however, options and limitations
to substitute *a and *c with alternative sources are mentioned in discussion.

Procedure
Murine Bone-marrow -derived Dendritic Cells (BMDCs) are used as an example in
this protocol.
I.

Reagent preparation:

1. Assay Media (MC-0)
a. MC-0 assay media supplemented with 5%FBS is prepared with the
following reagents: for 25mL of MC-0 medium, add 1.25mL of FBS,
500L of Pen Strep, and 50L of 200mM stock of glutamine into 23.5mL
of IF-M1 medium. (NOTE 1)
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b. Glycogen containing MC-0 medium is prepared from the MC-0 medium
from 1a to get a 10mg/mL (2x concentration). Glucose containing MC-0
medium with a final concentration 10mM (2x concentration) is prepared
similarly by using the MC-0 medium from 1a.
c. For dose titrations of pharmacological inhibitors, for example glycogen
phosphorylase inhibitor CP and DAB, inhibitor dilutions are prepared in
glycogen containing MC-0 medium from Ia.
2. Assay Media (IFM-1)
a. For testing a certain pharmacological inhibitor such as glucose transporter1 inhibitor (STF31), it is best to use IF-M1, without the addition of serum
to limit the contribution of exogenous glucose by serum. In this case,
glucose containing IF-M1 medium can be prepared by a certain
concentration of glucose in IF-M1 medium with a range of concentration
of the inhibitor.
II.

Preparation of cells

1. BMDCs are generated as previously described (1). Briefly, bone marrow cells are
flushed from femurs of 6-10-week-old C57/Bl6J mice, and cultured in CDCM,
which is composed of RPMI, 10%fetal bovine serum, 5mM glutamine, 1mM
beta-mercaptoethanol, and10IU Pen/Strep, supplemented in 20ng/L of murine
GM-CSF. The cells are cultured for 7 days, with a medium change every other
day.
2. Day 7 BMDCs, differentiated in GM-CSF, are washed 2x in PBS to eliminate any
trace of culture medium (See NOTE 2). After the final wash, the cells are re249

suspended in MC-0 basal medium from 1a at 1x10^6/mL concentration. Proceed
to III-1 to seed the cells.
3. If using other cell types such as T or B lymphocytes, the cell number must be
adjusted (See Note 2) as mentioned previously. If using human monocyte-derived
DCs, cell numbers must also be adjusted due to differences in cell sizes.
Furthermore, the redox dye mixes MA and MB should be compared for each cell
type to determine which works best.
III.

Setting up the experiment

1. BMDCs are seeded at 50,000 cells per well in technical duplicates or triplicates
per condition. To do this, add 50L of 1x10^6/mL BMDCs prepared in II-1 to
each well of a 96-microwell Biolog plate (NOTE 3). Then add 50 L of the
prepared medium (at 2x concentration) from I-1 (containing carbon substrates of
interest with and without the inhibitors). The total volume in each well will be
100 L. Note that the basal media alone, either MC-0 or IF-M1, without the cells
should be included for background correction.
2. Incubate the plate at 370C in 5%CO2 overnight.
3. The next morning, add 20 L of Biolog dye Mix MA (6x) to each well containing
100 L total medium volume (NOTE 4). This gives a final concentration of
tetrazolium at 500 M. Then, immediately measure the tetrazolium reduction at
590nm using a spectrophotometric plate reader (NOTE 2). This will be a time
zero “0”, baseline, reading. Return the plate to the incubator and continue reading
the assay at every 15 minutes for the first hour. After the first hour, continue the
assay with hourly readings for 6 hours or till the color change/the value of the
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kinetic reading is plateaued. This will provide the kinetics of formazan production
that is linear with time (NOTE 5)
4. The same day analysis (incubation) can also be performed using IF-M1 as a base
medium without addition of serum (See Note 1 and the Protocol for IF-M1 based
assay media). Then allow the cells for an hour or two of incubation time before
adding the Biolog dye MA for kinetics readings. Upon dye addition, continue
reading the assay using a colorimetric plate reader as mentioned above.

Data Analysis
Data are analyzed by normalizing to hour “0” (baseline) readings of each corresponding
media:
a. Check raw readings to see if the readouts from replicates are
approximately the same.
b. Average the replicates; the readings of technical replicates should be in a
close range to each other.
c. For background correction, subtract the readings of MC-0 (no cells) from
each group.
d. Next, normalize all the kinetic values to the baseline hour “0” by dividing
the readings of each time point to the hour “0” readings of corresponding
groups.
e. Graph the normalized values, with the baseline hour “0” as a starting point
to represent relative increase (fold change) over baseline.
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An example graph of glycogen utilization in mouse BMDCs with an inhibitor dose
titration are shown in Figure 3A. A dose titration for glycogen phosphorylase
pharmacological inhibitor, CP, in activated T cells is shown in Figure 3B.

Results
To validate the ability of DCs to metabolize glycogen from the PM screening
assay in our recently published article (11), we modified the PM assay technology, in
which untreated BMDCs were seeded in minimal nutrient medium (MC-0), MC-0 that
has glycogen or glucose (control), and a range of dilutions of glycogen phosphorylase
inhibitor, CP, in MC-0+glycogen. MC-0 medium alone with no cells was also included
for background subtraction. Workflow schematics is shown in Figure A-2. As shown in
Figure A-3A, NADH levels from the MC-0+glycogen group are comparable to those of
MC-0+glucose. Based on our previously published findings (2, 11), it is not surprising
that the cells release such a high level of NADH from MC-0+glucose as glucose is
considered a primary fuel source in these cells. To confirm that DCs can generate NADH
from glycogen, we titrated CP in a range of doses. Optimal dosage of the inhibitor is
determined by comparing the NADH of inhibitor-containing groups to that of MC-0 only
group. We identified that a 100M dosage of CP provides optimal inhibition of glycogen
phosphorylase.
Since BMDCs are partially adherent cells, we are interested in whether we could
conduct similar approaches in non-adherent immune cells. Thus, we set up a similar
assay using activated T cells as in Fig. A-3B and measured the kinetics of NADH
production. Although T cells can generate NADH, the optimal inhibitory dose of CP is
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much lower than that of BMDCs, which, we believe, is most likely due to a difference in
cell size.

Discussion
We have previously utilized pre-designed Biolog Inc. PM assay plates to
investigate the effect of inhibition of mechanistic target of rapamycin (mTOR) in various
nutrient sources (2). In our recent publication, we also utilized PM-M1 plates to screen
for potential nutrient sources that can serve as an intracellular carbon storage (11). While
the pre-designed PM assays are extremely beneficial in screening a mass number of
nutrient sources, the idea of utilizing this technology to conveniently investigate a
specific carbon source or metabolic pathway prompted us to modify this assay by using a
combination of in-house reagents and Biolog Inc. products.
Although the assay adaptation and procedure are relatively simple, there are
several steps that require attention in order to achieve optimal results. In this paper, we
examined and validated glycogen utilization in BMDCs and activated T cells. The
seeding density for both types of cells are different due to differences in cell size. It is
best to optimize the cell number for each cell type of interest in order to obtain optimal
assay signal. Too few or too many cells will result in inconsistent assay signal and high
variability among technical replicates. It is recommended that the cells be in a monolayer
(if adherent). If the wells are too crowded, nutrients in the basal medium can be
exhausted quickly even before dye addition, and this can result in inaccurate readings.
Table 3 describes the approximate cell numbers for each immune cell type we tested, for
a 96-well microplate from Biolog Inc. Other types of 96-well flat bottom plates can be
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used, in which case, the cell number and total medium volume per well should be
adjusted. Extreme deviation from a monolayer of cells can cause adverse effects on
nutrient utilization and impact the rate of NADH production.
In our assays, we incubated the cells overnight in MC-0 medium to allow the cells
to utilize minimal nutrients present in MC-0 before they switch to the saturating single
nutrient source. This incubation time can be adjusted to the same day or a longer period
by varying the serum concentration (usually from a range of 0 to 20% FBS) in IF-M1
media. In some cases, an extended incubation period might be necessary after the
addition of reduction dye to be able to observe distinct purple color formation. This is
likely due to slow metabolic responses in some cells. These adjustments depend on the
metabolic needs or activities of an individual cell type of interest. Serum can also be
omitted in IF-M1 medium if the same day analysis is performed or if testing for a certain
substrate or pharmacological inhibitor. Regardless of serum concentration, the end goal is
to obtain a linear reading of NADH over a certain period of time.
The choice of Biolog dye mix MA or MB depends on the cell type, and in this
work, we characterize the use of Dye Mix MA for myeloid (2) and lymphoid immune
cells (Fig A-3). For other cell types, extensive information about which dye to use can be
found
at:http://biolog.com/pdf/pmmlit/00P%20133rC%20Redox%20Dye%20Mix%20Brochure
%20JUL07.pdf. While other commercial formazan dyes are commercially available, we
found that, based on our experience, Biolog Dye Mix provides the most reliable results,
likely due to the fact that 1) a wide range of serum concentration does not impact the
spectral absorbance of the dye and 2) colored chemical inhibitors cause very little
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interference in absorption. Of note, these Dye Mixes should be protected from light as
discoloration can occur and create a higher background, thus potentially skewing the data
collected.
While we found this assay platform extremely useful and intuitive, one major
drawback could be found in rapidly proliferating cells, such as activated T cells. The rate
of proliferation could impact the results due to a varying degree of final cell numbers
over a period of kinetic readings or during overnight incubation. Such a problem can be
potentially solved by performing the same day assay and multiple replicates of
experiments. Another point to consider is that one has to choose the right type of base
medium, IF-M1 or IF-M2, depending on the type of metabolic pathways or nutrients of
interest. For instance, if there is interest in examining the metabolism of a specific amino
acid, it is best to substitute IF-M2, which lacks all 20 amino acids, for IF-M1, and
subsequently add back the amino acid/s of choice.
We measured dye reduction kinetically, according to the guidelines by Biolog Inc.
until the kinetics readings reach linear, which varies from one cell type to another
depending on their metabolic activities. For our purpose, we typically normalize the data
to baseline readings at time point “0” after dye addition so that our baseline is a value of
“1” and kinetic production of NADH reflects a fold-change of signal above baseline. One
of the real strengths of the Biolog assay platform is the ability to couple specific nutrient
conditions to energetic production over a dynamic kinetic range. This is in distinct
contrast to many other platforms in the field where researchers are forced to choose
between either nutrient or energetic constraints. In addition, other kinetic assays (such as
the Extracellular Flux Analysis from Agilent/Seahorse Biociences) are not directly
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coupled to the production of reducing equivalents. Overall, the benefits of this assay
outweigh its limitations, and this customizable assay platform presents a powerful tool to
better understand complex metabolic networks at the cellular level.
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Figures and Tables

Figure A-1: Illustration of NADH production (with dye reduction) from glucose
metabolism
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Figure A-2: Workflow for a customized Biolog assay set up (96-well plate picture
courtesy of Biolog Inc.)
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Figure A-3: (A) Titration of CP in BMDCs. BMDCs differentiated in GM-CSF were
seeded at 50,000 cells/well in a 96-well Biolog microplate plate in a total volume of
100L corresponding media and incubated overnight. 20L of Biolog Redox Dye Mix
MA was added the next morning. The assay was read hourly from basal time 0 (right
after dye addition) up to 7 hours. Data were analyzed by dividing the average readings of
each time point by basal time “0” of the corresponding medium. A representative of at
least 3independent experiments. (B) Titration of CP in activated T cells. Activated T cells
were seeded at 100,000 cells/well in a 96-well Biolog microplate in a total volume of
100L of corresponding media and incubated overnight. CP were titrated in MC0+glycogen medium. 20L of Biolog Redox Dye Mix MA was added to each well the
next morning. The assay was read hourly from basal time “0” through hour 3. Data were
analyzed by dividing the average readings of each time point by basal time “0” of the
corresponding medium. A representative of 3 independent experiments.
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Table 1

Triplicate

MC-0 (no
cells)

MC-0 only glucose
(with
cells)
BMDCs
BMDCs

Glycogen

BMDCs
BMDCs

BMDCs

Glucose+
PYG
inhibitor
BMDCs

Glycogen
+ PYG
inhibitor
BMDCs

BMDCs

BMDCs

BMDCs

BMDCs

BMDCs

BMDCs

BMDCs

BMDCs

Table 2: An example of customized layout for Biolog plate
An example of customized plate layout for validating DC utilization of glucose and
glycogen metabolic pathways with Biolog plates and the Biolog assay platform with
Bone-marrow -derived Dendritic Cells (BMDCs) and Glycogen Phosphorylase (PYG)
inhibitor.
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Table 2
Cell Type

Cell # per well of a 96-well Biolog
microplate

BMDCs (Murine Bone marrowderived DCs)

50,000

Human monocyte-derived DCs

50,000 – 80,000

Lymphocytes – naïve or activated B
and T cells

100,000

Table 3: Guidelines for different immune cell numbers for a 96-well microplate set-up.
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